<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/pharmacy">
		<title>Pharmacy</title>
		<description>Latest open access articles published in Pharmacy at https://www.mdpi.com/journal/pharmacy</description>
		<link>https://www.mdpi.com/journal/pharmacy</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/pharmacy"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1778581344"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/72" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/71" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/70" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/69" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/68" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/67" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/66" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/65" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/64" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/3/63" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/62" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/61" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/60" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/59" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/58" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/57" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/56" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/54" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/55" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/53" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/52" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/51" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/50" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/49" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/48" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/47" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/46" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/45" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/44" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/43" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/42" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/41" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/40" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/39" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/2/38" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/37" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/36" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/35" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/34" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/33" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/32" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/31" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/30" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/14/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/185" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/184" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/183" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/182" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/181" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/180" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/179" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/178" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/177" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/176" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/175" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/174" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/173" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/172" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/171" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/170" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/169" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/168" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/167" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/166" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/165" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/164" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/163" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/162" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/161" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/158" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/160" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2226-4787/13/6/159" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/72">

	<title>Pharmacy, Vol. 14, Pages 72: Integrating Drug Repurposing into EU Health Crisis Preparedness: The Strategic Role of Health Emergency Preparedness and Response Authority (HERA)</title>
	<link>https://www.mdpi.com/2226-4787/14/3/72</link>
	<description>The COVID-19 pandemic exposed significant vulnerabilities in the European Union&amp;amp;rsquo;s health security architecture and highlighted the need for stronger coordination mechanisms for managing cross-border health threats. In response, the European Union established the Health Emergency Preparedness and Response Authority (HERA) as a central body responsible for strengthening preparedness, coordinating procurement, and supporting the development and availability of medical countermeasures. This study examines the potential role of drug repurposing as a strategic tool within the evolving EU health crisis preparedness framework. A narrative literature review and policy analysis were conducted using scientific publications indexed in PubMed and Scopus, as well as institutional and regulatory documents from the European Commission, the European Medicines Agency (EMA), and other relevant organisations. The findings indicate that drug repurposing offers important advantages during health emergencies, including shorter development timelines, lower research costs, and the possibility of leveraging existing manufacturing and regulatory infrastructures. At the same time, several challenges remain, particularly regarding regulatory coordination, intellectual property considerations, and the scalability of pharmaceutical production during periods of increased demand. The analysis suggests that drug repurposing could evolve from an ad hoc response mechanism into a more institutionalised component of EU health crisis preparedness. Integrating repurposing strategies into HERA&amp;amp;rsquo;s threat prioritisation, regulatory coordination, and industrial preparedness mechanisms may significantly enhance the European Union&amp;amp;rsquo;s ability to respond rapidly and effectively to future health emergencies.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 72: Integrating Drug Repurposing into EU Health Crisis Preparedness: The Strategic Role of Health Emergency Preparedness and Response Authority (HERA)</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/72">doi: 10.3390/pharmacy14030072</a></p>
	<p>Authors:
		Atanas Toshev
		Stanislav Gueorguiev
		Anna Mihaylova
		Violeta Getova-Kolarova
		Vasil Madzharov
		Dimitar Mirchev
		Elina Petkova-Gueorguieva
		</p>
	<p>The COVID-19 pandemic exposed significant vulnerabilities in the European Union&amp;amp;rsquo;s health security architecture and highlighted the need for stronger coordination mechanisms for managing cross-border health threats. In response, the European Union established the Health Emergency Preparedness and Response Authority (HERA) as a central body responsible for strengthening preparedness, coordinating procurement, and supporting the development and availability of medical countermeasures. This study examines the potential role of drug repurposing as a strategic tool within the evolving EU health crisis preparedness framework. A narrative literature review and policy analysis were conducted using scientific publications indexed in PubMed and Scopus, as well as institutional and regulatory documents from the European Commission, the European Medicines Agency (EMA), and other relevant organisations. The findings indicate that drug repurposing offers important advantages during health emergencies, including shorter development timelines, lower research costs, and the possibility of leveraging existing manufacturing and regulatory infrastructures. At the same time, several challenges remain, particularly regarding regulatory coordination, intellectual property considerations, and the scalability of pharmaceutical production during periods of increased demand. The analysis suggests that drug repurposing could evolve from an ad hoc response mechanism into a more institutionalised component of EU health crisis preparedness. Integrating repurposing strategies into HERA&amp;amp;rsquo;s threat prioritisation, regulatory coordination, and industrial preparedness mechanisms may significantly enhance the European Union&amp;amp;rsquo;s ability to respond rapidly and effectively to future health emergencies.</p>
	]]></content:encoded>

	<dc:title>Integrating Drug Repurposing into EU Health Crisis Preparedness: The Strategic Role of Health Emergency Preparedness and Response Authority (HERA)</dc:title>
			<dc:creator>Atanas Toshev</dc:creator>
			<dc:creator>Stanislav Gueorguiev</dc:creator>
			<dc:creator>Anna Mihaylova</dc:creator>
			<dc:creator>Violeta Getova-Kolarova</dc:creator>
			<dc:creator>Vasil Madzharov</dc:creator>
			<dc:creator>Dimitar Mirchev</dc:creator>
			<dc:creator>Elina Petkova-Gueorguieva</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030072</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>72</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030072</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/72</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/71">

	<title>Pharmacy, Vol. 14, Pages 71: Enhancing Self-Care Consultation Skills in Pharmacy Education: Benefits of Virtual Patients and Artificial Intelligence&amp;mdash;A Scoping Review</title>
	<link>https://www.mdpi.com/2226-4787/14/3/71</link>
	<description>Virtual patients (VPs) and artificial intelligence (AI) are being implemented in pharmacy education across various countries in order to learn different techniques to improve communication skills, identify drug-related problems, assess the pharmacist&amp;amp;rsquo;s role in the self-medication process or assess students&amp;amp;rsquo; knowledge acquisition. The objective of this study was to assess the benefits of integrating VPs and AI in pharmacy education, particularly their impact on pharmacy students&amp;amp;rsquo; knowledge and skills in self-medication counselling. A literature search was conducted across PubMed, Scopus and Web of Science databases. Studies focused on the integration of VPs and AI tools in pharmacy education and their impact on students&amp;amp;rsquo; knowledge, counselling and communication skills related to self-medication, were evaluated. Eligible studies were full-text, peer-reviewed research articles published in English. No restrictions were applied regarding publication year. A total of 857 articles were identified through electronic databases and 9 met the inclusion criteria. Six studies were conducted in the USA and one each in Portugal, Sweden and Indonesia. Most studies employed a pre&amp;amp;ndash;post-study design. Six studies utilized VP simulations, while the remaining three implemented AI-based tools. Key outcomes covered in analyzed articles included improvements in knowledge score, communication, and consultation skills, along with positive perceptions, including increased student satisfaction and confidence levels. Using VP simulations and AI tools in pharmacy education could positively impact students by enhancing their knowledge as well as their confidence and counselling skills.</description>
	<pubDate>2026-05-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 71: Enhancing Self-Care Consultation Skills in Pharmacy Education: Benefits of Virtual Patients and Artificial Intelligence&amp;mdash;A Scoping Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/71">doi: 10.3390/pharmacy14030071</a></p>
	<p>Authors:
		Radiana Staynova
		Daniela Kafalova
		Evelina Gavazova
		Katerina Slavcheva
		Nelina Neycheva
		Adelina Boyanova
		Desislava Andonova
		Hristina Stoynova
		</p>
	<p>Virtual patients (VPs) and artificial intelligence (AI) are being implemented in pharmacy education across various countries in order to learn different techniques to improve communication skills, identify drug-related problems, assess the pharmacist&amp;amp;rsquo;s role in the self-medication process or assess students&amp;amp;rsquo; knowledge acquisition. The objective of this study was to assess the benefits of integrating VPs and AI in pharmacy education, particularly their impact on pharmacy students&amp;amp;rsquo; knowledge and skills in self-medication counselling. A literature search was conducted across PubMed, Scopus and Web of Science databases. Studies focused on the integration of VPs and AI tools in pharmacy education and their impact on students&amp;amp;rsquo; knowledge, counselling and communication skills related to self-medication, were evaluated. Eligible studies were full-text, peer-reviewed research articles published in English. No restrictions were applied regarding publication year. A total of 857 articles were identified through electronic databases and 9 met the inclusion criteria. Six studies were conducted in the USA and one each in Portugal, Sweden and Indonesia. Most studies employed a pre&amp;amp;ndash;post-study design. Six studies utilized VP simulations, while the remaining three implemented AI-based tools. Key outcomes covered in analyzed articles included improvements in knowledge score, communication, and consultation skills, along with positive perceptions, including increased student satisfaction and confidence levels. Using VP simulations and AI tools in pharmacy education could positively impact students by enhancing their knowledge as well as their confidence and counselling skills.</p>
	]]></content:encoded>

	<dc:title>Enhancing Self-Care Consultation Skills in Pharmacy Education: Benefits of Virtual Patients and Artificial Intelligence&amp;amp;mdash;A Scoping Review</dc:title>
			<dc:creator>Radiana Staynova</dc:creator>
			<dc:creator>Daniela Kafalova</dc:creator>
			<dc:creator>Evelina Gavazova</dc:creator>
			<dc:creator>Katerina Slavcheva</dc:creator>
			<dc:creator>Nelina Neycheva</dc:creator>
			<dc:creator>Adelina Boyanova</dc:creator>
			<dc:creator>Desislava Andonova</dc:creator>
			<dc:creator>Hristina Stoynova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030071</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-05-11</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-05-11</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>71</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030071</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/71</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/70">

	<title>Pharmacy, Vol. 14, Pages 70: Effect of Pharmacist-Led Educational Intervention on Switching to Generic Medicine Among Patients Using Brand-Name Medicines in Japan</title>
	<link>https://www.mdpi.com/2226-4787/14/3/70</link>
	<description>The use of generic medicines (GEs) is being promoted to reduce healthcare costs. This study aims to evaluate the effect of a pharmacist-led educational intervention on the number of patients switching from brand-name medicines to GEs among patients who preferred brand-name products. Pharmacists provided a standardized explanation using pamphlets about GEs to patients who wished to use brand-name medicines and allocated time to answer questions. Basic knowledge about GEs (nine items) and perceptions of GE use (three items) were assessed before and after the intervention to determine whether changes influenced switching behavior. Between 1 March and 30 July 2025, 40 patients were enrolled in the analysis. Following the intervention, the number of patients using one or more brand-name medicines significantly decreased to 25. Knowledge and perceptions of GEs significantly increased after the intervention and were associated with an increased rate of switching to GEs. Binominal logistic regression analysis identified age &amp;amp;ge; 65 years as a strong factor associated with preference for brand-name medicines (OR, 16.45; 95% CI, 1.48&amp;amp;ndash;182.65; p = 0.02). These findings indicate that pharmacist-led educational interventions are effective in promoting GE use among patients who prefer brand-name medicines. In the future, we plan to conduct comparative studies with a control group to further investigate the factors that lead to patients strongly preferring the use of brand-name medicines.</description>
	<pubDate>2026-05-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 70: Effect of Pharmacist-Led Educational Intervention on Switching to Generic Medicine Among Patients Using Brand-Name Medicines in Japan</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/70">doi: 10.3390/pharmacy14030070</a></p>
	<p>Authors:
		Tomohiko Tairabune
		Terutaka Goto
		Kentaro Yamazaki
		Kenzo Kudo
		Ken-Ichi Sako
		Tomoji Maeda
		Takeshi Chiba
		</p>
	<p>The use of generic medicines (GEs) is being promoted to reduce healthcare costs. This study aims to evaluate the effect of a pharmacist-led educational intervention on the number of patients switching from brand-name medicines to GEs among patients who preferred brand-name products. Pharmacists provided a standardized explanation using pamphlets about GEs to patients who wished to use brand-name medicines and allocated time to answer questions. Basic knowledge about GEs (nine items) and perceptions of GE use (three items) were assessed before and after the intervention to determine whether changes influenced switching behavior. Between 1 March and 30 July 2025, 40 patients were enrolled in the analysis. Following the intervention, the number of patients using one or more brand-name medicines significantly decreased to 25. Knowledge and perceptions of GEs significantly increased after the intervention and were associated with an increased rate of switching to GEs. Binominal logistic regression analysis identified age &amp;amp;ge; 65 years as a strong factor associated with preference for brand-name medicines (OR, 16.45; 95% CI, 1.48&amp;amp;ndash;182.65; p = 0.02). These findings indicate that pharmacist-led educational interventions are effective in promoting GE use among patients who prefer brand-name medicines. In the future, we plan to conduct comparative studies with a control group to further investigate the factors that lead to patients strongly preferring the use of brand-name medicines.</p>
	]]></content:encoded>

	<dc:title>Effect of Pharmacist-Led Educational Intervention on Switching to Generic Medicine Among Patients Using Brand-Name Medicines in Japan</dc:title>
			<dc:creator>Tomohiko Tairabune</dc:creator>
			<dc:creator>Terutaka Goto</dc:creator>
			<dc:creator>Kentaro Yamazaki</dc:creator>
			<dc:creator>Kenzo Kudo</dc:creator>
			<dc:creator>Ken-Ichi Sako</dc:creator>
			<dc:creator>Tomoji Maeda</dc:creator>
			<dc:creator>Takeshi Chiba</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030070</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-05-11</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-05-11</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>70</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030070</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/70</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/69">

	<title>Pharmacy, Vol. 14, Pages 69: The Use of Elevenies as a Novel Tool in Organic Chemistry Teaching for Pharmacy Students</title>
	<link>https://www.mdpi.com/2226-4787/14/3/69</link>
	<description>Teaching organic chemistry is also important for pharmacists to understand the synthesis and mechanism of action of organic drug molecules. Unfortunately, organic chemistry is considered one of the most difficult subjects. This impression affects students&amp;amp;rsquo; motivation. To provide students with a learning aid and hopefully boost their motivation, this pilot study tested the integration of 28 elevenies&amp;amp;mdash;a special form of short poem&amp;amp;mdash;during a semester in an organic chemistry lecture for pharmacists. An anonymous and voluntary questionnaire was conducted at the end of the lecture sessions to assess perceptions of the use of elevenies as a teaching tool. Overall, the student feedback on the implementation of elevenies was positive. In general, students felt (with nearly 94% agreement) that a wider variety of learning methods, such as elevenies, should be incorporated into university teaching. They found elevenies, a type of literature, suitable for summarizing content of organic chemistry, a natural science. The majority (about 65%) stated that they secretly looked forward to the presentation of the elevenies during the lecture, indicating an increase in motivation. In addition, 83% of the respondents wanted to adduce elevenies to repeat and learn the teaching material. However, only about 20% could imagine writing elevenies themselves as part of the learning process. With 94% approval, the respondents gave a clear vote to retain elevenies in future semesters. This suggests the students&amp;amp;rsquo; perception of elevenies as an educational tool. Their ease of use could certainly be extended to other subject areas, provided that the topics addressed are not too complex.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 69: The Use of Elevenies as a Novel Tool in Organic Chemistry Teaching for Pharmacy Students</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/69">doi: 10.3390/pharmacy14030069</a></p>
	<p>Authors:
		Daniel Baecker
		</p>
	<p>Teaching organic chemistry is also important for pharmacists to understand the synthesis and mechanism of action of organic drug molecules. Unfortunately, organic chemistry is considered one of the most difficult subjects. This impression affects students&amp;amp;rsquo; motivation. To provide students with a learning aid and hopefully boost their motivation, this pilot study tested the integration of 28 elevenies&amp;amp;mdash;a special form of short poem&amp;amp;mdash;during a semester in an organic chemistry lecture for pharmacists. An anonymous and voluntary questionnaire was conducted at the end of the lecture sessions to assess perceptions of the use of elevenies as a teaching tool. Overall, the student feedback on the implementation of elevenies was positive. In general, students felt (with nearly 94% agreement) that a wider variety of learning methods, such as elevenies, should be incorporated into university teaching. They found elevenies, a type of literature, suitable for summarizing content of organic chemistry, a natural science. The majority (about 65%) stated that they secretly looked forward to the presentation of the elevenies during the lecture, indicating an increase in motivation. In addition, 83% of the respondents wanted to adduce elevenies to repeat and learn the teaching material. However, only about 20% could imagine writing elevenies themselves as part of the learning process. With 94% approval, the respondents gave a clear vote to retain elevenies in future semesters. This suggests the students&amp;amp;rsquo; perception of elevenies as an educational tool. Their ease of use could certainly be extended to other subject areas, provided that the topics addressed are not too complex.</p>
	]]></content:encoded>

	<dc:title>The Use of Elevenies as a Novel Tool in Organic Chemistry Teaching for Pharmacy Students</dc:title>
			<dc:creator>Daniel Baecker</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030069</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>69</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030069</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/69</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/68">

	<title>Pharmacy, Vol. 14, Pages 68: A Multi-Framework Approach to Medication Adherence Evaluation in Pharmacy Student-Led Medication Reviews: An Observational Exploratory Study</title>
	<link>https://www.mdpi.com/2226-4787/14/3/68</link>
	<description>Background: Medication adherence is essential for treatment effectiveness and safety, but pharmacy students may find it difficult to assess adherence comprehensively during medication reviews (MRs). This study examined how pharmacy students assess medication adherence in real-world MRs and explored whether complementary adherence frameworks could support broader evaluation. Methods: This observational exploratory study was conducted in the integrated MSc (Master of Science) Pharmacy program at the University of Tartu, Estonia. During the internship, 21 pharmacy students performed a Brown Bag MR with patients aged 65 years or older who used at least 5 prescription medications. Data included patient interviews, e-prescription records, and a validated MR documentation form. An expert panel applied the World Health Organization Medication Adherence Model (WHO-MAM) and the Perceptions and Practicalities Approach (PAPA) to identify adherence determinants not captured by the student-used MR tool. Descriptive statistics and qualitative content analysis were used. Results: Students mainly documented therapy- and patient-related issues, such as incorrect dosing, side effects, and interactions, while socioeconomic and healthcare system factors were rarely identified. Students identified potential adherence-related issues in 19% of cases, whereas experts identified such issues in 57% of cases. Additional gaps included limited recognition of financial barriers, access difficulties, and social support factors. Conclusions: In this exploratory study, pharmacy students identified medication-use-related problems during MRs, but broader adherence-related determinants were less consistently documented. These preliminary findings suggest that structured frameworks such as WHO-MAM and PAPA may be useful for broadening adherence assessment in experiential pharmacy education.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 68: A Multi-Framework Approach to Medication Adherence Evaluation in Pharmacy Student-Led Medication Reviews: An Observational Exploratory Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/68">doi: 10.3390/pharmacy14030068</a></p>
	<p>Authors:
		Hanna Keidong
		Margit Valge
		Kaja-Triin Laisaar
		Afonso Miguel das Neves Cavaco
		Daisy Volmer
		</p>
	<p>Background: Medication adherence is essential for treatment effectiveness and safety, but pharmacy students may find it difficult to assess adherence comprehensively during medication reviews (MRs). This study examined how pharmacy students assess medication adherence in real-world MRs and explored whether complementary adherence frameworks could support broader evaluation. Methods: This observational exploratory study was conducted in the integrated MSc (Master of Science) Pharmacy program at the University of Tartu, Estonia. During the internship, 21 pharmacy students performed a Brown Bag MR with patients aged 65 years or older who used at least 5 prescription medications. Data included patient interviews, e-prescription records, and a validated MR documentation form. An expert panel applied the World Health Organization Medication Adherence Model (WHO-MAM) and the Perceptions and Practicalities Approach (PAPA) to identify adherence determinants not captured by the student-used MR tool. Descriptive statistics and qualitative content analysis were used. Results: Students mainly documented therapy- and patient-related issues, such as incorrect dosing, side effects, and interactions, while socioeconomic and healthcare system factors were rarely identified. Students identified potential adherence-related issues in 19% of cases, whereas experts identified such issues in 57% of cases. Additional gaps included limited recognition of financial barriers, access difficulties, and social support factors. Conclusions: In this exploratory study, pharmacy students identified medication-use-related problems during MRs, but broader adherence-related determinants were less consistently documented. These preliminary findings suggest that structured frameworks such as WHO-MAM and PAPA may be useful for broadening adherence assessment in experiential pharmacy education.</p>
	]]></content:encoded>

	<dc:title>A Multi-Framework Approach to Medication Adherence Evaluation in Pharmacy Student-Led Medication Reviews: An Observational Exploratory Study</dc:title>
			<dc:creator>Hanna Keidong</dc:creator>
			<dc:creator>Margit Valge</dc:creator>
			<dc:creator>Kaja-Triin Laisaar</dc:creator>
			<dc:creator>Afonso Miguel das Neves Cavaco</dc:creator>
			<dc:creator>Daisy Volmer</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030068</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>68</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030068</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/68</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/67">

	<title>Pharmacy, Vol. 14, Pages 67: From Discourse to Practice&amp;mdash;Facilitating Factors and Barriers to the Implementation of Pharmaceutical Care in Primary Health Care: A Qualitative Study</title>
	<link>https://www.mdpi.com/2226-4787/14/3/67</link>
	<description>Background: The implementation of pharmaceutical care (PC) in Primary Health Care (PHC) faces challenges related to interprofessional integration, management support, and infrastructure, despite its potential to improve patient-centered care. Objectives: To analyze, from the perspective of pharmacists working in PHC, the facilitating factors and barriers to the implementation of PC in the public health system in a post-implementation context. Methods: This is a qualitative, exploratory study, with eight individual semi-structured interviews conducted remotely between December 2024 and February 2025. The interviews were recorded, transcribed, and subjected to thematic content analysis by a trained team, with peer validation. Results: The main facilitators identified were: a solid relationship with the team, participation in continuing education, and a bond with patients. Barriers included a lack of adequate infrastructure, workload, staff turnover, and resistance from the health team. Management support, although frequently cited as a facilitator, did not always translate into concrete actions for service implementation. Even in the face of these barriers, the implementation of PC contributed to strengthening patient-centered care, the clinical protagonism of pharmacists, and improving health outcomes. Conclusions: The analysis highlighted that the sustainability of PC depends on structural and relational conditions that go beyond individual training. The study reveals that, after implementation and continuing education processes, organizational barriers persist that limit the consolidation of PC, highlighting the need for institutional policies and ongoing management support to effectively integrate pharmacists into healthcare.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 67: From Discourse to Practice&amp;mdash;Facilitating Factors and Barriers to the Implementation of Pharmaceutical Care in Primary Health Care: A Qualitative Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/67">doi: 10.3390/pharmacy14030067</a></p>
	<p>Authors:
		Jéssica Azevedo Aquino
		Denise Alves Guimarães
		Mariana Linhares Pereira
		Luanna G. Resende Silva
		João Pedro Vasconcelos Paolinelli
		André Oliveira Baldoni
		</p>
	<p>Background: The implementation of pharmaceutical care (PC) in Primary Health Care (PHC) faces challenges related to interprofessional integration, management support, and infrastructure, despite its potential to improve patient-centered care. Objectives: To analyze, from the perspective of pharmacists working in PHC, the facilitating factors and barriers to the implementation of PC in the public health system in a post-implementation context. Methods: This is a qualitative, exploratory study, with eight individual semi-structured interviews conducted remotely between December 2024 and February 2025. The interviews were recorded, transcribed, and subjected to thematic content analysis by a trained team, with peer validation. Results: The main facilitators identified were: a solid relationship with the team, participation in continuing education, and a bond with patients. Barriers included a lack of adequate infrastructure, workload, staff turnover, and resistance from the health team. Management support, although frequently cited as a facilitator, did not always translate into concrete actions for service implementation. Even in the face of these barriers, the implementation of PC contributed to strengthening patient-centered care, the clinical protagonism of pharmacists, and improving health outcomes. Conclusions: The analysis highlighted that the sustainability of PC depends on structural and relational conditions that go beyond individual training. The study reveals that, after implementation and continuing education processes, organizational barriers persist that limit the consolidation of PC, highlighting the need for institutional policies and ongoing management support to effectively integrate pharmacists into healthcare.</p>
	]]></content:encoded>

	<dc:title>From Discourse to Practice&amp;amp;mdash;Facilitating Factors and Barriers to the Implementation of Pharmaceutical Care in Primary Health Care: A Qualitative Study</dc:title>
			<dc:creator>Jéssica Azevedo Aquino</dc:creator>
			<dc:creator>Denise Alves Guimarães</dc:creator>
			<dc:creator>Mariana Linhares Pereira</dc:creator>
			<dc:creator>Luanna G. Resende Silva</dc:creator>
			<dc:creator>João Pedro Vasconcelos Paolinelli</dc:creator>
			<dc:creator>André Oliveira Baldoni</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030067</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>67</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030067</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/67</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/66">

	<title>Pharmacy, Vol. 14, Pages 66: Differences in Opioid Prescribing by Urban and Rural Pharmacists in Nova Scotia, Canada&amp;mdash;A Time Series Analysis from 2018 to 2022</title>
	<link>https://www.mdpi.com/2226-4787/14/3/66</link>
	<description>During the COVID-19 pandemic, Health Canada temporarily exempted pharmacists from specific restrictions under the Controlled Drugs and Substances Act (CDSA), allowing them to prescribe opioids. However, it is not yet established whether opioid dispensing patterns differ between urban and rural pharmacists. This study aims to assess the impact of the CDSA subsection 56(1) temporary exemption on opioid prescribing practices among urban and rural pharmacists between 1 February 2018 and 30 April 2022. Descriptive statistics and visualizations assessed differences in opioid prescribing between urban and rural pharmacists under the CDSA exemption. Initial analyses employed linear regression to examine changes, followed by evaluation of temporal dependence using autocorrelation and residual analysis. When appropriate, a suitable time series model was subsequently applied. Following the CDSA exemption, the mean weekly proportion of opioid claims prescribed by urban pharmacists increased from 0.0% to 1.03%. In contrast, rural pharmacists&amp;amp;rsquo; prescriptions rose from 0.0% to 0.35%. The estimated mean level change was 0.667% for urban pharmacists (95% CI: 0.520&amp;amp;ndash;0.838%, p &amp;amp;lt; 0.0001) and 0.201% for rural pharmacists (95% CI: 0.140&amp;amp;ndash;0.291%, p &amp;amp;lt; 0.0001). The study identified distinct differences in opioid prescribing practices between urban and rural pharmacists in Nova Scotia. Furthermore, opioid prescriptions increased steadily across all patient groups, indicating evolving patterns of opioid use within the province.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 66: Differences in Opioid Prescribing by Urban and Rural Pharmacists in Nova Scotia, Canada&amp;mdash;A Time Series Analysis from 2018 to 2022</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/66">doi: 10.3390/pharmacy14030066</a></p>
	<p>Authors:
		Edward Chisholm
		Ying Zhang
		Chiranjeev Sanyal
		</p>
	<p>During the COVID-19 pandemic, Health Canada temporarily exempted pharmacists from specific restrictions under the Controlled Drugs and Substances Act (CDSA), allowing them to prescribe opioids. However, it is not yet established whether opioid dispensing patterns differ between urban and rural pharmacists. This study aims to assess the impact of the CDSA subsection 56(1) temporary exemption on opioid prescribing practices among urban and rural pharmacists between 1 February 2018 and 30 April 2022. Descriptive statistics and visualizations assessed differences in opioid prescribing between urban and rural pharmacists under the CDSA exemption. Initial analyses employed linear regression to examine changes, followed by evaluation of temporal dependence using autocorrelation and residual analysis. When appropriate, a suitable time series model was subsequently applied. Following the CDSA exemption, the mean weekly proportion of opioid claims prescribed by urban pharmacists increased from 0.0% to 1.03%. In contrast, rural pharmacists&amp;amp;rsquo; prescriptions rose from 0.0% to 0.35%. The estimated mean level change was 0.667% for urban pharmacists (95% CI: 0.520&amp;amp;ndash;0.838%, p &amp;amp;lt; 0.0001) and 0.201% for rural pharmacists (95% CI: 0.140&amp;amp;ndash;0.291%, p &amp;amp;lt; 0.0001). The study identified distinct differences in opioid prescribing practices between urban and rural pharmacists in Nova Scotia. Furthermore, opioid prescriptions increased steadily across all patient groups, indicating evolving patterns of opioid use within the province.</p>
	]]></content:encoded>

	<dc:title>Differences in Opioid Prescribing by Urban and Rural Pharmacists in Nova Scotia, Canada&amp;amp;mdash;A Time Series Analysis from 2018 to 2022</dc:title>
			<dc:creator>Edward Chisholm</dc:creator>
			<dc:creator>Ying Zhang</dc:creator>
			<dc:creator>Chiranjeev Sanyal</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030066</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>66</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030066</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/66</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/65">

	<title>Pharmacy, Vol. 14, Pages 65: Prevalence and Association of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</title>
	<link>https://www.mdpi.com/2226-4787/14/3/65</link>
	<description>Older adults with type 2 diabetes mellitus (T2DM) are at high risk of polypharmacy and potentially inappropriate medication (PIM) use because of multimorbidity and complex treatment regimens. This systematic review and meta-analysis (PRISMA 2020; PROSPERO CRD420251149348) aimed to estimate the prevalence of polypharmacy and PIM use, describe PIM burden and patterns, and summarize the co-occurrence of PIMs among those with polypharmacy. On 7 September 2025, we searched PubMed, Scopus, Embase, Web of Science, and MEDLINE using a structured search strategy based on the PICO framework. Observational studies of older adults (&amp;amp;ge;65 years) with T2DM reporting polypharmacy and PIMs were included. Risk of bias was assessed using the JBI checklist, and prevalence estimates were synthesized using a random-effects meta-analysis. Five studies (13,350 participants) were included. Polypharmacy prevalence ranged from 43.6% to 95.3%, while PIM prevalence ranged from 23.4% to 74%. The co-occurrence of PIMs among polypharmacy users ranged from 39.6% to 74%. Commonly reported PIM classes included long-acting sulfonylureas, proton pump inhibitors, and benzodiazepines. Overall, polypharmacy and PIM use were frequently reported among older adults with T2DM; however, the wide variation in prevalence across studies indicates substantial clinical and methodological heterogeneity. These findings highlight the need for structured medication review and clinical context-based medication optimization beyond numerical thresholds.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 65: Prevalence and Association of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/65">doi: 10.3390/pharmacy14030065</a></p>
	<p>Authors:
		Raniah A. Aljaizani
		Arwa A. Althumairi
		Khalid A. Alamer
		Shakil Ahmad
		</p>
	<p>Older adults with type 2 diabetes mellitus (T2DM) are at high risk of polypharmacy and potentially inappropriate medication (PIM) use because of multimorbidity and complex treatment regimens. This systematic review and meta-analysis (PRISMA 2020; PROSPERO CRD420251149348) aimed to estimate the prevalence of polypharmacy and PIM use, describe PIM burden and patterns, and summarize the co-occurrence of PIMs among those with polypharmacy. On 7 September 2025, we searched PubMed, Scopus, Embase, Web of Science, and MEDLINE using a structured search strategy based on the PICO framework. Observational studies of older adults (&amp;amp;ge;65 years) with T2DM reporting polypharmacy and PIMs were included. Risk of bias was assessed using the JBI checklist, and prevalence estimates were synthesized using a random-effects meta-analysis. Five studies (13,350 participants) were included. Polypharmacy prevalence ranged from 43.6% to 95.3%, while PIM prevalence ranged from 23.4% to 74%. The co-occurrence of PIMs among polypharmacy users ranged from 39.6% to 74%. Commonly reported PIM classes included long-acting sulfonylureas, proton pump inhibitors, and benzodiazepines. Overall, polypharmacy and PIM use were frequently reported among older adults with T2DM; however, the wide variation in prevalence across studies indicates substantial clinical and methodological heterogeneity. These findings highlight the need for structured medication review and clinical context-based medication optimization beyond numerical thresholds.</p>
	]]></content:encoded>

	<dc:title>Prevalence and Association of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis</dc:title>
			<dc:creator>Raniah A. Aljaizani</dc:creator>
			<dc:creator>Arwa A. Althumairi</dc:creator>
			<dc:creator>Khalid A. Alamer</dc:creator>
			<dc:creator>Shakil Ahmad</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030065</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>65</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030065</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/65</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/64">

	<title>Pharmacy, Vol. 14, Pages 64: Blended Learning to Enhance Competencies Among Practicing Pharmacists: A Pre&amp;ndash;Post Evaluation of the European Health Professionals&amp;rsquo; and the DigitAl Team SkillS Advancement Project in Romania</title>
	<link>https://www.mdpi.com/2226-4787/14/3/64</link>
	<description>The digital transformation of healthcare requires stronger digital competencies among pharmacists, yet evidence on the effectiveness of structured training remains scarce. This study examines the impact of a blended digital health training programme delivered to practicing pharmacists in Bihor County, Romania, as part of the Romanian pilot of the EU-funded European Health Professionals&amp;amp;rsquo; and the DigitAl team SkillS (H-PASS) project. A single-group pre&amp;amp;ndash;post educational design was applied to pharmacists from Bihor County, Romania, participating in a modular digital health training programme delivered between May and July 2025. A total of 84 pharmacists completed both pre-training and post-training self-reported competency assessments comprising 18 items across three modules: digital innovation and change management, communication and collaboration, and data management and digital literacy. Paired samples t-tests, Cohen&amp;amp;rsquo;s d effect sizes, Cronbach&amp;amp;rsquo;s alpha, moderator analyses, and ceiling effect analyses were conducted using Python-based statistical workflows. Statistically significant improvements were observed across all three modules (all p &amp;amp;lt; 0.0001), with large effect sizes (d = 1.04&amp;amp;ndash;1.30). Post-training internal consistency increased substantially, with overall Cronbach&amp;amp;rsquo;s alpha reaching 0.74. The greatest item-level gains were recorded in adaptive communication, cultural adaptation of care, and data protection ethics. No significant moderation effects were found for age, gender, or years of experience. Course satisfaction showed a moderate positive correlation with competency gains (r = 0.528), while perceived improvement was not significantly associated with observed score change. A ceiling effect indicated greater gains among participants with lower baseline competencies. The Romanian implementation of the H-PASS training programme was associated with improved self-reported digital health competencies among practicing pharmacists, high-lighting its potential as a scalable model for digital upskilling in healthcare.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 64: Blended Learning to Enhance Competencies Among Practicing Pharmacists: A Pre&amp;ndash;Post Evaluation of the European Health Professionals&amp;rsquo; and the DigitAl Team SkillS Advancement Project in Romania</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/64">doi: 10.3390/pharmacy14030064</a></p>
	<p>Authors:
		Tünde Jurca
		Andrei-Flavius Radu
		Gabriela S. Bungau
		Annamária Pallag
		Anett Jolán Karetka
		Octavia Gligor
		Laura Graţiela Vicaş
		Florin Bănică
		Diana Teaha
		Claudia Costea
		Nóra Fazekas
		Zoltán Cserháti
		Ilie Cirstea
		Tiberiu Sebastian Nemeth
		</p>
	<p>The digital transformation of healthcare requires stronger digital competencies among pharmacists, yet evidence on the effectiveness of structured training remains scarce. This study examines the impact of a blended digital health training programme delivered to practicing pharmacists in Bihor County, Romania, as part of the Romanian pilot of the EU-funded European Health Professionals&amp;amp;rsquo; and the DigitAl team SkillS (H-PASS) project. A single-group pre&amp;amp;ndash;post educational design was applied to pharmacists from Bihor County, Romania, participating in a modular digital health training programme delivered between May and July 2025. A total of 84 pharmacists completed both pre-training and post-training self-reported competency assessments comprising 18 items across three modules: digital innovation and change management, communication and collaboration, and data management and digital literacy. Paired samples t-tests, Cohen&amp;amp;rsquo;s d effect sizes, Cronbach&amp;amp;rsquo;s alpha, moderator analyses, and ceiling effect analyses were conducted using Python-based statistical workflows. Statistically significant improvements were observed across all three modules (all p &amp;amp;lt; 0.0001), with large effect sizes (d = 1.04&amp;amp;ndash;1.30). Post-training internal consistency increased substantially, with overall Cronbach&amp;amp;rsquo;s alpha reaching 0.74. The greatest item-level gains were recorded in adaptive communication, cultural adaptation of care, and data protection ethics. No significant moderation effects were found for age, gender, or years of experience. Course satisfaction showed a moderate positive correlation with competency gains (r = 0.528), while perceived improvement was not significantly associated with observed score change. A ceiling effect indicated greater gains among participants with lower baseline competencies. The Romanian implementation of the H-PASS training programme was associated with improved self-reported digital health competencies among practicing pharmacists, high-lighting its potential as a scalable model for digital upskilling in healthcare.</p>
	]]></content:encoded>

	<dc:title>Blended Learning to Enhance Competencies Among Practicing Pharmacists: A Pre&amp;amp;ndash;Post Evaluation of the European Health Professionals&amp;amp;rsquo; and the DigitAl Team SkillS Advancement Project in Romania</dc:title>
			<dc:creator>Tünde Jurca</dc:creator>
			<dc:creator>Andrei-Flavius Radu</dc:creator>
			<dc:creator>Gabriela S. Bungau</dc:creator>
			<dc:creator>Annamária Pallag</dc:creator>
			<dc:creator>Anett Jolán Karetka</dc:creator>
			<dc:creator>Octavia Gligor</dc:creator>
			<dc:creator>Laura Graţiela Vicaş</dc:creator>
			<dc:creator>Florin Bănică</dc:creator>
			<dc:creator>Diana Teaha</dc:creator>
			<dc:creator>Claudia Costea</dc:creator>
			<dc:creator>Nóra Fazekas</dc:creator>
			<dc:creator>Zoltán Cserháti</dc:creator>
			<dc:creator>Ilie Cirstea</dc:creator>
			<dc:creator>Tiberiu Sebastian Nemeth</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030064</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>64</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030064</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/64</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/3/63">

	<title>Pharmacy, Vol. 14, Pages 63: Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)</title>
	<link>https://www.mdpi.com/2226-4787/14/3/63</link>
	<description>Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI &amp;amp;lt; 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI &amp;amp;lt; 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged &amp;amp;ge;65 years, confirming the drug&amp;amp;rsquo;s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 63: Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/3/63">doi: 10.3390/pharmacy14030063</a></p>
	<p>Authors:
		Mar Llamas-Velasco
		Mercedes Hospital
		Anna López-Ferrer
		Pedro Herranz
		Ricardo Ruíz-Villaverde
		Almudena Mateu
		Francisco Javier García-Latasa
		Raquel Rivera
		Lourdes Rodriguez Fernández-Freire
		Elena Del Alcazar
		Sergio Santos
		Salvador Arias
		Alvaro Gónzalez-Cantero
		Isabel Belinchon
		Gregorio Carretero
		Marta Ferran
		Diana Ruiz-Genao
		Noemí Eiris
		Antonio Sahuquillo
		Javier Mataix
		Jose-María Carrascosa
		Pablo de la Cueva
		Laura Salgado-Boquete
		</p>
	<p>Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI &amp;amp;lt; 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI &amp;amp;lt; 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged &amp;amp;ge;65 years, confirming the drug&amp;amp;rsquo;s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.</p>
	]]></content:encoded>

	<dc:title>Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)</dc:title>
			<dc:creator>Mar Llamas-Velasco</dc:creator>
			<dc:creator>Mercedes Hospital</dc:creator>
			<dc:creator>Anna López-Ferrer</dc:creator>
			<dc:creator>Pedro Herranz</dc:creator>
			<dc:creator>Ricardo Ruíz-Villaverde</dc:creator>
			<dc:creator>Almudena Mateu</dc:creator>
			<dc:creator>Francisco Javier García-Latasa</dc:creator>
			<dc:creator>Raquel Rivera</dc:creator>
			<dc:creator>Lourdes Rodriguez Fernández-Freire</dc:creator>
			<dc:creator>Elena Del Alcazar</dc:creator>
			<dc:creator>Sergio Santos</dc:creator>
			<dc:creator>Salvador Arias</dc:creator>
			<dc:creator>Alvaro Gónzalez-Cantero</dc:creator>
			<dc:creator>Isabel Belinchon</dc:creator>
			<dc:creator>Gregorio Carretero</dc:creator>
			<dc:creator>Marta Ferran</dc:creator>
			<dc:creator>Diana Ruiz-Genao</dc:creator>
			<dc:creator>Noemí Eiris</dc:creator>
			<dc:creator>Antonio Sahuquillo</dc:creator>
			<dc:creator>Javier Mataix</dc:creator>
			<dc:creator>Jose-María Carrascosa</dc:creator>
			<dc:creator>Pablo de la Cueva</dc:creator>
			<dc:creator>Laura Salgado-Boquete</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14030063</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>63</prism:startingPage>
		<prism:doi>10.3390/pharmacy14030063</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/3/63</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/62">

	<title>Pharmacy, Vol. 14, Pages 62: From Classroom to Cleanroom: Evaluating Industrial Field Visits as a Pedagogical Tool in Parenteral Pharmaceutical Manufacturing and Quality Control Education</title>
	<link>https://www.mdpi.com/2226-4787/14/2/62</link>
	<description>This study investigates the educational impact of an industrial field visit on the learning experience of second-year pharmacy students at Qatar University. The visit, integrated within the Pharmaceutics II course (PHAR 310), was designed to complement theoretical instruction by providing exposure to real-world pharmaceutical manufacturing and quality control processes, particularly for parenteral dosage forms. A mixed-methods approach was employed using quantitative and qualitative data derived from post-visit questionnaires. Findings indicated that students reported positive perceptions of the experience, with the majority indicating improved understanding of key pharmaceutical manufacturing concepts and strong support for the inclusion of similar activities within the curriculum. Qualitative analysis further suggested that the visit facilitated contextualization of theoretical knowledge, enhanced engagement, and supported early professional awareness. While these findings suggest that structured industrial visits may serve as a valuable complementary educational strategy in pharmacy training, the results should be interpreted with caution due to the small sample size and single-institution design. Further research incorporating larger cohorts, objective learning assessments, and longitudinal evaluation is underway to better establish the educational impact of these interventions.</description>
	<pubDate>2026-04-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 62: From Classroom to Cleanroom: Evaluating Industrial Field Visits as a Pedagogical Tool in Parenteral Pharmaceutical Manufacturing and Quality Control Education</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/62">doi: 10.3390/pharmacy14020062</a></p>
	<p>Authors:
		Sandi Ali Adib
		Husam M. Younes
		</p>
	<p>This study investigates the educational impact of an industrial field visit on the learning experience of second-year pharmacy students at Qatar University. The visit, integrated within the Pharmaceutics II course (PHAR 310), was designed to complement theoretical instruction by providing exposure to real-world pharmaceutical manufacturing and quality control processes, particularly for parenteral dosage forms. A mixed-methods approach was employed using quantitative and qualitative data derived from post-visit questionnaires. Findings indicated that students reported positive perceptions of the experience, with the majority indicating improved understanding of key pharmaceutical manufacturing concepts and strong support for the inclusion of similar activities within the curriculum. Qualitative analysis further suggested that the visit facilitated contextualization of theoretical knowledge, enhanced engagement, and supported early professional awareness. While these findings suggest that structured industrial visits may serve as a valuable complementary educational strategy in pharmacy training, the results should be interpreted with caution due to the small sample size and single-institution design. Further research incorporating larger cohorts, objective learning assessments, and longitudinal evaluation is underway to better establish the educational impact of these interventions.</p>
	]]></content:encoded>

	<dc:title>From Classroom to Cleanroom: Evaluating Industrial Field Visits as a Pedagogical Tool in Parenteral Pharmaceutical Manufacturing and Quality Control Education</dc:title>
			<dc:creator>Sandi Ali Adib</dc:creator>
			<dc:creator>Husam M. Younes</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020062</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-17</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-17</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>62</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020062</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/62</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/61">

	<title>Pharmacy, Vol. 14, Pages 61: Knowledge, Attitudes, and Practices Regarding the Disposal of Unused and Expired Medicines in Romania During the Early Implementation of the 2023 Hospital-Based Collection Framework</title>
	<link>https://www.mdpi.com/2226-4787/14/2/61</link>
	<description>Background: Improper disposal of unused and expired medicines represents an environmental and public health concern. In Romania, Law No. 269/2023 assigned the responsibility for collecting household pharmaceutical waste to public and private hospitals, while operational procedures were further detailed in the Ministry of Health (MoH) Instruction No. 6226/2024. Objectives: This study aimed to assess knowledge, attitudes, and practices (KAP) related to the disposal of unused and expired medicines among the general public and community pharmacy staff during the early phase of implementation of the hospital-based medicine take-back system in Romania. Methods: A cross-sectional survey using convenience sampling was conducted between 1 and 31 August 2023. Two structured questionnaires were administered: one targeting the general public/patients and another addressing community pharmacy staff. Data were analyzed descriptively using frequencies and percentages. Several items allowed multiple responses. Results: Among public respondents (n = 108; predominantly male, 90.7%; urban, 75.0%), household waste disposal was the most frequently reported method (58.3%), followed by pharmacy return (43.5%). Willingness to use a dedicated collection system was very high (96.3%). Among pharmacy staff (n = 71; predominantly female, 78.9%; urban, 74.6%), 40.8% reported no collection activity; where collection occurred, it was typically on demand. Disposal routes included transfer to specialized waste companies (56.3%) and regulated destruction (43.7%). Only 1.4% of pharmacies offered incentives, while 45.4% of the public indicated discounts could motivate returns. Conclusions: Findings indicate an implementation and communication gap during the transition to a hospital-based pharmaceutical waste collection system. Strengthening public communication on official collection points and providing clearer operational guidance may support safer disposal practices.</description>
	<pubDate>2026-04-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 61: Knowledge, Attitudes, and Practices Regarding the Disposal of Unused and Expired Medicines in Romania During the Early Implementation of the 2023 Hospital-Based Collection Framework</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/61">doi: 10.3390/pharmacy14020061</a></p>
	<p>Authors:
		Anca Lupu
		Ștefan Roșca
		Ancuța Iacob
		Marius Moroianu
		Ramona-Oana Roșca
		</p>
	<p>Background: Improper disposal of unused and expired medicines represents an environmental and public health concern. In Romania, Law No. 269/2023 assigned the responsibility for collecting household pharmaceutical waste to public and private hospitals, while operational procedures were further detailed in the Ministry of Health (MoH) Instruction No. 6226/2024. Objectives: This study aimed to assess knowledge, attitudes, and practices (KAP) related to the disposal of unused and expired medicines among the general public and community pharmacy staff during the early phase of implementation of the hospital-based medicine take-back system in Romania. Methods: A cross-sectional survey using convenience sampling was conducted between 1 and 31 August 2023. Two structured questionnaires were administered: one targeting the general public/patients and another addressing community pharmacy staff. Data were analyzed descriptively using frequencies and percentages. Several items allowed multiple responses. Results: Among public respondents (n = 108; predominantly male, 90.7%; urban, 75.0%), household waste disposal was the most frequently reported method (58.3%), followed by pharmacy return (43.5%). Willingness to use a dedicated collection system was very high (96.3%). Among pharmacy staff (n = 71; predominantly female, 78.9%; urban, 74.6%), 40.8% reported no collection activity; where collection occurred, it was typically on demand. Disposal routes included transfer to specialized waste companies (56.3%) and regulated destruction (43.7%). Only 1.4% of pharmacies offered incentives, while 45.4% of the public indicated discounts could motivate returns. Conclusions: Findings indicate an implementation and communication gap during the transition to a hospital-based pharmaceutical waste collection system. Strengthening public communication on official collection points and providing clearer operational guidance may support safer disposal practices.</p>
	]]></content:encoded>

	<dc:title>Knowledge, Attitudes, and Practices Regarding the Disposal of Unused and Expired Medicines in Romania During the Early Implementation of the 2023 Hospital-Based Collection Framework</dc:title>
			<dc:creator>Anca Lupu</dc:creator>
			<dc:creator>Ștefan Roșca</dc:creator>
			<dc:creator>Ancuța Iacob</dc:creator>
			<dc:creator>Marius Moroianu</dc:creator>
			<dc:creator>Ramona-Oana Roșca</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020061</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-16</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-16</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>61</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020061</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/61</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/60">

	<title>Pharmacy, Vol. 14, Pages 60: The Improper Disposal of Drugs and the Lack of Information About It Among a Highly Educated Population in Brazil: Analysis of the Factors Influencing Correct Disposal</title>
	<link>https://www.mdpi.com/2226-4787/14/2/60</link>
	<description>The improper disposal of household pharmaceuticals is a global public health concern, posing risks to both human health and the environment and highlighting the need to raise public awareness. This study aimed to identify individual characteristics associated with the inappropriate disposal of household pharmaceuticals and to determine which individuals may require greater awareness. This cross-sectional study included 310 participants who completed an online questionnaire collecting sociodemographic and clinical information, as well as data regarding the participants&amp;amp;rsquo; use, storage, and disposal of medications. Most participants were female (74%), single (57%), had a university degree (81%), and were 34 &amp;amp;plusmn; 12 years old; 37% had some non-communicable disease (NCD), 85% used some medication, and 62% disposed of pharmaceuticals inappropriately. Having no undergraduate degree (OR = 4.4; 95% CI = 2.01&amp;amp;ndash;9.8), an absence of NCDs (OR = 2.5; 95% CI = 1.1&amp;amp;ndash;5.6), a lack of knowledge about reverse logistics (OR = 3.6; 95% CI = 1.7&amp;amp;ndash;7.6) or environmental risks (OR = 13.5; 95% CI = 1.5&amp;amp;ndash;125), and a lack of guidance from healthcare professionals (OR = 3.6; 95% CI = 1.2&amp;amp;ndash;10.6) were associated with inappropriate disposal. Although most respondents (88.6%) were aware of the negative environmental impacts of improper disposal, 69.7% did not know what reverse logistics was or where to find collection points (73.5%). These findings highlight the importance of environmental education for the effective implementation of reverse logistics for household pharmaceuticals.</description>
	<pubDate>2026-04-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 60: The Improper Disposal of Drugs and the Lack of Information About It Among a Highly Educated Population in Brazil: Analysis of the Factors Influencing Correct Disposal</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/60">doi: 10.3390/pharmacy14020060</a></p>
	<p>Authors:
		Jamila Alessandra Perini
		Thais da Silva Figueiredo
		Mayara Calixto da Silva
		Daniel Escorsim Machado
		Jéssica Vilarinho Cardoso
		</p>
	<p>The improper disposal of household pharmaceuticals is a global public health concern, posing risks to both human health and the environment and highlighting the need to raise public awareness. This study aimed to identify individual characteristics associated with the inappropriate disposal of household pharmaceuticals and to determine which individuals may require greater awareness. This cross-sectional study included 310 participants who completed an online questionnaire collecting sociodemographic and clinical information, as well as data regarding the participants&amp;amp;rsquo; use, storage, and disposal of medications. Most participants were female (74%), single (57%), had a university degree (81%), and were 34 &amp;amp;plusmn; 12 years old; 37% had some non-communicable disease (NCD), 85% used some medication, and 62% disposed of pharmaceuticals inappropriately. Having no undergraduate degree (OR = 4.4; 95% CI = 2.01&amp;amp;ndash;9.8), an absence of NCDs (OR = 2.5; 95% CI = 1.1&amp;amp;ndash;5.6), a lack of knowledge about reverse logistics (OR = 3.6; 95% CI = 1.7&amp;amp;ndash;7.6) or environmental risks (OR = 13.5; 95% CI = 1.5&amp;amp;ndash;125), and a lack of guidance from healthcare professionals (OR = 3.6; 95% CI = 1.2&amp;amp;ndash;10.6) were associated with inappropriate disposal. Although most respondents (88.6%) were aware of the negative environmental impacts of improper disposal, 69.7% did not know what reverse logistics was or where to find collection points (73.5%). These findings highlight the importance of environmental education for the effective implementation of reverse logistics for household pharmaceuticals.</p>
	]]></content:encoded>

	<dc:title>The Improper Disposal of Drugs and the Lack of Information About It Among a Highly Educated Population in Brazil: Analysis of the Factors Influencing Correct Disposal</dc:title>
			<dc:creator>Jamila Alessandra Perini</dc:creator>
			<dc:creator>Thais da Silva Figueiredo</dc:creator>
			<dc:creator>Mayara Calixto da Silva</dc:creator>
			<dc:creator>Daniel Escorsim Machado</dc:creator>
			<dc:creator>Jéssica Vilarinho Cardoso</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020060</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-15</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-15</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>60</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020060</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/60</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/59">

	<title>Pharmacy, Vol. 14, Pages 59: A Faculty-Constructed AI Tutor for Personalized Learning and Remediation in a U.S. PharmD Immunology Course: An &amp;ldquo;In-House&amp;rdquo; Evaluation of New Learning Technology</title>
	<link>https://www.mdpi.com/2226-4787/14/2/59</link>
	<description>While generative AI becomes increasingly available in higher education, faculties find it challenging to design, implement, and evaluate AI-enabled personalized learning systems within accreditation-constrained professional curricula. This method paper describes ADAPT (Assessment-Driven AI for Personalized Tutoring), a home-grown AI tutoring and remediation ecosystem implemented in a required PharmD immunology course. Using standard learning management (Canvas) and assessment (ExamSoft) platforms, a 20-item quiz mapped to six immunology mastery domains (N = 34; mean 69.1%, SD 17.9; Cronbach&amp;amp;rsquo;s &amp;amp;alpha; = 0.73) was used to trigger tiered, structured generative AI remediation at both individual student and cohort levels. Instructional impact was evaluated using reliability indices, item-level difficulty analyses, and paired pre/post-assessment comparisons. Following AI-guided remediation, mean performance increased to 79.8% (+10.7 percentage points), variability decreased (SD 14.4), and assessment reliability improved (ExamSoft KR-20 0.87) compared with the diagnostic exam, the first midterm exam, and the final exam, respectively. Item difficulty stabilized (mean &amp;amp;asymp; 0.80), with sustained retention of targeted concepts on the final examination. ADAPT provides a replicable, low-cost methodological blueprint for faculties to independently construct assessment-driven AI tutoring systems and lays the foundational steps for future AI-based predictive analysis workflow for at-risk students.</description>
	<pubDate>2026-04-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 59: A Faculty-Constructed AI Tutor for Personalized Learning and Remediation in a U.S. PharmD Immunology Course: An &amp;ldquo;In-House&amp;rdquo; Evaluation of New Learning Technology</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/59">doi: 10.3390/pharmacy14020059</a></p>
	<p>Authors:
		Ashim Malhotra
		</p>
	<p>While generative AI becomes increasingly available in higher education, faculties find it challenging to design, implement, and evaluate AI-enabled personalized learning systems within accreditation-constrained professional curricula. This method paper describes ADAPT (Assessment-Driven AI for Personalized Tutoring), a home-grown AI tutoring and remediation ecosystem implemented in a required PharmD immunology course. Using standard learning management (Canvas) and assessment (ExamSoft) platforms, a 20-item quiz mapped to six immunology mastery domains (N = 34; mean 69.1%, SD 17.9; Cronbach&amp;amp;rsquo;s &amp;amp;alpha; = 0.73) was used to trigger tiered, structured generative AI remediation at both individual student and cohort levels. Instructional impact was evaluated using reliability indices, item-level difficulty analyses, and paired pre/post-assessment comparisons. Following AI-guided remediation, mean performance increased to 79.8% (+10.7 percentage points), variability decreased (SD 14.4), and assessment reliability improved (ExamSoft KR-20 0.87) compared with the diagnostic exam, the first midterm exam, and the final exam, respectively. Item difficulty stabilized (mean &amp;amp;asymp; 0.80), with sustained retention of targeted concepts on the final examination. ADAPT provides a replicable, low-cost methodological blueprint for faculties to independently construct assessment-driven AI tutoring systems and lays the foundational steps for future AI-based predictive analysis workflow for at-risk students.</p>
	]]></content:encoded>

	<dc:title>A Faculty-Constructed AI Tutor for Personalized Learning and Remediation in a U.S. PharmD Immunology Course: An &amp;amp;ldquo;In-House&amp;amp;rdquo; Evaluation of New Learning Technology</dc:title>
			<dc:creator>Ashim Malhotra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020059</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>59</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020059</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/59</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/58">

	<title>Pharmacy, Vol. 14, Pages 58: Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review</title>
	<link>https://www.mdpi.com/2226-4787/14/2/58</link>
	<description>(1) Background: The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2) Methods: To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3) Results: In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514/632). Major congenital malformations were reported in 2.5% (6/236) with LCM monotherapy and 11.9% (47/396) with polytherapy. (4) Conclusions: According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.</description>
	<pubDate>2026-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 58: Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/58">doi: 10.3390/pharmacy14020058</a></p>
	<p>Authors:
		Kamila Saramak
		Manuela Kaml
		Marina Peball
		Luisa Delazer
		Gerald Walser
		Anna Hussl
		Iris Unterberger
		Alexandra Astner-Rohracher
		</p>
	<p>(1) Background: The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2) Methods: To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3) Results: In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514/632). Major congenital malformations were reported in 2.5% (6/236) with LCM monotherapy and 11.9% (47/396) with polytherapy. (4) Conclusions: According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.</p>
	]]></content:encoded>

	<dc:title>Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review</dc:title>
			<dc:creator>Kamila Saramak</dc:creator>
			<dc:creator>Manuela Kaml</dc:creator>
			<dc:creator>Marina Peball</dc:creator>
			<dc:creator>Luisa Delazer</dc:creator>
			<dc:creator>Gerald Walser</dc:creator>
			<dc:creator>Anna Hussl</dc:creator>
			<dc:creator>Iris Unterberger</dc:creator>
			<dc:creator>Alexandra Astner-Rohracher</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020058</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-01</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>58</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020058</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/58</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/57">

	<title>Pharmacy, Vol. 14, Pages 57: Guidance for Use of Artificial Intelligence in Community Pharmacy Practice: Perspectives and Needs of Pharmacists in Ontario, Canada</title>
	<link>https://www.mdpi.com/2226-4787/14/2/57</link>
	<description>Background: As Artificial Intelligence (AI) proliferates in society, community pharmacists must make decisions as to how to responsibly adopt this technology in their practice. Currently, there are few regulatory requirements or tools to support pharmacists in ensuring safe and ethical integration of AI in their work. Methods: An exploratory qualitative study of community pharmacists in Ontario, Canada was undertaken to examine their needs for guidance, regulation, and support in adopting AI in their practice. Results: Semi-structured interviews with 24 community pharmacists were undertaken to the point of thematic saturation. Constant-comparative analysis highlighted three key themes: (a) currently, AI is being used in unstandardized and unregulated ways; (b) pharmacists desire guidance or regulation focused on patient safety considerations; and (c) in the absence of regulation, ad hoc informal decision making is occurring. Conclusions: With or without formal regulation, AI is being adopted in pharmacy practice. Current reliance on informal network support without clear regulatory guidance raises concerns for pharmacists regarding patient safety and their work as professionals.</description>
	<pubDate>2026-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 57: Guidance for Use of Artificial Intelligence in Community Pharmacy Practice: Perspectives and Needs of Pharmacists in Ontario, Canada</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/57">doi: 10.3390/pharmacy14020057</a></p>
	<p>Authors:
		Zubin Austin
		Paul Gregory
		</p>
	<p>Background: As Artificial Intelligence (AI) proliferates in society, community pharmacists must make decisions as to how to responsibly adopt this technology in their practice. Currently, there are few regulatory requirements or tools to support pharmacists in ensuring safe and ethical integration of AI in their work. Methods: An exploratory qualitative study of community pharmacists in Ontario, Canada was undertaken to examine their needs for guidance, regulation, and support in adopting AI in their practice. Results: Semi-structured interviews with 24 community pharmacists were undertaken to the point of thematic saturation. Constant-comparative analysis highlighted three key themes: (a) currently, AI is being used in unstandardized and unregulated ways; (b) pharmacists desire guidance or regulation focused on patient safety considerations; and (c) in the absence of regulation, ad hoc informal decision making is occurring. Conclusions: With or without formal regulation, AI is being adopted in pharmacy practice. Current reliance on informal network support without clear regulatory guidance raises concerns for pharmacists regarding patient safety and their work as professionals.</p>
	]]></content:encoded>

	<dc:title>Guidance for Use of Artificial Intelligence in Community Pharmacy Practice: Perspectives and Needs of Pharmacists in Ontario, Canada</dc:title>
			<dc:creator>Zubin Austin</dc:creator>
			<dc:creator>Paul Gregory</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020057</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-01</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>57</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020057</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/57</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/56">

	<title>Pharmacy, Vol. 14, Pages 56: Clinical Pharmacy in Radiopharmacy: A Cross-Sectional Survey of Practices Within the HUGOPharm Network</title>
	<link>https://www.mdpi.com/2226-4787/14/2/56</link>
	<description>Radiopharmacy is a specialized area of hospital pharmacy dedicated to the preparation and appropriate use of radiopharmaceuticals for diagnostic imaging and targeted therapies. While clinical pharmacy activities are well established in many hospital settings, their integration into radiopharmacy remains poorly documented and lacks standardization, particularly in the context of the rapid development of theranostic applications. This descriptive, cross-sectional study aimed to assess current clinical pharmacy practices in radiopharmacy across the HUGOPharm network. Between July and September 2025, an anonymous online questionnaire was distributed to radiopharmacy teams, collecting information on prescription analysis, biological monitoring, interdisciplinary collaboration, and other clinical pharmacy activities. Descriptive statistics were used to analyze responses. All participating centers reported verifying patient identity and key prescription parameters; however, substantial variability in practices was observed. Pharmacotherapeutic analysis was more frequently performed for therapeutic procedures (71%) than for diagnostic procedures (57%). Pre-procedure biological testing was common in therapeutic contexts (86%) but infrequent for diagnostic applications (29%). No center reported conducting structured medication reviews or pharmaceutical consultations. The implementation of radioligand therapies, such as [177Lu]-PSMA, was associated with enhanced safety checks and increased interdisciplinary collaboration. Overall, clinical pharmacy in radiopharmacy is developing but remains inconsistently implemented. Structured clinical pharmacy activities appear particularly relevant for theranostic procedures and may represent priorities for future practice development to support patient safety and integrated care.</description>
	<pubDate>2026-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 56: Clinical Pharmacy in Radiopharmacy: A Cross-Sectional Survey of Practices Within the HUGOPharm Network</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/56">doi: 10.3390/pharmacy14020056</a></p>
	<p>Authors:
		Evan Terrier
		Laura Foucault-Fruchard
		Nicolas Arlicot
		Yann Venel
		Mickaël Bourgeois
		Serge Maia
		Anne-Claire Dupont
		</p>
	<p>Radiopharmacy is a specialized area of hospital pharmacy dedicated to the preparation and appropriate use of radiopharmaceuticals for diagnostic imaging and targeted therapies. While clinical pharmacy activities are well established in many hospital settings, their integration into radiopharmacy remains poorly documented and lacks standardization, particularly in the context of the rapid development of theranostic applications. This descriptive, cross-sectional study aimed to assess current clinical pharmacy practices in radiopharmacy across the HUGOPharm network. Between July and September 2025, an anonymous online questionnaire was distributed to radiopharmacy teams, collecting information on prescription analysis, biological monitoring, interdisciplinary collaboration, and other clinical pharmacy activities. Descriptive statistics were used to analyze responses. All participating centers reported verifying patient identity and key prescription parameters; however, substantial variability in practices was observed. Pharmacotherapeutic analysis was more frequently performed for therapeutic procedures (71%) than for diagnostic procedures (57%). Pre-procedure biological testing was common in therapeutic contexts (86%) but infrequent for diagnostic applications (29%). No center reported conducting structured medication reviews or pharmaceutical consultations. The implementation of radioligand therapies, such as [177Lu]-PSMA, was associated with enhanced safety checks and increased interdisciplinary collaboration. Overall, clinical pharmacy in radiopharmacy is developing but remains inconsistently implemented. Structured clinical pharmacy activities appear particularly relevant for theranostic procedures and may represent priorities for future practice development to support patient safety and integrated care.</p>
	]]></content:encoded>

	<dc:title>Clinical Pharmacy in Radiopharmacy: A Cross-Sectional Survey of Practices Within the HUGOPharm Network</dc:title>
			<dc:creator>Evan Terrier</dc:creator>
			<dc:creator>Laura Foucault-Fruchard</dc:creator>
			<dc:creator>Nicolas Arlicot</dc:creator>
			<dc:creator>Yann Venel</dc:creator>
			<dc:creator>Mickaël Bourgeois</dc:creator>
			<dc:creator>Serge Maia</dc:creator>
			<dc:creator>Anne-Claire Dupont</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020056</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-04-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-04-01</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>56</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020056</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/56</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/54">

	<title>Pharmacy, Vol. 14, Pages 54: Community Pharmacies Face Critical Sustainability Challenges in the United States: Academic Pharmacy Can Help</title>
	<link>https://www.mdpi.com/2226-4787/14/2/54</link>
	<description>Community pharmacies in the United States (US) face an increasingly unsustainable future due to declining third-party reimbursement (remuneration) and ongoing cash flow challenges following the elimination of retroactive direct and indirect remuneration (DIR) fees. These pressures have contributed to widespread pharmacy closures, the emergence of pharmacy deserts, and reduced access to care for millions of patients. Despite these challenges, community pharmacy remains the most common employment setting for pharmacy school graduates in the US. However, currently required community pharmacy Advanced Pharmacy Practice Experience (APPE) student rotations may offer limited exposure to business, management, and entrepreneurial activities, potentially leaving students underprepared for practice in this setting. US colleges and schools of pharmacy are uniquely positioned to address this gap by partnering with their community pharmacy APPE rotation sites to intentionally integrate business- and practice-focused knowledge, skills, and attitudes (KSAs) into the APPE. Equipping students with these KSAs may enhance early career readiness while also supporting the financial sustainability of US community pharmacies through the development of innovative, revenue-generating services. These efforts further align with the 2025 Accreditation Council for Pharmacy Education (ACPE) Standards and may help advance the profession. Future research should examine optimal community pharmacy APPE structures, models, and assessment strategies to maximize student preparedness and long-term community pharmacy sustainability.</description>
	<pubDate>2026-03-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 54: Community Pharmacies Face Critical Sustainability Challenges in the United States: Academic Pharmacy Can Help</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/54">doi: 10.3390/pharmacy14020054</a></p>
	<p>Authors:
		Karl M. Hess
		Peter Lim
		</p>
	<p>Community pharmacies in the United States (US) face an increasingly unsustainable future due to declining third-party reimbursement (remuneration) and ongoing cash flow challenges following the elimination of retroactive direct and indirect remuneration (DIR) fees. These pressures have contributed to widespread pharmacy closures, the emergence of pharmacy deserts, and reduced access to care for millions of patients. Despite these challenges, community pharmacy remains the most common employment setting for pharmacy school graduates in the US. However, currently required community pharmacy Advanced Pharmacy Practice Experience (APPE) student rotations may offer limited exposure to business, management, and entrepreneurial activities, potentially leaving students underprepared for practice in this setting. US colleges and schools of pharmacy are uniquely positioned to address this gap by partnering with their community pharmacy APPE rotation sites to intentionally integrate business- and practice-focused knowledge, skills, and attitudes (KSAs) into the APPE. Equipping students with these KSAs may enhance early career readiness while also supporting the financial sustainability of US community pharmacies through the development of innovative, revenue-generating services. These efforts further align with the 2025 Accreditation Council for Pharmacy Education (ACPE) Standards and may help advance the profession. Future research should examine optimal community pharmacy APPE structures, models, and assessment strategies to maximize student preparedness and long-term community pharmacy sustainability.</p>
	]]></content:encoded>

	<dc:title>Community Pharmacies Face Critical Sustainability Challenges in the United States: Academic Pharmacy Can Help</dc:title>
			<dc:creator>Karl M. Hess</dc:creator>
			<dc:creator>Peter Lim</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020054</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-29</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-29</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>54</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020054</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/54</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/55">

	<title>Pharmacy, Vol. 14, Pages 55: Effectiveness of Gabapentinoids in Neuropathic Pain: A Single-Center Retrospective Study at a Specialized Institution in Mexico</title>
	<link>https://www.mdpi.com/2226-4787/14/2/55</link>
	<description>Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited. This study aimed to evaluate the effectiveness and safety profile of gabapentinoid therapy in patients managed within a specialized pain relief institution. Methods: A retrospective cohort study (n = 109) was conducted (January 2024 to December 2024). Effectiveness was assessed via DN4 and VAS over one year. Time to improvement was analyzed using Kaplan&amp;amp;ndash;Meier curves. Results: The cohort (mean age 66.2 &amp;amp;plusmn; 15.3 years) presented 100% comorbidity and polypharmacy (66.1% opioids; 67.9% antidepressants). Although all patients showed improvement, only 35.8% achieved &amp;amp;ldquo;maximal improvement.&amp;amp;rdquo; Pregabalin demonstrated faster VAS reduction than gabapentin (p = 0.029), though long-term success was comparable (p = 0.30). Significantly, 100% of patients reported at least one adverse drug event (ADE), primarily somnolence (66.1%), though no serious ADEs occurred. Lower baseline pain scores were significant predictors of therapeutic success. Conclusions: Gabapentinoids are effective for long-term NP management; however, their use is consistently associated with non-serious ADEs. In specialized settings characterized by extensive CNS-active polypharmacy, proactive pharmacovigilance and multidisciplinary oversight are essential to balance analgesic effectiveness with medication safety.</description>
	<pubDate>2026-03-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 55: Effectiveness of Gabapentinoids in Neuropathic Pain: A Single-Center Retrospective Study at a Specialized Institution in Mexico</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/55">doi: 10.3390/pharmacy14020055</a></p>
	<p>Authors:
		Carlos Eduardo Estrada-De La Rosa
		Felipe Alexis Avalos-Salgado
		Nancy Evelyn Navarro-Ruiz
		Erika Fabiola López-Villalobos
		Roberto de Jesús Sandoval-Muñiz
		Monserratt Abud-González
		María Luisa Muñoz-Almaguer
		Raymundo Escutia-Gutiérrez
		</p>
	<p>Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited. This study aimed to evaluate the effectiveness and safety profile of gabapentinoid therapy in patients managed within a specialized pain relief institution. Methods: A retrospective cohort study (n = 109) was conducted (January 2024 to December 2024). Effectiveness was assessed via DN4 and VAS over one year. Time to improvement was analyzed using Kaplan&amp;amp;ndash;Meier curves. Results: The cohort (mean age 66.2 &amp;amp;plusmn; 15.3 years) presented 100% comorbidity and polypharmacy (66.1% opioids; 67.9% antidepressants). Although all patients showed improvement, only 35.8% achieved &amp;amp;ldquo;maximal improvement.&amp;amp;rdquo; Pregabalin demonstrated faster VAS reduction than gabapentin (p = 0.029), though long-term success was comparable (p = 0.30). Significantly, 100% of patients reported at least one adverse drug event (ADE), primarily somnolence (66.1%), though no serious ADEs occurred. Lower baseline pain scores were significant predictors of therapeutic success. Conclusions: Gabapentinoids are effective for long-term NP management; however, their use is consistently associated with non-serious ADEs. In specialized settings characterized by extensive CNS-active polypharmacy, proactive pharmacovigilance and multidisciplinary oversight are essential to balance analgesic effectiveness with medication safety.</p>
	]]></content:encoded>

	<dc:title>Effectiveness of Gabapentinoids in Neuropathic Pain: A Single-Center Retrospective Study at a Specialized Institution in Mexico</dc:title>
			<dc:creator>Carlos Eduardo Estrada-De La Rosa</dc:creator>
			<dc:creator>Felipe Alexis Avalos-Salgado</dc:creator>
			<dc:creator>Nancy Evelyn Navarro-Ruiz</dc:creator>
			<dc:creator>Erika Fabiola López-Villalobos</dc:creator>
			<dc:creator>Roberto de Jesús Sandoval-Muñiz</dc:creator>
			<dc:creator>Monserratt Abud-González</dc:creator>
			<dc:creator>María Luisa Muñoz-Almaguer</dc:creator>
			<dc:creator>Raymundo Escutia-Gutiérrez</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020055</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-29</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-29</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>55</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020055</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/55</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/53">

	<title>Pharmacy, Vol. 14, Pages 53: Assessing the Frequency, Prescribing Patterns, and Characteristics of Patients Receiving Drugs with Pharmacogenomic (PGx) Guidelines Through an EMR: Follow-Up Analysis 5 Years Later</title>
	<link>https://www.mdpi.com/2226-4787/14/2/53</link>
	<description>(1) Background: This follow-up retrospective analysis used electronic medical record (EMR) data from a health system to identify patients and medications prescribed in accordance with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. (2) Methods: This analysis included EMR data from a clinical research data warehouse encompassing 928,291 patients seen at an academic medical center between 2020 and 2024. The study evaluated 75 commercially available medications linked to 52 evidence-based CPIC pharmacogenomic (PGx) guidelines. (3) Results: Of the 928,291 patient encounters, 709,673 medication orders were recorded, with 416,621 patients (44.8%) prescribed at least 1 of the 75 CPIC-associated medications. This compares with 845,518 patients who had an encounter in 2015&amp;amp;ndash;2019 with 590,526 medication orders, and 335,849 (56.9%) patients had medication orders represented by CPIC-associated medications. One to three CPIC-associated medications accounted for 76.6% of patients in 2020&amp;amp;ndash;2024 compared to 75.6% in 2015&amp;amp;ndash;2019. (4) Conclusions: The findings demonstrate that the proportion of patients prescribed a CPIC-actionable medication remained just under half of those evaluated within a single institution&amp;amp;rsquo;s EMR. About three-quarters of patients over the ten-year period had between one to three CPIC-associated medications identified, and the top five classes of medications remained the same in the two periods. This understanding of patient volume may help organizations as they begin to assess the implementation of PGx services.</description>
	<pubDate>2026-03-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 53: Assessing the Frequency, Prescribing Patterns, and Characteristics of Patients Receiving Drugs with Pharmacogenomic (PGx) Guidelines Through an EMR: Follow-Up Analysis 5 Years Later</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/53">doi: 10.3390/pharmacy14020053</a></p>
	<p>Authors:
		George E. MacKinnon
		Megan Mills
		Ulrich Broeckel
		</p>
	<p>(1) Background: This follow-up retrospective analysis used electronic medical record (EMR) data from a health system to identify patients and medications prescribed in accordance with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. (2) Methods: This analysis included EMR data from a clinical research data warehouse encompassing 928,291 patients seen at an academic medical center between 2020 and 2024. The study evaluated 75 commercially available medications linked to 52 evidence-based CPIC pharmacogenomic (PGx) guidelines. (3) Results: Of the 928,291 patient encounters, 709,673 medication orders were recorded, with 416,621 patients (44.8%) prescribed at least 1 of the 75 CPIC-associated medications. This compares with 845,518 patients who had an encounter in 2015&amp;amp;ndash;2019 with 590,526 medication orders, and 335,849 (56.9%) patients had medication orders represented by CPIC-associated medications. One to three CPIC-associated medications accounted for 76.6% of patients in 2020&amp;amp;ndash;2024 compared to 75.6% in 2015&amp;amp;ndash;2019. (4) Conclusions: The findings demonstrate that the proportion of patients prescribed a CPIC-actionable medication remained just under half of those evaluated within a single institution&amp;amp;rsquo;s EMR. About three-quarters of patients over the ten-year period had between one to three CPIC-associated medications identified, and the top five classes of medications remained the same in the two periods. This understanding of patient volume may help organizations as they begin to assess the implementation of PGx services.</p>
	]]></content:encoded>

	<dc:title>Assessing the Frequency, Prescribing Patterns, and Characteristics of Patients Receiving Drugs with Pharmacogenomic (PGx) Guidelines Through an EMR: Follow-Up Analysis 5 Years Later</dc:title>
			<dc:creator>George E. MacKinnon</dc:creator>
			<dc:creator>Megan Mills</dc:creator>
			<dc:creator>Ulrich Broeckel</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020053</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-25</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-25</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>53</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020053</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/53</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/52">

	<title>Pharmacy, Vol. 14, Pages 52: Access to Medicines in Bulgaria and North Macedonia: Legislative, Pricing, and Reimbursement Perspectives</title>
	<link>https://www.mdpi.com/2226-4787/14/2/52</link>
	<description>National legislative frameworks governing prescribing, pricing, reimbursement, and dispensing play a decisive role in shaping access to medicines. This study examines the financial availability of medicines in Bulgaria and North Macedonia through a comparative review of national pharmaceutical legislation, pricing mechanisms, reimbursement models, and digitalisation policies, assessed in relation to European Union standards. The findings indicate that access to medicines in both countries is shaped by the combined effects of multiple regulatory and financial instruments rather than by individual policy measures. Both systems apply strict control of prescribing and dispensing, external reference pricing, and positive reimbursement lists, reflecting alignment with international recommendations. However, significant differences in policy design lead to divergent access outcomes. Bulgaria&amp;amp;rsquo;s more advanced digitalisation of prescribing and reimbursement, including mandatory electronic prescribing for selected therapeutic groups, enhances regulatory oversight and expenditure control but is associated with higher patient out-of-pocket expenditure, partly due to the application of the standard value-added tax on medicines. In contrast, North Macedonia combines lower taxation with capped patient co-payments, higher regulated pharmacy margins, and fixed pharmacy remuneration per prescription, contributing to improved financial affordability for patients while supporting pharmacy sustainability. Additional instruments, such as the Generics without Co-Payment List, further strengthen patient financial protection. The study provides comparative evidence relevant to pharmaceutical policy reforms and highlights the importance of balanced regulatory approaches that promote affordability, system sustainability, and equitable access to medicines.</description>
	<pubDate>2026-03-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 52: Access to Medicines in Bulgaria and North Macedonia: Legislative, Pricing, and Reimbursement Perspectives</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/52">doi: 10.3390/pharmacy14020052</a></p>
	<p>Authors:
		Anna Todorova
		Dijana Miceva
		Mariya Ivanova
		Tanya Kazakova
		Bistra Angelovska
		</p>
	<p>National legislative frameworks governing prescribing, pricing, reimbursement, and dispensing play a decisive role in shaping access to medicines. This study examines the financial availability of medicines in Bulgaria and North Macedonia through a comparative review of national pharmaceutical legislation, pricing mechanisms, reimbursement models, and digitalisation policies, assessed in relation to European Union standards. The findings indicate that access to medicines in both countries is shaped by the combined effects of multiple regulatory and financial instruments rather than by individual policy measures. Both systems apply strict control of prescribing and dispensing, external reference pricing, and positive reimbursement lists, reflecting alignment with international recommendations. However, significant differences in policy design lead to divergent access outcomes. Bulgaria&amp;amp;rsquo;s more advanced digitalisation of prescribing and reimbursement, including mandatory electronic prescribing for selected therapeutic groups, enhances regulatory oversight and expenditure control but is associated with higher patient out-of-pocket expenditure, partly due to the application of the standard value-added tax on medicines. In contrast, North Macedonia combines lower taxation with capped patient co-payments, higher regulated pharmacy margins, and fixed pharmacy remuneration per prescription, contributing to improved financial affordability for patients while supporting pharmacy sustainability. Additional instruments, such as the Generics without Co-Payment List, further strengthen patient financial protection. The study provides comparative evidence relevant to pharmaceutical policy reforms and highlights the importance of balanced regulatory approaches that promote affordability, system sustainability, and equitable access to medicines.</p>
	]]></content:encoded>

	<dc:title>Access to Medicines in Bulgaria and North Macedonia: Legislative, Pricing, and Reimbursement Perspectives</dc:title>
			<dc:creator>Anna Todorova</dc:creator>
			<dc:creator>Dijana Miceva</dc:creator>
			<dc:creator>Mariya Ivanova</dc:creator>
			<dc:creator>Tanya Kazakova</dc:creator>
			<dc:creator>Bistra Angelovska</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020052</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-23</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-23</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>52</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020052</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/52</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/51">

	<title>Pharmacy, Vol. 14, Pages 51: Assessment of Potential Exposure to Pregnancy-Contraindicated Medications Among Women of Reproductive Age in Japan: A Retrospective Database Study</title>
	<link>https://www.mdpi.com/2226-4787/14/2/51</link>
	<description>Preconception care is globally recognized as essential for optimizing pregnancy outcomes; however, in Japan, comprehensive data on medication-related potential exposure to pregnancy-contraindicated medications among women of reproductive age remain limited. We conducted a retrospective cross-sectional descriptive study using data from Japan&amp;amp;rsquo;s National Database of Health Insurance Claims (fiscal year 2022) to assess the potential exposure to pregnancy-contraindicated medications among women of reproductive age. Outpatient prescriptions for oral medications dispensed to women aged 15&amp;amp;ndash;49 years were analyzed. In total, 270 medications classified as contraindicated during pregnancy were identified, of which 75 were also contraindicated for women planning pregnancy. Of these, 58 active ingredients were restricted in both phases. Notably, 212 medications were uniquely contraindicated during pregnancy, highlighting the broader contraindication profiles during fetal development than during the preconception period. Despite these contraindications, high prescription volumes were observed for medications such as loxoprofen sodium hydrate, sodium valproate, and metformin hydrochloride among women of reproductive age. These findings illustrate a high baseline utilization of pregnancy-contraindicated medications among women of reproductive age. As most women in this demographic are neither pregnant nor actively planning conception, these volumes primarily reflect standard care rather than inappropriate prescribing. In conclusion, pharmacists serve as an important supplementary safety net by routinely confirming pregnancy status to prevent inadvertent exposure.</description>
	<pubDate>2026-03-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 51: Assessment of Potential Exposure to Pregnancy-Contraindicated Medications Among Women of Reproductive Age in Japan: A Retrospective Database Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/51">doi: 10.3390/pharmacy14020051</a></p>
	<p>Authors:
		Hiroyuki Ura
		Noriko Matsuoka
		</p>
	<p>Preconception care is globally recognized as essential for optimizing pregnancy outcomes; however, in Japan, comprehensive data on medication-related potential exposure to pregnancy-contraindicated medications among women of reproductive age remain limited. We conducted a retrospective cross-sectional descriptive study using data from Japan&amp;amp;rsquo;s National Database of Health Insurance Claims (fiscal year 2022) to assess the potential exposure to pregnancy-contraindicated medications among women of reproductive age. Outpatient prescriptions for oral medications dispensed to women aged 15&amp;amp;ndash;49 years were analyzed. In total, 270 medications classified as contraindicated during pregnancy were identified, of which 75 were also contraindicated for women planning pregnancy. Of these, 58 active ingredients were restricted in both phases. Notably, 212 medications were uniquely contraindicated during pregnancy, highlighting the broader contraindication profiles during fetal development than during the preconception period. Despite these contraindications, high prescription volumes were observed for medications such as loxoprofen sodium hydrate, sodium valproate, and metformin hydrochloride among women of reproductive age. These findings illustrate a high baseline utilization of pregnancy-contraindicated medications among women of reproductive age. As most women in this demographic are neither pregnant nor actively planning conception, these volumes primarily reflect standard care rather than inappropriate prescribing. In conclusion, pharmacists serve as an important supplementary safety net by routinely confirming pregnancy status to prevent inadvertent exposure.</p>
	]]></content:encoded>

	<dc:title>Assessment of Potential Exposure to Pregnancy-Contraindicated Medications Among Women of Reproductive Age in Japan: A Retrospective Database Study</dc:title>
			<dc:creator>Hiroyuki Ura</dc:creator>
			<dc:creator>Noriko Matsuoka</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020051</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-20</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-20</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>51</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020051</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/51</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/50">

	<title>Pharmacy, Vol. 14, Pages 50: Global Pharmaceutical Regulation: Comparative Frameworks and Operations</title>
	<link>https://www.mdpi.com/2226-4787/14/2/50</link>
	<description>Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan&amp;amp;rsquo;s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.</description>
	<pubDate>2026-03-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 50: Global Pharmaceutical Regulation: Comparative Frameworks and Operations</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/50">doi: 10.3390/pharmacy14020050</a></p>
	<p>Authors:
		Omolayo Tinuke Umaru
		Adebowale Sylvester Adeyemi
		Olajumoke Aderonmu
		Balyodh Singh Bhangu
		Harjot Singh Dhaliwal
		Hae Lim
		Taiwo Opeyemi Aremu
		</p>
	<p>Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan&amp;amp;rsquo;s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.</p>
	]]></content:encoded>

	<dc:title>Global Pharmaceutical Regulation: Comparative Frameworks and Operations</dc:title>
			<dc:creator>Omolayo Tinuke Umaru</dc:creator>
			<dc:creator>Adebowale Sylvester Adeyemi</dc:creator>
			<dc:creator>Olajumoke Aderonmu</dc:creator>
			<dc:creator>Balyodh Singh Bhangu</dc:creator>
			<dc:creator>Harjot Singh Dhaliwal</dc:creator>
			<dc:creator>Hae Lim</dc:creator>
			<dc:creator>Taiwo Opeyemi Aremu</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020050</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-18</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-18</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>50</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020050</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/50</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/49">

	<title>Pharmacy, Vol. 14, Pages 49: Drug-Induced Hyponatremia as a Cause of Emergency Department Attendance</title>
	<link>https://www.mdpi.com/2226-4787/14/2/49</link>
	<description>Background: Hyponatremia is one of the most common electrolyte disturbances in emergency departments. This study aimed to describe the characteristics of patients presenting with drug-induced hyponatremia and analyse factors associated with 30-day revisits. Methods: Retrospective observational study including adult patients who attended the emergency department for drug-induced hyponatremia between 2020 and 2024. Results: 141 patients were analysed (mean age 80.5 years; 78% women). Thiazide diuretics were the most frequently implicated pharmacological class (50.3%). In univariable analyses, polypharmacy, dementia, and treatment changes at discharge were associated with a higher risk of revisit for hyponatremia. In the multivariable model, only polypharmacy remained significantly associated with 30-day revisits. Conclusions: Thiazide diuretics were the leading drug-related cause of hyponatremia in the emergency setting. Polypharmacy was identified as an independent factor associated with increased revisit risk, underscoring the need for systematic medication review and close clinical follow-up after hospital discharge.</description>
	<pubDate>2026-03-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 49: Drug-Induced Hyponatremia as a Cause of Emergency Department Attendance</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/49">doi: 10.3390/pharmacy14020049</a></p>
	<p>Authors:
		Joel Gené Grasa
		Natalia Sanz López
		Marta Docio Alfaya
		Verónica Mate García
		Alicia Serrano García-Calvo
		Adrián Plaza Díaz
		Jesús Ruiz Ramos
		</p>
	<p>Background: Hyponatremia is one of the most common electrolyte disturbances in emergency departments. This study aimed to describe the characteristics of patients presenting with drug-induced hyponatremia and analyse factors associated with 30-day revisits. Methods: Retrospective observational study including adult patients who attended the emergency department for drug-induced hyponatremia between 2020 and 2024. Results: 141 patients were analysed (mean age 80.5 years; 78% women). Thiazide diuretics were the most frequently implicated pharmacological class (50.3%). In univariable analyses, polypharmacy, dementia, and treatment changes at discharge were associated with a higher risk of revisit for hyponatremia. In the multivariable model, only polypharmacy remained significantly associated with 30-day revisits. Conclusions: Thiazide diuretics were the leading drug-related cause of hyponatremia in the emergency setting. Polypharmacy was identified as an independent factor associated with increased revisit risk, underscoring the need for systematic medication review and close clinical follow-up after hospital discharge.</p>
	]]></content:encoded>

	<dc:title>Drug-Induced Hyponatremia as a Cause of Emergency Department Attendance</dc:title>
			<dc:creator>Joel Gené Grasa</dc:creator>
			<dc:creator>Natalia Sanz López</dc:creator>
			<dc:creator>Marta Docio Alfaya</dc:creator>
			<dc:creator>Verónica Mate García</dc:creator>
			<dc:creator>Alicia Serrano García-Calvo</dc:creator>
			<dc:creator>Adrián Plaza Díaz</dc:creator>
			<dc:creator>Jesús Ruiz Ramos</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020049</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-17</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-17</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>49</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020049</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/49</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/48">

	<title>Pharmacy, Vol. 14, Pages 48: Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections</title>
	<link>https://www.mdpi.com/2226-4787/14/2/48</link>
	<description>Well-designed randomized controlled trials (RCTs) have demonstrated safe and effective use of oral antimicrobial therapy for bone and joint infections. Application of data for implementation into real-world practice, however, has inherent challenges. This retrospective cohort study compared real-world use of intravenous versus oral antimicrobial therapy in bone and joint infections within a large healthcare system comprising both academic and community medical centers. The primary outcome was the proportion of treatment failure. Key secondary outcomes included the proportion of patients with logistical failure and risk factors associated with treatment and logistical failure. Among 166 patients included, 136 (82%) and 30 (18%) received predominantly intravenous and oral antimicrobial therapy, respectively. Treatment failure occurred in (77/121) 64% versus (18/25) 72% of patients in the intravenous and oral antimicrobial groups (p = 0.491; OR, 1.38; 95% CI, 0.56&amp;amp;ndash;3.33). Logistical failure occurred in 29% versus 47% of patients in the intravenous and oral antimicrobial groups (p = 0.150; OR, 1.93; 95% CI 0.79&amp;amp;ndash;4.70). Risk factors for treatment failure included peripheral vascular disease (OR, 2.61; 95% CI 1.02&amp;amp;ndash;7.80) and higher Charlson Comorbidity Index scores (OR, 1.18; 95% CI 1.04&amp;amp;ndash;1.36). Similar to previously published RCTs, treatment failure appeared comparable between groups; however, oral antimicrobial therapy was overall underutilized.</description>
	<pubDate>2026-03-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 48: Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/48">doi: 10.3390/pharmacy14020048</a></p>
	<p>Authors:
		Maura Kreiser
		Sarah Al Mansi
		Ismaeel Yunusa
		Caroline Derrick
		P. Brandon Bookstaver
		Majdi N. Al-Hasan
		Yorika Hammett
		Morgan Pizzuti
		</p>
	<p>Well-designed randomized controlled trials (RCTs) have demonstrated safe and effective use of oral antimicrobial therapy for bone and joint infections. Application of data for implementation into real-world practice, however, has inherent challenges. This retrospective cohort study compared real-world use of intravenous versus oral antimicrobial therapy in bone and joint infections within a large healthcare system comprising both academic and community medical centers. The primary outcome was the proportion of treatment failure. Key secondary outcomes included the proportion of patients with logistical failure and risk factors associated with treatment and logistical failure. Among 166 patients included, 136 (82%) and 30 (18%) received predominantly intravenous and oral antimicrobial therapy, respectively. Treatment failure occurred in (77/121) 64% versus (18/25) 72% of patients in the intravenous and oral antimicrobial groups (p = 0.491; OR, 1.38; 95% CI, 0.56&amp;amp;ndash;3.33). Logistical failure occurred in 29% versus 47% of patients in the intravenous and oral antimicrobial groups (p = 0.150; OR, 1.93; 95% CI 0.79&amp;amp;ndash;4.70). Risk factors for treatment failure included peripheral vascular disease (OR, 2.61; 95% CI 1.02&amp;amp;ndash;7.80) and higher Charlson Comorbidity Index scores (OR, 1.18; 95% CI 1.04&amp;amp;ndash;1.36). Similar to previously published RCTs, treatment failure appeared comparable between groups; however, oral antimicrobial therapy was overall underutilized.</p>
	]]></content:encoded>

	<dc:title>Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections</dc:title>
			<dc:creator>Maura Kreiser</dc:creator>
			<dc:creator>Sarah Al Mansi</dc:creator>
			<dc:creator>Ismaeel Yunusa</dc:creator>
			<dc:creator>Caroline Derrick</dc:creator>
			<dc:creator>P. Brandon Bookstaver</dc:creator>
			<dc:creator>Majdi N. Al-Hasan</dc:creator>
			<dc:creator>Yorika Hammett</dc:creator>
			<dc:creator>Morgan Pizzuti</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020048</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-14</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-14</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>48</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020048</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/48</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/47">

	<title>Pharmacy, Vol. 14, Pages 47: Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020&amp;ndash;2025)</title>
	<link>https://www.mdpi.com/2226-4787/14/2/47</link>
	<description>This systematic integrative review evaluates the effectiveness of SGLT2 inhibitors in relation to improving glycaemic control, reducing cardiovascular events, and preserving renal function based on the latest published evidence. Search for publications referenced in PubMed, from January 2020 to January 2025, was conducted; 48 abstracts were reviewed, and 27 full-text articles were included for analysis&amp;amp;mdash;systematic reviews, meta-analyses, narrative reviews and comparative effectiveness studies. SGLT2 inhibitors are effective in reducing glucose levels, but the magnitude of reduction varies compared to other classes of antidiabetics. A noticeable reduction in the risk of major cardiovascular events, cardiovascular and all-cause mortality was reported, particularly compared to DPP-4 inhibitors and placebo. SGLT2 inhibitors demonstrated the most pronounced and consistent benefits in reducing hospitalisation for heart failure among all other evaluated classes. However, outcomes like myocardial infarction and stroke results were inconsistent. Renal outcomes consistently favoured SGLT2 inhibitors in reducing the risk of acute kidney injury, slowing chronic kidney disease and lowering the risk of end-stage kidney disease. SGLT2 inhibitors provide consistent glucose-lowering, cardiovascular and renal benefits. However, heterogeneity in study designs, patient populations, and treatment durations does not allow drawing definitive conclusions and highlights the need for future research focused on conducting well-designed trials with standardised methodology.</description>
	<pubDate>2026-03-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 47: Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020&amp;ndash;2025)</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/47">doi: 10.3390/pharmacy14020047</a></p>
	<p>Authors:
		Desislava Stanimirova
		Guenka Petrova
		Zornitsa Mitkova
		</p>
	<p>This systematic integrative review evaluates the effectiveness of SGLT2 inhibitors in relation to improving glycaemic control, reducing cardiovascular events, and preserving renal function based on the latest published evidence. Search for publications referenced in PubMed, from January 2020 to January 2025, was conducted; 48 abstracts were reviewed, and 27 full-text articles were included for analysis&amp;amp;mdash;systematic reviews, meta-analyses, narrative reviews and comparative effectiveness studies. SGLT2 inhibitors are effective in reducing glucose levels, but the magnitude of reduction varies compared to other classes of antidiabetics. A noticeable reduction in the risk of major cardiovascular events, cardiovascular and all-cause mortality was reported, particularly compared to DPP-4 inhibitors and placebo. SGLT2 inhibitors demonstrated the most pronounced and consistent benefits in reducing hospitalisation for heart failure among all other evaluated classes. However, outcomes like myocardial infarction and stroke results were inconsistent. Renal outcomes consistently favoured SGLT2 inhibitors in reducing the risk of acute kidney injury, slowing chronic kidney disease and lowering the risk of end-stage kidney disease. SGLT2 inhibitors provide consistent glucose-lowering, cardiovascular and renal benefits. However, heterogeneity in study designs, patient populations, and treatment durations does not allow drawing definitive conclusions and highlights the need for future research focused on conducting well-designed trials with standardised methodology.</p>
	]]></content:encoded>

	<dc:title>Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020&amp;amp;ndash;2025)</dc:title>
			<dc:creator>Desislava Stanimirova</dc:creator>
			<dc:creator>Guenka Petrova</dc:creator>
			<dc:creator>Zornitsa Mitkova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020047</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>47</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020047</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/47</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/46">

	<title>Pharmacy, Vol. 14, Pages 46: Older Adults&amp;rsquo; Access to Pharmacological Treatment, a Human Right to Health: Scoping Review (2020&amp;ndash;2025)</title>
	<link>https://www.mdpi.com/2226-4787/14/2/46</link>
	<description>Background: Limitations in timely and equitable access to essential medicines among older adults not only constitute a clinical barrier to the effective management of chronic conditions, but also represent a violation of the fundamental right to life, health and the principles of dignity, equality and non-discrimination that safeguard this population within the framework of human rights. Objective: To examine access to essential medicines for older adults with high-cost chronic conditions as a constitutive dimension of the fundamental rights to health, life and human dignity, in accordance with international human rights standards. Design: A literature review was conducted of articles published between 2020 and March 2025 in five databases, using the search terms: &amp;amp;ldquo;pharmacological treatment,&amp;amp;rdquo; &amp;amp;ldquo;access to health,&amp;amp;rdquo; &amp;amp;ldquo;chronic diseases,&amp;amp;rdquo; and &amp;amp;ldquo;barriers to access.&amp;amp;rdquo; After evaluating the inclusion criteria (language and year) and exclusion criteria (case studies), 12 articles were selected. A narrative synthesis was performed on the following aspects: application of the principles of the right to health, barriers to access, and rights violated or at risk. Results: The expansion of health coverage faces several barriers that violate fundamental principles of the right to health: equity, accessibility to medical advances, and long-term, quality, and specialized services, thus limiting autonomy. In conclusion, guaranteeing access to pharmacological treatments in old age will contribute to building more just and humane societies through public policies on coverage and pharmaceutical education, the simplification of treatment regimens, and the implementation of programs that allow people to age with dignity, considering health a human right based on equality and non-discrimination, participation and transparency.</description>
	<pubDate>2026-03-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 46: Older Adults&amp;rsquo; Access to Pharmacological Treatment, a Human Right to Health: Scoping Review (2020&amp;ndash;2025)</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/46">doi: 10.3390/pharmacy14020046</a></p>
	<p>Authors:
		Doris Cardona
		Valeria Santacruz-Restrepo
		Juliana Madrigal-Cadavid
		Alejandra Rendón-Montoya
		Angela Segura-Cardona
		Jorge Iván Estrada-Acevedo
		Marcela Agudelo-Botero
		</p>
	<p>Background: Limitations in timely and equitable access to essential medicines among older adults not only constitute a clinical barrier to the effective management of chronic conditions, but also represent a violation of the fundamental right to life, health and the principles of dignity, equality and non-discrimination that safeguard this population within the framework of human rights. Objective: To examine access to essential medicines for older adults with high-cost chronic conditions as a constitutive dimension of the fundamental rights to health, life and human dignity, in accordance with international human rights standards. Design: A literature review was conducted of articles published between 2020 and March 2025 in five databases, using the search terms: &amp;amp;ldquo;pharmacological treatment,&amp;amp;rdquo; &amp;amp;ldquo;access to health,&amp;amp;rdquo; &amp;amp;ldquo;chronic diseases,&amp;amp;rdquo; and &amp;amp;ldquo;barriers to access.&amp;amp;rdquo; After evaluating the inclusion criteria (language and year) and exclusion criteria (case studies), 12 articles were selected. A narrative synthesis was performed on the following aspects: application of the principles of the right to health, barriers to access, and rights violated or at risk. Results: The expansion of health coverage faces several barriers that violate fundamental principles of the right to health: equity, accessibility to medical advances, and long-term, quality, and specialized services, thus limiting autonomy. In conclusion, guaranteeing access to pharmacological treatments in old age will contribute to building more just and humane societies through public policies on coverage and pharmaceutical education, the simplification of treatment regimens, and the implementation of programs that allow people to age with dignity, considering health a human right based on equality and non-discrimination, participation and transparency.</p>
	]]></content:encoded>

	<dc:title>Older Adults&amp;amp;rsquo; Access to Pharmacological Treatment, a Human Right to Health: Scoping Review (2020&amp;amp;ndash;2025)</dc:title>
			<dc:creator>Doris Cardona</dc:creator>
			<dc:creator>Valeria Santacruz-Restrepo</dc:creator>
			<dc:creator>Juliana Madrigal-Cadavid</dc:creator>
			<dc:creator>Alejandra Rendón-Montoya</dc:creator>
			<dc:creator>Angela Segura-Cardona</dc:creator>
			<dc:creator>Jorge Iván Estrada-Acevedo</dc:creator>
			<dc:creator>Marcela Agudelo-Botero</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020046</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>46</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020046</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/46</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/45">

	<title>Pharmacy, Vol. 14, Pages 45: Intention/Reflection (I/R) Practice Creates a Deeper APPE Connection for Student Pharmacists After COVID-19</title>
	<link>https://www.mdpi.com/2226-4787/14/2/45</link>
	<description>(1) Background: In response to the educational challenges brought on by the COVID-19 pandemic, APPE preceptors implemented the Intention/Reflection (I/R) practice as a structured engagement tool. I/R is designed to promote engagement, motivation, metacognitive growth, and self-awareness among student pharmacists with the goal of enhancing learning experiences in diverse APPE settings. This project aimed to assess the impact of I/R strategies on student pharmacist engagement during APPEs in the post-pandemic landscape, with the overarching goal of identifying and advancing best practices in experiential pharmacy education. (2) Methods: This retrospective qualitative study included 20 student pharmacists from two U.S. colleges who participated in APPE elective rotations featuring I/R activities. Student pharmacists&amp;amp;rsquo; responses to five structured I/R prompts were collected and thematically analyzed by two independent researchers using qualitative data analysis software. (3) Results: Four themes were identified in the I/R responses: two themes each from the intention and reflection responses. The intention themes &amp;amp;ldquo;Embracing Discomfort as a Catalyst for Confidence, Engagement, and Leadership Growth&amp;amp;rdquo; and &amp;amp;ldquo;Purposeful Precision: Growing into Adaptive Leadership&amp;amp;rdquo; both illustrate the students&amp;amp;rsquo; journeys as they develop greater confidence and resilience in overcoming challenges. The reflection themes &amp;amp;ldquo;Reflection as a Catalyst for Professional Learning and Engagement&amp;amp;rdquo; and &amp;amp;ldquo;Reflection as a Tool for Focused Growth and Self-Awareness&amp;amp;rdquo; synthesized the evolution of the student pharmacist and forward thinking for future career. (4) Conclusion: Overall, participants perceived the I/R practice as transformative, citing benefits such as sustained learning, increased confidence, and continued professional development. These findings suggest that integrating I/R into experiential pharmacy education can significantly enhance student engagement and contribute to best practices for post-pandemic pharmacy training.</description>
	<pubDate>2026-03-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 45: Intention/Reflection (I/R) Practice Creates a Deeper APPE Connection for Student Pharmacists After COVID-19</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/45">doi: 10.3390/pharmacy14020045</a></p>
	<p>Authors:
		Kerry K. Fierke
		Gardner A. Lepp
		Alina Cernasev
		</p>
	<p>(1) Background: In response to the educational challenges brought on by the COVID-19 pandemic, APPE preceptors implemented the Intention/Reflection (I/R) practice as a structured engagement tool. I/R is designed to promote engagement, motivation, metacognitive growth, and self-awareness among student pharmacists with the goal of enhancing learning experiences in diverse APPE settings. This project aimed to assess the impact of I/R strategies on student pharmacist engagement during APPEs in the post-pandemic landscape, with the overarching goal of identifying and advancing best practices in experiential pharmacy education. (2) Methods: This retrospective qualitative study included 20 student pharmacists from two U.S. colleges who participated in APPE elective rotations featuring I/R activities. Student pharmacists&amp;amp;rsquo; responses to five structured I/R prompts were collected and thematically analyzed by two independent researchers using qualitative data analysis software. (3) Results: Four themes were identified in the I/R responses: two themes each from the intention and reflection responses. The intention themes &amp;amp;ldquo;Embracing Discomfort as a Catalyst for Confidence, Engagement, and Leadership Growth&amp;amp;rdquo; and &amp;amp;ldquo;Purposeful Precision: Growing into Adaptive Leadership&amp;amp;rdquo; both illustrate the students&amp;amp;rsquo; journeys as they develop greater confidence and resilience in overcoming challenges. The reflection themes &amp;amp;ldquo;Reflection as a Catalyst for Professional Learning and Engagement&amp;amp;rdquo; and &amp;amp;ldquo;Reflection as a Tool for Focused Growth and Self-Awareness&amp;amp;rdquo; synthesized the evolution of the student pharmacist and forward thinking for future career. (4) Conclusion: Overall, participants perceived the I/R practice as transformative, citing benefits such as sustained learning, increased confidence, and continued professional development. These findings suggest that integrating I/R into experiential pharmacy education can significantly enhance student engagement and contribute to best practices for post-pandemic pharmacy training.</p>
	]]></content:encoded>

	<dc:title>Intention/Reflection (I/R) Practice Creates a Deeper APPE Connection for Student Pharmacists After COVID-19</dc:title>
			<dc:creator>Kerry K. Fierke</dc:creator>
			<dc:creator>Gardner A. Lepp</dc:creator>
			<dc:creator>Alina Cernasev</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020045</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-05</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-05</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>45</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020045</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/45</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/44">

	<title>Pharmacy, Vol. 14, Pages 44: Effects of Thickening Agents Used in Dysphagia on the In Vitro Dissolution of Gliclazide</title>
	<link>https://www.mdpi.com/2226-4787/14/2/44</link>
	<description>Dysphagia is common among older adults and frequently necessitates the use of thickening agents to facilitate safe swallowing of medicines, which may in turn alter their bioavailability. This study investigated the impact of two commercially available lubricants&amp;amp;mdash;Gloup&amp;amp;reg; Forte and extremely thick water&amp;amp;mdash;on the in vitro dissolution behaviour of immediate-release gliclazide tablets. Dissolution studies were conducted using crushed and whole tablets in different media consisting of reverse osmosis water, phosphate buffer (pH 6.8), and 0.1 N HCl at 37 &amp;amp;deg;C. Dissolution profiles were compared using similarity factor (f2) analysis and modelled using established kinetic equations. Gliclazide dissolution was significantly delayed in the presence of Gloup&amp;amp;reg; Forte across all media for both crushed and whole tablets, with f2 values below 50, indicating dissimilar profiles. Dissolution kinetics confirmed that mixing the formulated gliclazide with Gloup&amp;amp;reg; Forte delayed the release and reduced the dissolution rate constant for drug from both crushed and whole gliclazide tablets in media studied.</description>
	<pubDate>2026-03-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 44: Effects of Thickening Agents Used in Dysphagia on the In Vitro Dissolution of Gliclazide</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/44">doi: 10.3390/pharmacy14020044</a></p>
	<p>Authors:
		Ayman Allahham
		Seerat Fatima
		Ieva Stupans
		Thilini Thrimawithana
		Vivek B. Nooney
		</p>
	<p>Dysphagia is common among older adults and frequently necessitates the use of thickening agents to facilitate safe swallowing of medicines, which may in turn alter their bioavailability. This study investigated the impact of two commercially available lubricants&amp;amp;mdash;Gloup&amp;amp;reg; Forte and extremely thick water&amp;amp;mdash;on the in vitro dissolution behaviour of immediate-release gliclazide tablets. Dissolution studies were conducted using crushed and whole tablets in different media consisting of reverse osmosis water, phosphate buffer (pH 6.8), and 0.1 N HCl at 37 &amp;amp;deg;C. Dissolution profiles were compared using similarity factor (f2) analysis and modelled using established kinetic equations. Gliclazide dissolution was significantly delayed in the presence of Gloup&amp;amp;reg; Forte across all media for both crushed and whole tablets, with f2 values below 50, indicating dissimilar profiles. Dissolution kinetics confirmed that mixing the formulated gliclazide with Gloup&amp;amp;reg; Forte delayed the release and reduced the dissolution rate constant for drug from both crushed and whole gliclazide tablets in media studied.</p>
	]]></content:encoded>

	<dc:title>Effects of Thickening Agents Used in Dysphagia on the In Vitro Dissolution of Gliclazide</dc:title>
			<dc:creator>Ayman Allahham</dc:creator>
			<dc:creator>Seerat Fatima</dc:creator>
			<dc:creator>Ieva Stupans</dc:creator>
			<dc:creator>Thilini Thrimawithana</dc:creator>
			<dc:creator>Vivek B. Nooney</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020044</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-04</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-04</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>44</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020044</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/44</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/43">

	<title>Pharmacy, Vol. 14, Pages 43: Beta Blocker Intoxications in Belgium: A Data Analysis with Focus on Propranolol</title>
	<link>https://www.mdpi.com/2226-4787/14/2/43</link>
	<description>Background: The issue of beta blocker poisoning has received little attention, despite the widespread use of these compounds in cardiac and neuropsychiatric care. Safety profiles differ, and some beta blockers appear in poisonings far beyond what their usage rates imply. This study characterizes beta blocker intoxication patterns in Belgium, focusing on propranolol, by integrating national prescription data, poisoning reports, and adverse drug reaction records. Methods: Belgian prescription data, poison centre reports, and European ADR databases were analysed to identify intoxication patterns and demographic or clinical characteristics associated with these events. Results: Poisoning data revealed propranolol as markedly overrepresented compared to prescription rates and was the primary beta blocker implicated in self-harm-related overdoses. These cases occurred mainly in women, younger individuals, and patients with psychiatric or cardiovascular comorbidities. Co-exposures with benzodiazepines, antidepressants, and other psychoactive agents were frequent, and propranolol was linked to more complex intoxication patterns than other beta blockers. Conclusions: Propranolol shows a distinct toxicological profile and is disproportionately involved in intoxications, especially in vulnerable groups and in combination with psychoactive drugs. These findings highlight the need for greater awareness, targeted prevention, and careful monitoring.</description>
	<pubDate>2026-03-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 43: Beta Blocker Intoxications in Belgium: A Data Analysis with Focus on Propranolol</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/43">doi: 10.3390/pharmacy14020043</a></p>
	<p>Authors:
		Brechje van den Boogaard
		Maria van de Lavoir
		Rani Robeyns
		Celine Gys
		Adrian Covaci
		Hans De Loof
		</p>
	<p>Background: The issue of beta blocker poisoning has received little attention, despite the widespread use of these compounds in cardiac and neuropsychiatric care. Safety profiles differ, and some beta blockers appear in poisonings far beyond what their usage rates imply. This study characterizes beta blocker intoxication patterns in Belgium, focusing on propranolol, by integrating national prescription data, poisoning reports, and adverse drug reaction records. Methods: Belgian prescription data, poison centre reports, and European ADR databases were analysed to identify intoxication patterns and demographic or clinical characteristics associated with these events. Results: Poisoning data revealed propranolol as markedly overrepresented compared to prescription rates and was the primary beta blocker implicated in self-harm-related overdoses. These cases occurred mainly in women, younger individuals, and patients with psychiatric or cardiovascular comorbidities. Co-exposures with benzodiazepines, antidepressants, and other psychoactive agents were frequent, and propranolol was linked to more complex intoxication patterns than other beta blockers. Conclusions: Propranolol shows a distinct toxicological profile and is disproportionately involved in intoxications, especially in vulnerable groups and in combination with psychoactive drugs. These findings highlight the need for greater awareness, targeted prevention, and careful monitoring.</p>
	]]></content:encoded>

	<dc:title>Beta Blocker Intoxications in Belgium: A Data Analysis with Focus on Propranolol</dc:title>
			<dc:creator>Brechje van den Boogaard</dc:creator>
			<dc:creator>Maria van de Lavoir</dc:creator>
			<dc:creator>Rani Robeyns</dc:creator>
			<dc:creator>Celine Gys</dc:creator>
			<dc:creator>Adrian Covaci</dc:creator>
			<dc:creator>Hans De Loof</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020043</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-04</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-04</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>43</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020043</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/43</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/42">

	<title>Pharmacy, Vol. 14, Pages 42: A University-Led Take-Back Program for Pharmaceutical Waste Management: Eleven Years of Real-World Evidence on Medication Non-Use and Disposal Patterns</title>
	<link>https://www.mdpi.com/2226-4787/14/2/42</link>
	<description>Background/Objectives: Improper medication use, premature treatment discontinuation, and inadequate disposal contribute to irrational drug consumption and environmental contamination. Although pharmaceutical take-back programs have expanded globally, real-world evidence on household medication accumulation in academic and community settings remains limited. This study aimed to describe longitudinal patterns of medication collection during an eleven-year university-based take-back campaign, with detailed pharmacological characterization available for selected post-pandemic years. Methods: Real-world data were analyzed from a sustainable medication take-back campaign conducted annually at the University of Colima between 2015 and 2025. Expired or unused medications were voluntarily returned by students and community members. Total collected weight was recorded for all years, while detailed classification by dosage form, Anatomical Therapeutic Chemical (ATC) group, and Mexican regulatory fraction (Fractions II, IV, V, and VI) was performed for years with complete records (2023&amp;amp;ndash;2025). All materials were disposed of through an authorized hazardous-waste company in compliance with NOM-052-SEMARNAT-2005. Descriptive analyses were performed using SPSS version 29.0. Results: Approximately 3.9 tons of pharmaceutical products were collected over eleven years, reflecting persistent household accumulation of unused or expired medicines. In the years with detailed analysis, oral solid dosage forms predominated. In 2025, ATC groups M, A, and C were most frequently returned, consistent with medications used for chronic conditions. Therapeutic composition varied annually, with NSAIDs/analgesics predominating in 2023&amp;amp;ndash;2024 and antibiotics in 2025. Across analyzed years, 5&amp;amp;ndash;7% of collected items corresponded to non-medication products. Conclusions: This long-term campaign provides valuable real-world evidence on medication non-use and disposal, highlighting ongoing challenges in rational medicine use, treatment continuity, and environmentally responsible pharmaceutical waste management.</description>
	<pubDate>2026-03-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 42: A University-Led Take-Back Program for Pharmaceutical Waste Management: Eleven Years of Real-World Evidence on Medication Non-Use and Disposal Patterns</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/42">doi: 10.3390/pharmacy14020042</a></p>
	<p>Authors:
		Alejandra E. Hernández-Rangel
		Gustavo A. Hernández-Fuentes
		Iván Delgado-Enciso
		Hortensia Parra-Delgado
		Jesús E. Castrejón-Antonio
		Héctor R. Galván-Salazar
		Alicia Olvera-Montejano
		José Guzmán-Esquivel
		Fabian Rojas-Larios
		Josuel Delgado-Enciso
		César G. Silva-Vázquez
		Uriel Díaz-Llerenas
		Juan M. Sánchez-Galindo
		Mario A. Alcalá-Pérez
		Daniel A. Montes-Galindo
		</p>
	<p>Background/Objectives: Improper medication use, premature treatment discontinuation, and inadequate disposal contribute to irrational drug consumption and environmental contamination. Although pharmaceutical take-back programs have expanded globally, real-world evidence on household medication accumulation in academic and community settings remains limited. This study aimed to describe longitudinal patterns of medication collection during an eleven-year university-based take-back campaign, with detailed pharmacological characterization available for selected post-pandemic years. Methods: Real-world data were analyzed from a sustainable medication take-back campaign conducted annually at the University of Colima between 2015 and 2025. Expired or unused medications were voluntarily returned by students and community members. Total collected weight was recorded for all years, while detailed classification by dosage form, Anatomical Therapeutic Chemical (ATC) group, and Mexican regulatory fraction (Fractions II, IV, V, and VI) was performed for years with complete records (2023&amp;amp;ndash;2025). All materials were disposed of through an authorized hazardous-waste company in compliance with NOM-052-SEMARNAT-2005. Descriptive analyses were performed using SPSS version 29.0. Results: Approximately 3.9 tons of pharmaceutical products were collected over eleven years, reflecting persistent household accumulation of unused or expired medicines. In the years with detailed analysis, oral solid dosage forms predominated. In 2025, ATC groups M, A, and C were most frequently returned, consistent with medications used for chronic conditions. Therapeutic composition varied annually, with NSAIDs/analgesics predominating in 2023&amp;amp;ndash;2024 and antibiotics in 2025. Across analyzed years, 5&amp;amp;ndash;7% of collected items corresponded to non-medication products. Conclusions: This long-term campaign provides valuable real-world evidence on medication non-use and disposal, highlighting ongoing challenges in rational medicine use, treatment continuity, and environmentally responsible pharmaceutical waste management.</p>
	]]></content:encoded>

	<dc:title>A University-Led Take-Back Program for Pharmaceutical Waste Management: Eleven Years of Real-World Evidence on Medication Non-Use and Disposal Patterns</dc:title>
			<dc:creator>Alejandra E. Hernández-Rangel</dc:creator>
			<dc:creator>Gustavo A. Hernández-Fuentes</dc:creator>
			<dc:creator>Iván Delgado-Enciso</dc:creator>
			<dc:creator>Hortensia Parra-Delgado</dc:creator>
			<dc:creator>Jesús E. Castrejón-Antonio</dc:creator>
			<dc:creator>Héctor R. Galván-Salazar</dc:creator>
			<dc:creator>Alicia Olvera-Montejano</dc:creator>
			<dc:creator>José Guzmán-Esquivel</dc:creator>
			<dc:creator>Fabian Rojas-Larios</dc:creator>
			<dc:creator>Josuel Delgado-Enciso</dc:creator>
			<dc:creator>César G. Silva-Vázquez</dc:creator>
			<dc:creator>Uriel Díaz-Llerenas</dc:creator>
			<dc:creator>Juan M. Sánchez-Galindo</dc:creator>
			<dc:creator>Mario A. Alcalá-Pérez</dc:creator>
			<dc:creator>Daniel A. Montes-Galindo</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020042</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>42</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020042</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/42</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/41">

	<title>Pharmacy, Vol. 14, Pages 41: Pharmacy Students&amp;rsquo; Perceptions of Self-Reflection and Peer and Educator Feedback on the Development of Patient Counselling Skills: A Qualitative Analysis</title>
	<link>https://www.mdpi.com/2226-4787/14/2/41</link>
	<description>(1) Background: Simulation is an effective way to develop practical pharmacy skills; combining simulation and self-reflection can increase impacts on learning. While existing literature highlights the benefits of reflection in developing self-awareness, critical thinking, and professional skills, there are few specific insights into how reflective practices enhance learning in patient counselling role-plays. This study aimed to explore pharmacy students&amp;amp;rsquo; perceptions of self-reflection and peer and educator feedback on the development of patient counselling skills. (2) Methods: Thematic analysis of student reflections on learning in patient counselling activities. Responses to four structured self-reflection prompts were collected and analyzed thematically. (3) Results: Reflections from 201 students were analyzed. We identified four themes and ten associated subthemes: impact of peer feedback (subthemes supportive peer dynamics and developing a personal counselling style through peer practice); impact of self-reflection and assessment (subthemes goal setting through self-reflection and video review as a tool for skill refinement); impact of educator feedback (subthemes feedback variation in learning growth and addressing self-doubt); and professional identity (subthemes value pharmacists can bring, struggles in real-life practice, incorporating feedback to working opportunities, and reinforcing skills to self-reflect in future practice). (4) Conclusions: Integrating consistent, high-quality feedback from educators and peers with self-reflection in patient counselling activities is perceived as valuable to enhancing enhances students&amp;amp;rsquo; learning experiences and preparing them for professional practice.</description>
	<pubDate>2026-03-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 41: Pharmacy Students&amp;rsquo; Perceptions of Self-Reflection and Peer and Educator Feedback on the Development of Patient Counselling Skills: A Qualitative Analysis</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/41">doi: 10.3390/pharmacy14020041</a></p>
	<p>Authors:
		Jessica Pace
		Andrew Bartlett
		Tiffany Iu
		Jonathan Penm
		</p>
	<p>(1) Background: Simulation is an effective way to develop practical pharmacy skills; combining simulation and self-reflection can increase impacts on learning. While existing literature highlights the benefits of reflection in developing self-awareness, critical thinking, and professional skills, there are few specific insights into how reflective practices enhance learning in patient counselling role-plays. This study aimed to explore pharmacy students&amp;amp;rsquo; perceptions of self-reflection and peer and educator feedback on the development of patient counselling skills. (2) Methods: Thematic analysis of student reflections on learning in patient counselling activities. Responses to four structured self-reflection prompts were collected and analyzed thematically. (3) Results: Reflections from 201 students were analyzed. We identified four themes and ten associated subthemes: impact of peer feedback (subthemes supportive peer dynamics and developing a personal counselling style through peer practice); impact of self-reflection and assessment (subthemes goal setting through self-reflection and video review as a tool for skill refinement); impact of educator feedback (subthemes feedback variation in learning growth and addressing self-doubt); and professional identity (subthemes value pharmacists can bring, struggles in real-life practice, incorporating feedback to working opportunities, and reinforcing skills to self-reflect in future practice). (4) Conclusions: Integrating consistent, high-quality feedback from educators and peers with self-reflection in patient counselling activities is perceived as valuable to enhancing enhances students&amp;amp;rsquo; learning experiences and preparing them for professional practice.</p>
	]]></content:encoded>

	<dc:title>Pharmacy Students&amp;amp;rsquo; Perceptions of Self-Reflection and Peer and Educator Feedback on the Development of Patient Counselling Skills: A Qualitative Analysis</dc:title>
			<dc:creator>Jessica Pace</dc:creator>
			<dc:creator>Andrew Bartlett</dc:creator>
			<dc:creator>Tiffany Iu</dc:creator>
			<dc:creator>Jonathan Penm</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020041</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>41</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020041</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/41</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/40">

	<title>Pharmacy, Vol. 14, Pages 40: Analysis of Pharmacist Interventions to Reduce Medication-Related Problems in a Neonatal Clinical Care Unit</title>
	<link>https://www.mdpi.com/2226-4787/14/2/40</link>
	<description>(1) Background: Medication-related problems (MRPs) are a significant burden on health care systems. Pharmacists play an important role in preventing and reducing MRPs through clinical review, education, and policy governance. This study analyzed pharmacist interventions within a 92-bed neonatal clinical care unit to better understand MRPs and guide targeted medication safety initiatives. (2) Methods: All pharmacist interventions documented in REDCap&amp;amp;reg; between 1 July 2022 and 30 June 2025 were analyzed identifying MRP incidence, types, and acceptability following interventions. (3) Results: A total of 873 pharmacist interventions were recorded during the study period. The most common MRPs were related to dosing errors (320/873, 36.7%), compliance with hospital policy (152/873, 17.4%), no indication apparent (106/873, 12.1%), drug interactions (66/873, 7.6%), and inadequate laboratory monitoring (40/873, 4.6%). Of these, 545/873, 62.4% were accepted by prescribers, while 228/873, 26.1% had unknown outcomes at the time of data entry. 343/873, 39.3% of interventions documented were from the Neonatal Intensive Care Unit, involving medications such as gentamicin (n = 46/343, 13.4%), benzylpenicillin (n = 37/343, 10.8%), caffeine (n = 34/343, 9.9%), parenteral nutrition (n = 23/343, 6.7%), and morphine (n = 16/343, 4.7%) and meropenem (n = 16/343, 4.7%)). (4) Conclusions: Regular analysis of pharmacist interventions provides valuable insights into local MRP trends and highlights opportunities for quality improvement and education.</description>
	<pubDate>2026-03-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 40: Analysis of Pharmacist Interventions to Reduce Medication-Related Problems in a Neonatal Clinical Care Unit</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/40">doi: 10.3390/pharmacy14020040</a></p>
	<p>Authors:
		Stephanie W. K. Teoh
		Tamara Lebedevs
		Geena Dickson
		Marcus Femia
		Nabeelah Mukadam
		</p>
	<p>(1) Background: Medication-related problems (MRPs) are a significant burden on health care systems. Pharmacists play an important role in preventing and reducing MRPs through clinical review, education, and policy governance. This study analyzed pharmacist interventions within a 92-bed neonatal clinical care unit to better understand MRPs and guide targeted medication safety initiatives. (2) Methods: All pharmacist interventions documented in REDCap&amp;amp;reg; between 1 July 2022 and 30 June 2025 were analyzed identifying MRP incidence, types, and acceptability following interventions. (3) Results: A total of 873 pharmacist interventions were recorded during the study period. The most common MRPs were related to dosing errors (320/873, 36.7%), compliance with hospital policy (152/873, 17.4%), no indication apparent (106/873, 12.1%), drug interactions (66/873, 7.6%), and inadequate laboratory monitoring (40/873, 4.6%). Of these, 545/873, 62.4% were accepted by prescribers, while 228/873, 26.1% had unknown outcomes at the time of data entry. 343/873, 39.3% of interventions documented were from the Neonatal Intensive Care Unit, involving medications such as gentamicin (n = 46/343, 13.4%), benzylpenicillin (n = 37/343, 10.8%), caffeine (n = 34/343, 9.9%), parenteral nutrition (n = 23/343, 6.7%), and morphine (n = 16/343, 4.7%) and meropenem (n = 16/343, 4.7%)). (4) Conclusions: Regular analysis of pharmacist interventions provides valuable insights into local MRP trends and highlights opportunities for quality improvement and education.</p>
	]]></content:encoded>

	<dc:title>Analysis of Pharmacist Interventions to Reduce Medication-Related Problems in a Neonatal Clinical Care Unit</dc:title>
			<dc:creator>Stephanie W. K. Teoh</dc:creator>
			<dc:creator>Tamara Lebedevs</dc:creator>
			<dc:creator>Geena Dickson</dc:creator>
			<dc:creator>Marcus Femia</dc:creator>
			<dc:creator>Nabeelah Mukadam</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020040</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>40</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020040</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/40</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/39">

	<title>Pharmacy, Vol. 14, Pages 39: Exploring Community Pharmacists&amp;rsquo; Awareness, Attitudes, and Experiences with Digital Health Technologies: A Focus on Mobile Applications for Diabetes Mellitus Self-Management</title>
	<link>https://www.mdpi.com/2226-4787/14/2/39</link>
	<description>Diabetes mellitus is a growing global health challenge, and digital health technologies offer new opportunities to support self-management. Mobile applications can benefit both patients and healthcare professionals; however, awareness and integration of these tools into community pharmacy practice remain limited. As accessible frontline providers, pharmacists are well positioned to promote digital health, yet their readiness and engagement require further investigation. A cross-sectional survey was conducted among community pharmacists in Serbia using a structured questionnaire. Developed through a consensus-based process, the instrument assessed pharmacists&amp;amp;rsquo; awareness, attitudes, and experiences with digital health technologies, focusing on mobile applications for diabetes self-management. Only 15.8% of pharmacists were aware of such applications, and 2.4% reported receiving relevant training. Higher digital health technology literacy was associated with greater awareness, confidence, and preference for digital learning. Most participants supported expanding pharmacists&amp;amp;rsquo; roles in advising patients on digital tools and expressed interest in structured education and official guidance. These findings indicate limited awareness and training in mobile health applications among community pharmacists. Enhancing digital competencies through targeted education and structured guidance may facilitate greater integration of digital tools into routine pharmacy practice and strengthen pharmacists&amp;amp;rsquo; roles in chronic disease management.</description>
	<pubDate>2026-03-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 39: Exploring Community Pharmacists&amp;rsquo; Awareness, Attitudes, and Experiences with Digital Health Technologies: A Focus on Mobile Applications for Diabetes Mellitus Self-Management</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/39">doi: 10.3390/pharmacy14020039</a></p>
	<p>Authors:
		Dušan Vukmirović
		Dušanka Krajnović
		Marina Odalović
		</p>
	<p>Diabetes mellitus is a growing global health challenge, and digital health technologies offer new opportunities to support self-management. Mobile applications can benefit both patients and healthcare professionals; however, awareness and integration of these tools into community pharmacy practice remain limited. As accessible frontline providers, pharmacists are well positioned to promote digital health, yet their readiness and engagement require further investigation. A cross-sectional survey was conducted among community pharmacists in Serbia using a structured questionnaire. Developed through a consensus-based process, the instrument assessed pharmacists&amp;amp;rsquo; awareness, attitudes, and experiences with digital health technologies, focusing on mobile applications for diabetes self-management. Only 15.8% of pharmacists were aware of such applications, and 2.4% reported receiving relevant training. Higher digital health technology literacy was associated with greater awareness, confidence, and preference for digital learning. Most participants supported expanding pharmacists&amp;amp;rsquo; roles in advising patients on digital tools and expressed interest in structured education and official guidance. These findings indicate limited awareness and training in mobile health applications among community pharmacists. Enhancing digital competencies through targeted education and structured guidance may facilitate greater integration of digital tools into routine pharmacy practice and strengthen pharmacists&amp;amp;rsquo; roles in chronic disease management.</p>
	]]></content:encoded>

	<dc:title>Exploring Community Pharmacists&amp;amp;rsquo; Awareness, Attitudes, and Experiences with Digital Health Technologies: A Focus on Mobile Applications for Diabetes Mellitus Self-Management</dc:title>
			<dc:creator>Dušan Vukmirović</dc:creator>
			<dc:creator>Dušanka Krajnović</dc:creator>
			<dc:creator>Marina Odalović</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020039</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>39</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020039</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/39</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/2/38">

	<title>Pharmacy, Vol. 14, Pages 38: Impact of the COVID-19 Pandemic on Community Pharmacy Services in New Zealand: A Repeated Cross-Sectional Best&amp;ndash;Worst Scaling Analysis</title>
	<link>https://www.mdpi.com/2226-4787/14/2/38</link>
	<description>Introduction: This repeated cross-sectional study examined community pharmacies in Aotearoa New Zealand and the services they provide, including retail, dispensing, and expanded scope services (e.g., minor ailment management). Methods: Two cross-sectional surveys were conducted in 2021 (n = 504) and 2023 (n = 1000). Both assessed demographics, service use, and perceptions of pharmacists. The 2021 survey focused on trust, approachability, and role awareness, while the 2023 survey added willingness to pay, telehealth use, and comparisons with other health professionals. Best&amp;amp;ndash;Worst Scaling and logistic regression quantified and compared preferences. Results: Prescription filling remained the most preferred service, while beauty product sales were least preferred. Preference for vaccination declined, indicating post-pandemic shifts in preventive care. Trust in pharmacists remained high, with strong comfort discussing health needs. Awareness of pharmacist roles improved slightly, though cost barriers persisted. Conclusions: Consumer priorities for prescription services remained stable, while interest in vaccination declined. The low preference for non-clinical retail activities suggests pharmacies should focus on health services. The high trust in pharmacists supports expanded clinical roles, but targeted policies and funding are needed to reduce cost barriers and enhance equitable access to primary healthcare.</description>
	<pubDate>2026-03-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 38: Impact of the COVID-19 Pandemic on Community Pharmacy Services in New Zealand: A Repeated Cross-Sectional Best&amp;ndash;Worst Scaling Analysis</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/2/38">doi: 10.3390/pharmacy14020038</a></p>
	<p>Authors:
		Sepideh Sharif
		Carla Dillon
		Shane Scahill
		Carlo Marra
		</p>
	<p>Introduction: This repeated cross-sectional study examined community pharmacies in Aotearoa New Zealand and the services they provide, including retail, dispensing, and expanded scope services (e.g., minor ailment management). Methods: Two cross-sectional surveys were conducted in 2021 (n = 504) and 2023 (n = 1000). Both assessed demographics, service use, and perceptions of pharmacists. The 2021 survey focused on trust, approachability, and role awareness, while the 2023 survey added willingness to pay, telehealth use, and comparisons with other health professionals. Best&amp;amp;ndash;Worst Scaling and logistic regression quantified and compared preferences. Results: Prescription filling remained the most preferred service, while beauty product sales were least preferred. Preference for vaccination declined, indicating post-pandemic shifts in preventive care. Trust in pharmacists remained high, with strong comfort discussing health needs. Awareness of pharmacist roles improved slightly, though cost barriers persisted. Conclusions: Consumer priorities for prescription services remained stable, while interest in vaccination declined. The low preference for non-clinical retail activities suggests pharmacies should focus on health services. The high trust in pharmacists supports expanded clinical roles, but targeted policies and funding are needed to reduce cost barriers and enhance equitable access to primary healthcare.</p>
	]]></content:encoded>

	<dc:title>Impact of the COVID-19 Pandemic on Community Pharmacy Services in New Zealand: A Repeated Cross-Sectional Best&amp;amp;ndash;Worst Scaling Analysis</dc:title>
			<dc:creator>Sepideh Sharif</dc:creator>
			<dc:creator>Carla Dillon</dc:creator>
			<dc:creator>Shane Scahill</dc:creator>
			<dc:creator>Carlo Marra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14020038</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-03-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-03-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>38</prism:startingPage>
		<prism:doi>10.3390/pharmacy14020038</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/2/38</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/37">

	<title>Pharmacy, Vol. 14, Pages 37: PharmReaDy: A Longitudinal Platform for Industry Career Preparation for Student Pharmacists in the U.S.</title>
	<link>https://www.mdpi.com/2226-4787/14/1/37</link>
	<description>As pharmacy career pathways diversify, professional doctoral programs such as PharmD face increasing pressure to demonstrate measurable workforce readiness outcomes within accreditation-constrained curricula. This study describes and evaluates PharmReaDy, a longitudinal, theory-informed workforce readiness platform embedded within a U.S. PharmD program. Guided by Tinto&amp;amp;rsquo;s student retention framework, the platform integrates curricular, co-curricular, and experiential elements, including an industry-focused elective course, national professional competitions, targeted skills workshops, micro-credentialing opportunities, and experiential placements. Outcomes were assessed using enrollment trends, aggregate course evaluation data, academic performance indicators, and downstream participation in industry-aligned opportunities. Enrollment in the elective increased from 8 to 20 to 30 students across three offerings. Mean course evaluation scores across seven learning domains remained consistently high, ranging from 3.7 to 3.9 on a 4-point scale, with no statistically significant differences between cohorts (Welch&amp;amp;rsquo;s t-tests, adjusted p &amp;amp;gt; 0.05) and small positive effect sizes observed over time (Hedges&amp;amp;rsquo; g &amp;amp;asymp; 0.20&amp;amp;ndash;0.29). Students demonstrated strong academic performance and increased participation in industry-focused competitions, scholarships, and post-graduate fellowship pathways. Findings from PharmReaDy indicate that workforce readiness can be meaningfully operationalized as a structured educational function embedded within professional curricula rather than being exclusively deferred to post-graduate training.</description>
	<pubDate>2026-02-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 37: PharmReaDy: A Longitudinal Platform for Industry Career Preparation for Student Pharmacists in the U.S.</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/37">doi: 10.3390/pharmacy14010037</a></p>
	<p>Authors:
		Ashim Malhotra
		</p>
	<p>As pharmacy career pathways diversify, professional doctoral programs such as PharmD face increasing pressure to demonstrate measurable workforce readiness outcomes within accreditation-constrained curricula. This study describes and evaluates PharmReaDy, a longitudinal, theory-informed workforce readiness platform embedded within a U.S. PharmD program. Guided by Tinto&amp;amp;rsquo;s student retention framework, the platform integrates curricular, co-curricular, and experiential elements, including an industry-focused elective course, national professional competitions, targeted skills workshops, micro-credentialing opportunities, and experiential placements. Outcomes were assessed using enrollment trends, aggregate course evaluation data, academic performance indicators, and downstream participation in industry-aligned opportunities. Enrollment in the elective increased from 8 to 20 to 30 students across three offerings. Mean course evaluation scores across seven learning domains remained consistently high, ranging from 3.7 to 3.9 on a 4-point scale, with no statistically significant differences between cohorts (Welch&amp;amp;rsquo;s t-tests, adjusted p &amp;amp;gt; 0.05) and small positive effect sizes observed over time (Hedges&amp;amp;rsquo; g &amp;amp;asymp; 0.20&amp;amp;ndash;0.29). Students demonstrated strong academic performance and increased participation in industry-focused competitions, scholarships, and post-graduate fellowship pathways. Findings from PharmReaDy indicate that workforce readiness can be meaningfully operationalized as a structured educational function embedded within professional curricula rather than being exclusively deferred to post-graduate training.</p>
	]]></content:encoded>

	<dc:title>PharmReaDy: A Longitudinal Platform for Industry Career Preparation for Student Pharmacists in the U.S.</dc:title>
			<dc:creator>Ashim Malhotra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010037</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-13</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-13</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>37</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010037</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/37</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/36">

	<title>Pharmacy, Vol. 14, Pages 36: Pharmacist-Led Flu Vaccination Services in Romanian Community Pharmacies: Barriers, Perceptions, and Implementation Challenges</title>
	<link>https://www.mdpi.com/2226-4787/14/1/36</link>
	<description>Although pharmacist-led vaccination is a global standard for expanding immunization coverage, its adoption in Romania remains at an early stage. While previous studies have focused on early adopters, this research evaluates barriers, perceptions, and readiness among community pharmacies that do not yet provide this service, thereby addressing a critical knowledge gap regarding the &amp;amp;ldquo;non-vaccinating&amp;amp;rdquo; majority. A cross-sectional mixed-methods study was conducted among 208 pharmacists representing national chains, regional networks, and independent pharmacies. Quantitative data were analyzed using Chi-square tests and Spearman correlations to identify structural disparities, while a thematic analysis was employed to explore qualitative insights related to professional identity and operational barriers. We identified a clear mismatch between pharmacies&amp;amp;rsquo; willingness to provide vaccination services and their practical ability to implement them. Independent pharmacies demonstrated a strong intention to adopt vaccination services (71.4%) but were limited by financial constraints, with high implementation costs identified as a significant barrier (p = 0.014). In contrast, national pharmacy chains had sufficient resources yet faced marked staff resistance, with 43.9% reporting extreme reluctance (p = 0.038). These chains were concentrated in the capital region (p = 0.002), thereby positioning other pharmacies as key providers in underserved areas. Furthermore, thematic analysis revealed a deep-seated &amp;amp;ldquo;professional identity&amp;amp;rdquo; crisis, in which pharmacists struggle with the transition from medication specialists to clinical practitioners. The expansion of vaccination services cannot rely on a &amp;amp;ldquo;one-size-fits-all&amp;amp;rdquo; strategy. Successful national implementation requires a segmented policy approach, including financial subsidies to support independent pharmacies, change management strategies to engage the corporate workforce, and targeted regulatory education for regional networks to prevent vaccination deserts.</description>
	<pubDate>2026-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 36: Pharmacist-Led Flu Vaccination Services in Romanian Community Pharmacies: Barriers, Perceptions, and Implementation Challenges</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/36">doi: 10.3390/pharmacy14010036</a></p>
	<p>Authors:
		Marius Calin Chereches
		Mihaela Simona Naidin
		Alexandra Grosan
		Radu Antoniu Patrascu
		Anca-Maria Capraru
		Marina Daniela Dimulescu
		Adina Turcu-Stiolica
		</p>
	<p>Although pharmacist-led vaccination is a global standard for expanding immunization coverage, its adoption in Romania remains at an early stage. While previous studies have focused on early adopters, this research evaluates barriers, perceptions, and readiness among community pharmacies that do not yet provide this service, thereby addressing a critical knowledge gap regarding the &amp;amp;ldquo;non-vaccinating&amp;amp;rdquo; majority. A cross-sectional mixed-methods study was conducted among 208 pharmacists representing national chains, regional networks, and independent pharmacies. Quantitative data were analyzed using Chi-square tests and Spearman correlations to identify structural disparities, while a thematic analysis was employed to explore qualitative insights related to professional identity and operational barriers. We identified a clear mismatch between pharmacies&amp;amp;rsquo; willingness to provide vaccination services and their practical ability to implement them. Independent pharmacies demonstrated a strong intention to adopt vaccination services (71.4%) but were limited by financial constraints, with high implementation costs identified as a significant barrier (p = 0.014). In contrast, national pharmacy chains had sufficient resources yet faced marked staff resistance, with 43.9% reporting extreme reluctance (p = 0.038). These chains were concentrated in the capital region (p = 0.002), thereby positioning other pharmacies as key providers in underserved areas. Furthermore, thematic analysis revealed a deep-seated &amp;amp;ldquo;professional identity&amp;amp;rdquo; crisis, in which pharmacists struggle with the transition from medication specialists to clinical practitioners. The expansion of vaccination services cannot rely on a &amp;amp;ldquo;one-size-fits-all&amp;amp;rdquo; strategy. Successful national implementation requires a segmented policy approach, including financial subsidies to support independent pharmacies, change management strategies to engage the corporate workforce, and targeted regulatory education for regional networks to prevent vaccination deserts.</p>
	]]></content:encoded>

	<dc:title>Pharmacist-Led Flu Vaccination Services in Romanian Community Pharmacies: Barriers, Perceptions, and Implementation Challenges</dc:title>
			<dc:creator>Marius Calin Chereches</dc:creator>
			<dc:creator>Mihaela Simona Naidin</dc:creator>
			<dc:creator>Alexandra Grosan</dc:creator>
			<dc:creator>Radu Antoniu Patrascu</dc:creator>
			<dc:creator>Anca-Maria Capraru</dc:creator>
			<dc:creator>Marina Daniela Dimulescu</dc:creator>
			<dc:creator>Adina Turcu-Stiolica</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010036</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>36</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010036</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/36</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/35">

	<title>Pharmacy, Vol. 14, Pages 35: Self-Management, Adherence, and the Role of Pharmaceutical Care in Patients with T2DM in Primary Practice: A Cross-Sectional Survey in Bulgaria</title>
	<link>https://www.mdpi.com/2226-4787/14/1/35</link>
	<description>Background: Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease requiring effective pharmacological treatment, sustained self-management, and patient education. Pharmacists are increasingly recognized as key contributors to diabetes care; however, their role remains underutilized in Bulgaria. This study aimed to assess self-management behaviors, medication adherence, patient awareness, and the perceived role of pharmacists among patients with T2DM in Bulgarian primary care. Methods: A cross-sectional observational study was conducted among 105 patients with T2DM using an anonymous questionnaire based on the Diabetes Self-Management Questionnaire and supplementary items adapted to the local healthcare context. Data were analyzed using descriptive statistics and non-parametric tests to explore associations between demographic characteristics, treatment patterns, self-management behaviors, and educational needs. Results: Most patients were treated with oral antidiabetic therapy (90.0%), predominantly metformin-based regimens (64.0%). Adherence to prescribed pharmacological treatment was high (93.0%), while adherence to dietary recommendations (70.0%), regular physical activity (60.0%), and blood glucose self-monitoring (63.0%) was less consistent. Although 92.0% of participants reported good or excellent disease awareness, 41.0% expressed a need for additional education, particularly regarding confidence in managing hypoglycemia and the use of digital monitoring tools. More than half of respondents (54.0%) had received diabetes-related information from a pharmacist; however, only 38.0% expressed willingness to participate in pharmacist-led education, while 34.0% were undecided. Female sex was associated with a higher prevalence of comorbidities (p = 0.010), while increasing age was associated with reduced metformin use (p = 0.004). Conclusions: Despite good pharmacological adherence and self-reported awareness, gaps remain in lifestyle-related self-management and patient education. The findings support an expanded role for pharmacists in diabetes care, particularly through structured educational and counseling interventions to enhance self-management and complement physician-led treatment.</description>
	<pubDate>2026-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 35: Self-Management, Adherence, and the Role of Pharmaceutical Care in Patients with T2DM in Primary Practice: A Cross-Sectional Survey in Bulgaria</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/35">doi: 10.3390/pharmacy14010035</a></p>
	<p>Authors:
		Petya Milushewa
		Nataliya Chenesheva
		Valentina Petkova
		</p>
	<p>Background: Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease requiring effective pharmacological treatment, sustained self-management, and patient education. Pharmacists are increasingly recognized as key contributors to diabetes care; however, their role remains underutilized in Bulgaria. This study aimed to assess self-management behaviors, medication adherence, patient awareness, and the perceived role of pharmacists among patients with T2DM in Bulgarian primary care. Methods: A cross-sectional observational study was conducted among 105 patients with T2DM using an anonymous questionnaire based on the Diabetes Self-Management Questionnaire and supplementary items adapted to the local healthcare context. Data were analyzed using descriptive statistics and non-parametric tests to explore associations between demographic characteristics, treatment patterns, self-management behaviors, and educational needs. Results: Most patients were treated with oral antidiabetic therapy (90.0%), predominantly metformin-based regimens (64.0%). Adherence to prescribed pharmacological treatment was high (93.0%), while adherence to dietary recommendations (70.0%), regular physical activity (60.0%), and blood glucose self-monitoring (63.0%) was less consistent. Although 92.0% of participants reported good or excellent disease awareness, 41.0% expressed a need for additional education, particularly regarding confidence in managing hypoglycemia and the use of digital monitoring tools. More than half of respondents (54.0%) had received diabetes-related information from a pharmacist; however, only 38.0% expressed willingness to participate in pharmacist-led education, while 34.0% were undecided. Female sex was associated with a higher prevalence of comorbidities (p = 0.010), while increasing age was associated with reduced metformin use (p = 0.004). Conclusions: Despite good pharmacological adherence and self-reported awareness, gaps remain in lifestyle-related self-management and patient education. The findings support an expanded role for pharmacists in diabetes care, particularly through structured educational and counseling interventions to enhance self-management and complement physician-led treatment.</p>
	]]></content:encoded>

	<dc:title>Self-Management, Adherence, and the Role of Pharmaceutical Care in Patients with T2DM in Primary Practice: A Cross-Sectional Survey in Bulgaria</dc:title>
			<dc:creator>Petya Milushewa</dc:creator>
			<dc:creator>Nataliya Chenesheva</dc:creator>
			<dc:creator>Valentina Petkova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010035</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>35</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010035</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/35</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/34">

	<title>Pharmacy, Vol. 14, Pages 34: AIM (Analyze&amp;ndash;Interpret&amp;ndash;Manage): A Novel NAPLEX-Aligned Analytical Assessment Framework for Measuring Individual and Team Critical Thinking Using Generative AI</title>
	<link>https://www.mdpi.com/2226-4787/14/1/34</link>
	<description>Critical thinking is emphasized across ACPE Standards 2025, the Pharmacist Patient Care Process, interprofessional education (IPE) frameworks, and licensure preparation (NAPLEX). Despite this, pharmacy education lacks a practical, theory-grounded framework that operationalizes critical thinking as an observable, assessable reasoning process, particularly in team-based and interprofessional contexts. We developed the AIM (Analyze&amp;amp;ndash;Interpret&amp;amp;ndash;Manage) framework by integrating the Delphi Consensus definition of critical thinking with the AAC&amp;amp;amp;U VALUE framework, translating foundational theory into a concise, measurable, stage-based model applicable to both individual and collective cognition. AIM was tested using qualitative analysis of transcripts of student team discursive narratives of an assigned IPE scenario. Reasoning behaviors were coded by AIM stage and mapped to the 2016 IPEC Core Competencies and the 2025 NAPLEX competencies to ensure professional relevance and external validity. AIM reliably distinguished discrete stages of critical thinking across teams, revealing consistent patterns in how learners analyzed information, interpreted clinical and ethical significance, and managed decisions collaboratively. Mapping demonstrated strong alignment between AIM stages and IPEC and NAPLEX competencies. Our novel AIM framework offers a scalable approach for defining, teaching, and assessing team-based critical thinking in pharmacy education. By operationalizing critical thinking as a staged reasoning process aligned with professional standards, AIM fills a critical gap between educational theory, interprofessional practice, and licensure preparation.</description>
	<pubDate>2026-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 34: AIM (Analyze&amp;ndash;Interpret&amp;ndash;Manage): A Novel NAPLEX-Aligned Analytical Assessment Framework for Measuring Individual and Team Critical Thinking Using Generative AI</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/34">doi: 10.3390/pharmacy14010034</a></p>
	<p>Authors:
		Ashim Malhotra
		</p>
	<p>Critical thinking is emphasized across ACPE Standards 2025, the Pharmacist Patient Care Process, interprofessional education (IPE) frameworks, and licensure preparation (NAPLEX). Despite this, pharmacy education lacks a practical, theory-grounded framework that operationalizes critical thinking as an observable, assessable reasoning process, particularly in team-based and interprofessional contexts. We developed the AIM (Analyze&amp;amp;ndash;Interpret&amp;amp;ndash;Manage) framework by integrating the Delphi Consensus definition of critical thinking with the AAC&amp;amp;amp;U VALUE framework, translating foundational theory into a concise, measurable, stage-based model applicable to both individual and collective cognition. AIM was tested using qualitative analysis of transcripts of student team discursive narratives of an assigned IPE scenario. Reasoning behaviors were coded by AIM stage and mapped to the 2016 IPEC Core Competencies and the 2025 NAPLEX competencies to ensure professional relevance and external validity. AIM reliably distinguished discrete stages of critical thinking across teams, revealing consistent patterns in how learners analyzed information, interpreted clinical and ethical significance, and managed decisions collaboratively. Mapping demonstrated strong alignment between AIM stages and IPEC and NAPLEX competencies. Our novel AIM framework offers a scalable approach for defining, teaching, and assessing team-based critical thinking in pharmacy education. By operationalizing critical thinking as a staged reasoning process aligned with professional standards, AIM fills a critical gap between educational theory, interprofessional practice, and licensure preparation.</p>
	]]></content:encoded>

	<dc:title>AIM (Analyze&amp;amp;ndash;Interpret&amp;amp;ndash;Manage): A Novel NAPLEX-Aligned Analytical Assessment Framework for Measuring Individual and Team Critical Thinking Using Generative AI</dc:title>
			<dc:creator>Ashim Malhotra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010034</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-12</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-12</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>34</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010034</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/34</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/33">

	<title>Pharmacy, Vol. 14, Pages 33: Impact of a Pharmacist-Driven Penicillin Allergy De-Labeling Service (PADLS) on Hospitalized Patients</title>
	<link>https://www.mdpi.com/2226-4787/14/1/33</link>
	<description>Penicillin (PCN) allergies are frequently reported despite a true prevalence of less than 1%, leading to unnecessary avoidance of beta-lactams, broader antimicrobial use, and increased healthcare costs. Pharmacist-driven de-labeling programs offer a strategy to improve antimicrobial stewardship. This single-center, retrospective study evaluated hospitalized adults with a documented PCN allergy and screened by the pharmacist-driven penicillin allergy de-labeling service (PADLS) between 16 January and 26 June 2025. Patients were categorized into a screened cohort and a Full Allergy Reconciliation (FAR) cohort if interviewed using PEN-FAST. Eligible patients underwent direct oral challenge (DOC), penicillin skin testing (PST) plus DOC, or direct de-labeling based on PEN-FAST scoring. Sixty-three patients were screened, and 32 (50.8%) underwent full reconciliation. Among FAR patients, the median PEN-FAST score was 0, and 25 (78.1%) underwent DOC. De-labeling was successful in 28 FAR patients (87.5%). One patient (4%) experienced a mild reaction. Allergy field updates occurred in 69.8% of screened and 96.9% of FAR patients. Antibiotic optimization occurred in 12 FAR patients, saving 78 days of therapy. Estimated cost savings totaled $37,632. PADLS effectively and safely de-labeled PCN allergies, resulting in improved antimicrobial selection, and could generate cost savings, supporting broader implementation of pharmacist-led allergy stewardship programs.</description>
	<pubDate>2026-02-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 33: Impact of a Pharmacist-Driven Penicillin Allergy De-Labeling Service (PADLS) on Hospitalized Patients</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/33">doi: 10.3390/pharmacy14010033</a></p>
	<p>Authors:
		Parker Kaleo
		Natt Patimavirujh
		Kristen Greene
		Nicholas Piccicacco
		Melissa O’Neal
		</p>
	<p>Penicillin (PCN) allergies are frequently reported despite a true prevalence of less than 1%, leading to unnecessary avoidance of beta-lactams, broader antimicrobial use, and increased healthcare costs. Pharmacist-driven de-labeling programs offer a strategy to improve antimicrobial stewardship. This single-center, retrospective study evaluated hospitalized adults with a documented PCN allergy and screened by the pharmacist-driven penicillin allergy de-labeling service (PADLS) between 16 January and 26 June 2025. Patients were categorized into a screened cohort and a Full Allergy Reconciliation (FAR) cohort if interviewed using PEN-FAST. Eligible patients underwent direct oral challenge (DOC), penicillin skin testing (PST) plus DOC, or direct de-labeling based on PEN-FAST scoring. Sixty-three patients were screened, and 32 (50.8%) underwent full reconciliation. Among FAR patients, the median PEN-FAST score was 0, and 25 (78.1%) underwent DOC. De-labeling was successful in 28 FAR patients (87.5%). One patient (4%) experienced a mild reaction. Allergy field updates occurred in 69.8% of screened and 96.9% of FAR patients. Antibiotic optimization occurred in 12 FAR patients, saving 78 days of therapy. Estimated cost savings totaled $37,632. PADLS effectively and safely de-labeled PCN allergies, resulting in improved antimicrobial selection, and could generate cost savings, supporting broader implementation of pharmacist-led allergy stewardship programs.</p>
	]]></content:encoded>

	<dc:title>Impact of a Pharmacist-Driven Penicillin Allergy De-Labeling Service (PADLS) on Hospitalized Patients</dc:title>
			<dc:creator>Parker Kaleo</dc:creator>
			<dc:creator>Natt Patimavirujh</dc:creator>
			<dc:creator>Kristen Greene</dc:creator>
			<dc:creator>Nicholas Piccicacco</dc:creator>
			<dc:creator>Melissa O’Neal</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010033</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-11</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-11</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>33</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010033</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/33</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/32">

	<title>Pharmacy, Vol. 14, Pages 32: Process-Related Incidents in Nuclear Medicine: A Four-Year Single-Center Retrospective Analysis to Support the Implementation of a Scenario-Based Radiopharmacy Training</title>
	<link>https://www.mdpi.com/2226-4787/14/1/32</link>
	<description>Nuclear medicine is a medical specialty combining parenteral radioactive drug handling and complex clinical workflows, making systematic process-related incident (PRI) analysis essential to support healthcare quality improvement. This study reports a four-year single-center retrospective analysis of PRIs in a nuclear medicine department and describes the development and implementation of a scenario-based radiopharmacy training program for nuclear medicine technologists (NMTs) derived from these findings. PRIs were extracted from the institutional reporting system and categorized according to a structured classification. Training scenarios were designed from recurrent radiopharmacy-related PRIs, and their impact was evaluated using a knowledge questionnaire administered pre and post training. A total of 223 PRIs were analyzed, of which 38.6% (n = 86) were related to the radiopharmaceutical circuit. Among these, 28.3% occurred exclusively within the radiopharmacy cleanroom. Administration (19%), dispensing (15%), delivery and reception (15%), and preparation and quality control (15%) of radiopharmaceuticals were the most frequently involved stages. No PRI exceeded a moderate criticality level. Eight NMTs participated in the training program, consisting of an analysis of videos depicting the developed scenarios. The mean knowledge score increased significantly from 7.51/10 before training to 8.46/10 four weeks after training (p = 0.02), with marked improvements in hygiene- and radioactivity-related topics. These results support the use of retrospective PRI analysis as an operational basis for specific, scenario-based training to strengthen safety practices in radiopharmacy settings.</description>
	<pubDate>2026-02-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 32: Process-Related Incidents in Nuclear Medicine: A Four-Year Single-Center Retrospective Analysis to Support the Implementation of a Scenario-Based Radiopharmacy Training</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/32">doi: 10.3390/pharmacy14010032</a></p>
	<p>Authors:
		Yasmine Soualy
		Stéphane C. Renaud
		Jade Torchio
		Juliette Fouillet
		Julie Ensenat
		Léa Rubira
		Cyril Fersing
		</p>
	<p>Nuclear medicine is a medical specialty combining parenteral radioactive drug handling and complex clinical workflows, making systematic process-related incident (PRI) analysis essential to support healthcare quality improvement. This study reports a four-year single-center retrospective analysis of PRIs in a nuclear medicine department and describes the development and implementation of a scenario-based radiopharmacy training program for nuclear medicine technologists (NMTs) derived from these findings. PRIs were extracted from the institutional reporting system and categorized according to a structured classification. Training scenarios were designed from recurrent radiopharmacy-related PRIs, and their impact was evaluated using a knowledge questionnaire administered pre and post training. A total of 223 PRIs were analyzed, of which 38.6% (n = 86) were related to the radiopharmaceutical circuit. Among these, 28.3% occurred exclusively within the radiopharmacy cleanroom. Administration (19%), dispensing (15%), delivery and reception (15%), and preparation and quality control (15%) of radiopharmaceuticals were the most frequently involved stages. No PRI exceeded a moderate criticality level. Eight NMTs participated in the training program, consisting of an analysis of videos depicting the developed scenarios. The mean knowledge score increased significantly from 7.51/10 before training to 8.46/10 four weeks after training (p = 0.02), with marked improvements in hygiene- and radioactivity-related topics. These results support the use of retrospective PRI analysis as an operational basis for specific, scenario-based training to strengthen safety practices in radiopharmacy settings.</p>
	]]></content:encoded>

	<dc:title>Process-Related Incidents in Nuclear Medicine: A Four-Year Single-Center Retrospective Analysis to Support the Implementation of a Scenario-Based Radiopharmacy Training</dc:title>
			<dc:creator>Yasmine Soualy</dc:creator>
			<dc:creator>Stéphane C. Renaud</dc:creator>
			<dc:creator>Jade Torchio</dc:creator>
			<dc:creator>Juliette Fouillet</dc:creator>
			<dc:creator>Julie Ensenat</dc:creator>
			<dc:creator>Léa Rubira</dc:creator>
			<dc:creator>Cyril Fersing</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010032</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-10</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-10</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>32</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010032</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/32</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/31">

	<title>Pharmacy, Vol. 14, Pages 31: From Cosmetic Abuse to Clinical Mismanagement: A National Simulated Patient Study Assessing Community Pharmacists&amp;rsquo; Stewardship of Topical Corticosteroids in Jordan</title>
	<link>https://www.mdpi.com/2226-4787/14/1/31</link>
	<description>Background: Topical Corticosteroids (TCS) are potent therapeutic agents associated with severe local and systemic adverse effects if misused. In Jordan, the unauthorized supply of TCS for cosmetic purposes and the mismanagement of dermatological conditions remain significant public health concerns. This study utilized a repeated-measures simulated patient (SP) methodology to evaluate community pharmacists&amp;amp;rsquo; stewardship of TCS across a spectrum of clinical risks. Methods: A national cross-sectional study was conducted across 380 randomly selected community pharmacies in Jordan. Each pharmacy received four covert visits (N = 1520) corresponding to four distinct clinical scenarios representing different risk levels: cosmetic whitening, acne management, fungal infection, and pediatric diaper rash. The primary outcome was appropriate Practice, defined as the refusal to dispense unsafe medication or the provision of evidence-based alternatives. Results: Stewardship behavior varied significantly by clinical context (p &amp;amp;lt; 0.001). Pharmacists demonstrated a hierarchy of safety, adhering to guidelines most strictly in the Pediatric scenario (82.1% appropriate refusal) but frequently abandoning safety standards in the Cosmetic scenario (30.0% appropriate refusal). Notably, 70.0% of pharmacists dispensed potent steroids for facial whitening, and 26.1% voluntarily offered to compound unauthorized steroid mixtures (Khaltat). In the acne scenario, 52.1% dispensed the contraindicated TCS, while only 37.9% appropriately switched the patient to an evidence-based alternative. In the fungal scenario, 60.0% failed to visually inspect the lesion, leading to a 40.0% rate of inappropriate TCS dispensing. Multivariable regression indicated that pharmacists working in chain pharmacies (aOR: 2.15, 95% CI: 1.68&amp;amp;ndash;2.75) and those holding advanced degrees (PharmD/MSc) (aOR &amp;amp;gt; 1.38) were significantly more likely to practice appropriate TCS stewardship. High workload (&amp;amp;gt;200 prescriptions/day) was a significant barrier to safety (aOR: 0.55). Conclusions: Community pharmacists in Jordan exhibited selective TCS stewardship, demonstrating high vigilance for pediatric safety, but widespread illegal practice regarding cosmetic misuse and differential diagnosis that may be unethical. The study results warrant the need for further urgent research to understand why these practices are occurring and how best to address them.</description>
	<pubDate>2026-02-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 31: From Cosmetic Abuse to Clinical Mismanagement: A National Simulated Patient Study Assessing Community Pharmacists&amp;rsquo; Stewardship of Topical Corticosteroids in Jordan</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/31">doi: 10.3390/pharmacy14010031</a></p>
	<p>Authors:
		Derar H. Abdel-Qader
		Abdullah Albassam
		Esra’ Taybeh
		Nadia Al Mazrouei
		Rana Ibrahim
		Reham Aljalamdeh
		Salim Hamadi
		Alia Saleh
		Sahar Jaradat
		Shorouq Al-Omoush
		</p>
	<p>Background: Topical Corticosteroids (TCS) are potent therapeutic agents associated with severe local and systemic adverse effects if misused. In Jordan, the unauthorized supply of TCS for cosmetic purposes and the mismanagement of dermatological conditions remain significant public health concerns. This study utilized a repeated-measures simulated patient (SP) methodology to evaluate community pharmacists&amp;amp;rsquo; stewardship of TCS across a spectrum of clinical risks. Methods: A national cross-sectional study was conducted across 380 randomly selected community pharmacies in Jordan. Each pharmacy received four covert visits (N = 1520) corresponding to four distinct clinical scenarios representing different risk levels: cosmetic whitening, acne management, fungal infection, and pediatric diaper rash. The primary outcome was appropriate Practice, defined as the refusal to dispense unsafe medication or the provision of evidence-based alternatives. Results: Stewardship behavior varied significantly by clinical context (p &amp;amp;lt; 0.001). Pharmacists demonstrated a hierarchy of safety, adhering to guidelines most strictly in the Pediatric scenario (82.1% appropriate refusal) but frequently abandoning safety standards in the Cosmetic scenario (30.0% appropriate refusal). Notably, 70.0% of pharmacists dispensed potent steroids for facial whitening, and 26.1% voluntarily offered to compound unauthorized steroid mixtures (Khaltat). In the acne scenario, 52.1% dispensed the contraindicated TCS, while only 37.9% appropriately switched the patient to an evidence-based alternative. In the fungal scenario, 60.0% failed to visually inspect the lesion, leading to a 40.0% rate of inappropriate TCS dispensing. Multivariable regression indicated that pharmacists working in chain pharmacies (aOR: 2.15, 95% CI: 1.68&amp;amp;ndash;2.75) and those holding advanced degrees (PharmD/MSc) (aOR &amp;amp;gt; 1.38) were significantly more likely to practice appropriate TCS stewardship. High workload (&amp;amp;gt;200 prescriptions/day) was a significant barrier to safety (aOR: 0.55). Conclusions: Community pharmacists in Jordan exhibited selective TCS stewardship, demonstrating high vigilance for pediatric safety, but widespread illegal practice regarding cosmetic misuse and differential diagnosis that may be unethical. The study results warrant the need for further urgent research to understand why these practices are occurring and how best to address them.</p>
	]]></content:encoded>

	<dc:title>From Cosmetic Abuse to Clinical Mismanagement: A National Simulated Patient Study Assessing Community Pharmacists&amp;amp;rsquo; Stewardship of Topical Corticosteroids in Jordan</dc:title>
			<dc:creator>Derar H. Abdel-Qader</dc:creator>
			<dc:creator>Abdullah Albassam</dc:creator>
			<dc:creator>Esra’ Taybeh</dc:creator>
			<dc:creator>Nadia Al Mazrouei</dc:creator>
			<dc:creator>Rana Ibrahim</dc:creator>
			<dc:creator>Reham Aljalamdeh</dc:creator>
			<dc:creator>Salim Hamadi</dc:creator>
			<dc:creator>Alia Saleh</dc:creator>
			<dc:creator>Sahar Jaradat</dc:creator>
			<dc:creator>Shorouq Al-Omoush</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010031</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-09</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-09</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>31</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010031</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/31</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/30">

	<title>Pharmacy, Vol. 14, Pages 30: Oral Contraceptive Knowledge Among Adolescents and Young Women</title>
	<link>https://www.mdpi.com/2226-4787/14/1/30</link>
	<description>This study aims to describe oral contraceptive knowledge among adolescents and young women, and to examine individuals&amp;amp;rsquo; characteristics associated with oral contraceptive knowledge. A cross-sectional survey was administered using an online panel. Females aged 16 to 24 were recruited. Oral contraceptive knowledge was measured using nine items with six domains, including oral contraceptive use, efficacy, indication, mechanism of action, risks, and side effects. A summated score was created, with a score of 9 indicating highest level of knowledge. Multivariable regression was used to examine significant socio-demographics and clinical characteristics. Among the 700 included responses, largest proportion of respondents were White (45.43%) and were covered by public insurance (43.14%). A total of 446 (63.71%) respondents expressed at least slight interest in using over-the-counter oral contraceptives. Overall, the mean score of knowledge was 4.08 out of 9. Most did not correctly answer questions about side effects, the mechanism of action and appropriate use. Similar patterns were observed among those who were interested in over-the-counter oral contraceptives (mean = 4.11). Adolescents and young women had a low level of oral contraceptive knowledge. With a high proportion of individuals interested in over-the-counter oral contraceptives, additional information support is needed to support informed contraception choice and use.</description>
	<pubDate>2026-02-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 30: Oral Contraceptive Knowledge Among Adolescents and Young Women</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/30">doi: 10.3390/pharmacy14010030</a></p>
	<p>Authors:
		Nga-Weng (Ivy) Leong
		Marie Barnard
		Meagen Rosenthal
		Erin Holmes
		</p>
	<p>This study aims to describe oral contraceptive knowledge among adolescents and young women, and to examine individuals&amp;amp;rsquo; characteristics associated with oral contraceptive knowledge. A cross-sectional survey was administered using an online panel. Females aged 16 to 24 were recruited. Oral contraceptive knowledge was measured using nine items with six domains, including oral contraceptive use, efficacy, indication, mechanism of action, risks, and side effects. A summated score was created, with a score of 9 indicating highest level of knowledge. Multivariable regression was used to examine significant socio-demographics and clinical characteristics. Among the 700 included responses, largest proportion of respondents were White (45.43%) and were covered by public insurance (43.14%). A total of 446 (63.71%) respondents expressed at least slight interest in using over-the-counter oral contraceptives. Overall, the mean score of knowledge was 4.08 out of 9. Most did not correctly answer questions about side effects, the mechanism of action and appropriate use. Similar patterns were observed among those who were interested in over-the-counter oral contraceptives (mean = 4.11). Adolescents and young women had a low level of oral contraceptive knowledge. With a high proportion of individuals interested in over-the-counter oral contraceptives, additional information support is needed to support informed contraception choice and use.</p>
	]]></content:encoded>

	<dc:title>Oral Contraceptive Knowledge Among Adolescents and Young Women</dc:title>
			<dc:creator>Nga-Weng (Ivy) Leong</dc:creator>
			<dc:creator>Marie Barnard</dc:creator>
			<dc:creator>Meagen Rosenthal</dc:creator>
			<dc:creator>Erin Holmes</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010030</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-05</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-05</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>30</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010030</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/30</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/29">

	<title>Pharmacy, Vol. 14, Pages 29: Evaluation of Pharmacist-Developed Educational Leaflets for Women&amp;rsquo;s Health: A Pre&amp;ndash;Post Study of Knowledge and Perceived Usefulness</title>
	<link>https://www.mdpi.com/2226-4787/14/1/29</link>
	<description>Background: Written educational materials are widely used in community pharmacies to support patient education, and available evidence suggests their effectiveness in improving short-term knowledge. However, there remains a need for well-documented, practice-oriented evaluations of pharmacist-developed materials in real-world community pharmacy settings. The aim of this study was to evaluate the immediate impact of a pharmacist-developed educational leaflet on women&amp;amp;rsquo;s health knowledge and its perceived usefulness, clarity, and acceptability. Methods: This study evaluated pharmacist-developed educational leaflets addressing women&amp;amp;rsquo;s health topics using a pre&amp;amp;ndash;post study design. The study was conducted in Poland and involved 266 adult women. All participants completed a five-question knowledge test before and immediately after reading the educational leaflet, followed by a self-assessment of perceived usefulness, clarity, and visual appeal. Descriptive statistics were performed to summarize the results. Results: A statistically significant increase in knowledge was observed after exposure to the educational material, with mean scores rising from 2.8 &amp;amp;plusmn; 1.2 to 4.6 &amp;amp;plusmn; 0.7 (out of 5, p &amp;amp;lt; 0.001). The greatest improvements were noted in topics related to sexually transmitted infection self-testing and pregnancy testing. Most participants rated the leaflet as useful, comprehensible, attractive, and engaging, with higher ratings reported among younger and better-educated respondents. Conclusions: Pharmacist-developed educational leaflets can support short-term knowledge acquisition and are perceived positively by women across age groups. These findings highlight the potential role of community pharmacies in delivering accessible written health education, while underscoring the need for future studies to assess long-term knowledge retention, behavioral outcomes, and topic-specific, targeted materials.</description>
	<pubDate>2026-02-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 29: Evaluation of Pharmacist-Developed Educational Leaflets for Women&amp;rsquo;s Health: A Pre&amp;ndash;Post Study of Knowledge and Perceived Usefulness</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/29">doi: 10.3390/pharmacy14010029</a></p>
	<p>Authors:
		Weronika Guzenda
		Zuzanna Berdzińska
		Piotr Przymuszała
		Olga Sierpniowska
		Magdalena Jasińska-Stroschein
		Magdalena Waszyk-Nowaczyk
		</p>
	<p>Background: Written educational materials are widely used in community pharmacies to support patient education, and available evidence suggests their effectiveness in improving short-term knowledge. However, there remains a need for well-documented, practice-oriented evaluations of pharmacist-developed materials in real-world community pharmacy settings. The aim of this study was to evaluate the immediate impact of a pharmacist-developed educational leaflet on women&amp;amp;rsquo;s health knowledge and its perceived usefulness, clarity, and acceptability. Methods: This study evaluated pharmacist-developed educational leaflets addressing women&amp;amp;rsquo;s health topics using a pre&amp;amp;ndash;post study design. The study was conducted in Poland and involved 266 adult women. All participants completed a five-question knowledge test before and immediately after reading the educational leaflet, followed by a self-assessment of perceived usefulness, clarity, and visual appeal. Descriptive statistics were performed to summarize the results. Results: A statistically significant increase in knowledge was observed after exposure to the educational material, with mean scores rising from 2.8 &amp;amp;plusmn; 1.2 to 4.6 &amp;amp;plusmn; 0.7 (out of 5, p &amp;amp;lt; 0.001). The greatest improvements were noted in topics related to sexually transmitted infection self-testing and pregnancy testing. Most participants rated the leaflet as useful, comprehensible, attractive, and engaging, with higher ratings reported among younger and better-educated respondents. Conclusions: Pharmacist-developed educational leaflets can support short-term knowledge acquisition and are perceived positively by women across age groups. These findings highlight the potential role of community pharmacies in delivering accessible written health education, while underscoring the need for future studies to assess long-term knowledge retention, behavioral outcomes, and topic-specific, targeted materials.</p>
	]]></content:encoded>

	<dc:title>Evaluation of Pharmacist-Developed Educational Leaflets for Women&amp;amp;rsquo;s Health: A Pre&amp;amp;ndash;Post Study of Knowledge and Perceived Usefulness</dc:title>
			<dc:creator>Weronika Guzenda</dc:creator>
			<dc:creator>Zuzanna Berdzińska</dc:creator>
			<dc:creator>Piotr Przymuszała</dc:creator>
			<dc:creator>Olga Sierpniowska</dc:creator>
			<dc:creator>Magdalena Jasińska-Stroschein</dc:creator>
			<dc:creator>Magdalena Waszyk-Nowaczyk</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010029</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-05</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-05</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>29</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010029</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/28">

	<title>Pharmacy, Vol. 14, Pages 28: Role of the Pharmacist in Supporting the Use of Connected Health Devices: Example of Connected Watches</title>
	<link>https://www.mdpi.com/2226-4787/14/1/28</link>
	<description>The use of Connected Medical Devices (CMDs) is growing significantly throughout the world. Although they are not dispensed in pharmacies and are not part of the pharmacy-only drug dispensing system, clinical pharmacists must be able to support patients in the use of these new technologies, which are central to their care. The aim of this study is to identify the role of the community pharmacist in supporting patients who use CMDs, using the case of connected watches in electrophysiology. Semi-structured interviews were conducted between 15 February and 20 April 2024 by a pharmacy student. The questionnaires were drafted in collaboration with a pharmacist, a cardiac electrophysiologist, a methodologist specializing in the evaluation of medical devices, and an ethical philosopher specializing in the support and acceptability of new technologies. The aim of these questionnaires was to study the use of connected watches and support for patients who own them. A total of 4 cardiac electrophysiologists and 10 cardiac electrophysiology patients were interviewed, and then 6 pharmacists were also questioned about the roles identified by physicians and patients. This study identified a major need on the part of specialist physicians for clinical pharmacist support in helping patients use connected watches. Patients expressed a high level of confidence in their pharmacists to support them, and in the motivation of pharmacists&amp;amp;rsquo; ability to take up these challenges. A number of challenges remain, such as the effective integration of this support into pharmacy practice, remuneration, and the organization of collaboration between clinical pharmacists and hospital electrophysiologists.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 28: Role of the Pharmacist in Supporting the Use of Connected Health Devices: Example of Connected Watches</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/28">doi: 10.3390/pharmacy14010028</a></p>
	<p>Authors:
		Cordélia Salomez-Ihl
		Léa Liaigre
		Wiceme Dala
		Ambre Davat
		Maud Barbado
		Sébastien Chanoine
		Philippe Py
		Delphine Schmitt
		Pascal Defaye
		Pierrick Bedouch
		</p>
	<p>The use of Connected Medical Devices (CMDs) is growing significantly throughout the world. Although they are not dispensed in pharmacies and are not part of the pharmacy-only drug dispensing system, clinical pharmacists must be able to support patients in the use of these new technologies, which are central to their care. The aim of this study is to identify the role of the community pharmacist in supporting patients who use CMDs, using the case of connected watches in electrophysiology. Semi-structured interviews were conducted between 15 February and 20 April 2024 by a pharmacy student. The questionnaires were drafted in collaboration with a pharmacist, a cardiac electrophysiologist, a methodologist specializing in the evaluation of medical devices, and an ethical philosopher specializing in the support and acceptability of new technologies. The aim of these questionnaires was to study the use of connected watches and support for patients who own them. A total of 4 cardiac electrophysiologists and 10 cardiac electrophysiology patients were interviewed, and then 6 pharmacists were also questioned about the roles identified by physicians and patients. This study identified a major need on the part of specialist physicians for clinical pharmacist support in helping patients use connected watches. Patients expressed a high level of confidence in their pharmacists to support them, and in the motivation of pharmacists&amp;amp;rsquo; ability to take up these challenges. A number of challenges remain, such as the effective integration of this support into pharmacy practice, remuneration, and the organization of collaboration between clinical pharmacists and hospital electrophysiologists.</p>
	]]></content:encoded>

	<dc:title>Role of the Pharmacist in Supporting the Use of Connected Health Devices: Example of Connected Watches</dc:title>
			<dc:creator>Cordélia Salomez-Ihl</dc:creator>
			<dc:creator>Léa Liaigre</dc:creator>
			<dc:creator>Wiceme Dala</dc:creator>
			<dc:creator>Ambre Davat</dc:creator>
			<dc:creator>Maud Barbado</dc:creator>
			<dc:creator>Sébastien Chanoine</dc:creator>
			<dc:creator>Philippe Py</dc:creator>
			<dc:creator>Delphine Schmitt</dc:creator>
			<dc:creator>Pascal Defaye</dc:creator>
			<dc:creator>Pierrick Bedouch</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010028</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>28</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010028</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/27">

	<title>Pharmacy, Vol. 14, Pages 27: International Benchmarking of Pharmacology Curricula and Prescribing Related Learning Outcomes, Implications for Australian Health Professional Education: A Systematic Review and Meta-Analysis</title>
	<link>https://www.mdpi.com/2226-4787/14/1/27</link>
	<description>Background: Pharmacology plays a central role in linking biomedical science concepts with their application in clinical practice across medical and healthcare education. Globally, the pharmacological curriculum has evolved, just like other disciplines, through the integration of case-based, problem-based, and hybrid teaching models that led to firm clinical reasoning and long-term learning. Thus, this study aims to evaluate and compare the learning outcomes of pharmacology curricula across the globe by adopting a systematic review and meta-analysis research approach. Methods: This comprehensive review was conducted with transparency and integrity in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines and was registered with PROSPERO (CRD420251207753). Five electronic databases, including MEDLINE (PubMed), EMBASE, CINAHL, PsycINFO, and the Cochrane Library were searched from January 2000 to October 2025. The Cochrane Library tool was used for the risk of bias assessment of randomised controlled trials, while the Joanna Briggs Institute (JBI) checklist was used for mixed-design, quasi-experimental, and cross-sectional cohorts. Review Manager 5.4 was used for statistical analysis. Results: Out of 3300 identified studies, 11 met the inclusion criteria, spanning 11 countries (published between 2007 and 2025). Integrated and case-based curricula significantly improved pharmacology knowledge compared to traditional lecture-based methods (SMD = 0.35; 95% CI: 0.07&amp;amp;ndash;0.64; I2 = 75%). Student satisfaction also favours integrated learning (OR = 1.53; 95% CI: 1.16&amp;amp;ndash;2.02; I2 = 46%). Most included studies were of moderate-to-high methodological quality. Conclusion: Globally, active and integrated pharmacology curricula foster greater cognitive understanding and learner satisfaction than conventional models. However, significant variability persists in resource-limited settings, leading to unequal competency in prescribing and therapeutic reasoning. Australian pharmacology programmes align broadly with international standards but require greater standardisation in assessment and experiential learning.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 27: International Benchmarking of Pharmacology Curricula and Prescribing Related Learning Outcomes, Implications for Australian Health Professional Education: A Systematic Review and Meta-Analysis</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/27">doi: 10.3390/pharmacy14010027</a></p>
	<p>Authors:
		Syed Haris Omar
		Anna Barwick
		</p>
	<p>Background: Pharmacology plays a central role in linking biomedical science concepts with their application in clinical practice across medical and healthcare education. Globally, the pharmacological curriculum has evolved, just like other disciplines, through the integration of case-based, problem-based, and hybrid teaching models that led to firm clinical reasoning and long-term learning. Thus, this study aims to evaluate and compare the learning outcomes of pharmacology curricula across the globe by adopting a systematic review and meta-analysis research approach. Methods: This comprehensive review was conducted with transparency and integrity in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines and was registered with PROSPERO (CRD420251207753). Five electronic databases, including MEDLINE (PubMed), EMBASE, CINAHL, PsycINFO, and the Cochrane Library were searched from January 2000 to October 2025. The Cochrane Library tool was used for the risk of bias assessment of randomised controlled trials, while the Joanna Briggs Institute (JBI) checklist was used for mixed-design, quasi-experimental, and cross-sectional cohorts. Review Manager 5.4 was used for statistical analysis. Results: Out of 3300 identified studies, 11 met the inclusion criteria, spanning 11 countries (published between 2007 and 2025). Integrated and case-based curricula significantly improved pharmacology knowledge compared to traditional lecture-based methods (SMD = 0.35; 95% CI: 0.07&amp;amp;ndash;0.64; I2 = 75%). Student satisfaction also favours integrated learning (OR = 1.53; 95% CI: 1.16&amp;amp;ndash;2.02; I2 = 46%). Most included studies were of moderate-to-high methodological quality. Conclusion: Globally, active and integrated pharmacology curricula foster greater cognitive understanding and learner satisfaction than conventional models. However, significant variability persists in resource-limited settings, leading to unequal competency in prescribing and therapeutic reasoning. Australian pharmacology programmes align broadly with international standards but require greater standardisation in assessment and experiential learning.</p>
	]]></content:encoded>

	<dc:title>International Benchmarking of Pharmacology Curricula and Prescribing Related Learning Outcomes, Implications for Australian Health Professional Education: A Systematic Review and Meta-Analysis</dc:title>
			<dc:creator>Syed Haris Omar</dc:creator>
			<dc:creator>Anna Barwick</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010027</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>27</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010027</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/26">

	<title>Pharmacy, Vol. 14, Pages 26: Roles and Responsibilities in Pharmacy Practice as Determinants of Burnout: A Comparative Cross-Sectional Survey of Community Pharmacists and Pharmacy Assistants in the Northeastern Region of Bulgaria</title>
	<link>https://www.mdpi.com/2226-4787/14/1/26</link>
	<description>Background: Burnout is a significant occupational risk among healthcare professionals, including community pharmacy staff, whose differing roles and responsibilities may influence burnout determinants. This study aimed to compare burnout levels and associated work characteristics between master pharmacists (MPs) and assistant pharmacists (APs) working in community pharmacies in Northeastern Bulgaria. Methods: A cross-sectional observational survey was conducted between November 2023 and December 2024 using an anonymous, self-administered online questionnaire completed by 221 MPs and 151 APs. Burnout was assessed using the Maslach Burnout Inventory&amp;amp;mdash;Human Services Survey for Medical Personnel, measuring emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA). Work characteristics were evaluated using items adapted from an internationally recognized European Commission guideline on occupational health and safety risks in the healthcare sector. Results: High levels of EE and DP were observed in both groups, with no statistically significant differences in mean burnout scores. Age and years of professional experience were not significantly associated with burnout. However, work environment factors differed: poor team communication and a negative workplace climate affected both groups, whereas lack of recognition and support was more influential for MPs, and physical workload and frequent interruptions were more prominent stressors for APs. Conclusions: Burnout is prevalent among community pharmacy professionals, with role-specific organizational factors shaping its determinants and highlighting the need for targeted preventive strategies.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 26: Roles and Responsibilities in Pharmacy Practice as Determinants of Burnout: A Comparative Cross-Sectional Survey of Community Pharmacists and Pharmacy Assistants in the Northeastern Region of Bulgaria</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/26">doi: 10.3390/pharmacy14010026</a></p>
	<p>Authors:
		Mariya Ivanova
		Antoaneta Tsvetkova
		Anna Todorova
		</p>
	<p>Background: Burnout is a significant occupational risk among healthcare professionals, including community pharmacy staff, whose differing roles and responsibilities may influence burnout determinants. This study aimed to compare burnout levels and associated work characteristics between master pharmacists (MPs) and assistant pharmacists (APs) working in community pharmacies in Northeastern Bulgaria. Methods: A cross-sectional observational survey was conducted between November 2023 and December 2024 using an anonymous, self-administered online questionnaire completed by 221 MPs and 151 APs. Burnout was assessed using the Maslach Burnout Inventory&amp;amp;mdash;Human Services Survey for Medical Personnel, measuring emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA). Work characteristics were evaluated using items adapted from an internationally recognized European Commission guideline on occupational health and safety risks in the healthcare sector. Results: High levels of EE and DP were observed in both groups, with no statistically significant differences in mean burnout scores. Age and years of professional experience were not significantly associated with burnout. However, work environment factors differed: poor team communication and a negative workplace climate affected both groups, whereas lack of recognition and support was more influential for MPs, and physical workload and frequent interruptions were more prominent stressors for APs. Conclusions: Burnout is prevalent among community pharmacy professionals, with role-specific organizational factors shaping its determinants and highlighting the need for targeted preventive strategies.</p>
	]]></content:encoded>

	<dc:title>Roles and Responsibilities in Pharmacy Practice as Determinants of Burnout: A Comparative Cross-Sectional Survey of Community Pharmacists and Pharmacy Assistants in the Northeastern Region of Bulgaria</dc:title>
			<dc:creator>Mariya Ivanova</dc:creator>
			<dc:creator>Antoaneta Tsvetkova</dc:creator>
			<dc:creator>Anna Todorova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010026</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>26</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010026</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/25">

	<title>Pharmacy, Vol. 14, Pages 25: Regulation of Food Supplements and Pharmacists&amp;rsquo; Responsibility in Professional Practice: A Review</title>
	<link>https://www.mdpi.com/2226-4787/14/1/25</link>
	<description>(1) Background: Regulations governing food supplements vary considerably across countries, allowing products that are prohibited in one jurisdiction to be legally sold in another. Furthermore, online sales enable and facilitate this practice. Regarding pharmaceutical malpractice, the absence of a standardized European framework complicates the evaluation of pharmacist liability. As a result, the specific elements of the liability framework are defined by the national legislation of each Member State. The aim of our review is to map the global regulatory landscape of food supplements and to examine the pharmacist&amp;amp;rsquo;s professional responsibilities, including instances of malpractice related to this area. (2) Methods: A literature review covering publications from January 2020 to December 2024 was performed using four databases: Scopus, PubMed, Embase, and Web of Science. The search retrieved 8243 records, of which 77 studies fulfilled the eligibility criteria. The extracted data were organized into five main themes: pharmacist responsibility and malpractice, food supplement regulation, consumer safety, health claims, and pharmacist knowledge. (3) Results: The literature reviewed indicated a relatively low number of malpractice cases within the pharmacy profession compared to other professions. A higher incidence of cases is observed among male pharmacists and those practicing in the private sector. Notably, no cases have been identified addressing pharmacists&amp;amp;rsquo; responsibilities in the dispensing of food supplements. In the context of food supplement regulation, the reviewed literature highlights a lack of standardized terminology and harmonized legislation across different jurisdictions. Therefore, products may be classified differently across jurisdictions. Another observed barrier is the considerable variation in market access requirements across countries. Regarding consumer safety, several irregularities have been observed. Substantial non-compliance in both product composition and labeling has been observed, reflecting insufficient quality control measures. Concerning health claims, significant regulatory non-compliance with European Union regulations has been documented. In addition, widespread misleading advertising practices have been observed. With respect to pharmacists&amp;amp;rsquo; knowledge, the reviewed literature identifies several professional challenges within pharmacy practice, particularly those concerning the dispensing of food supplements. (4) Conclusions: This research offers a comprehensive analysis of the literature published over the past five years concerning pharmaceutical malpractice cases, as well as an examination of food supplement regulation and the professional responsibilities of pharmacists. A recurring barrier identified is the absence of unified regulatory frameworks worldwide. This results in uncertainty concerning the pharmacist&amp;amp;rsquo;s professional role and responsibilities.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 25: Regulation of Food Supplements and Pharmacists&amp;rsquo; Responsibility in Professional Practice: A Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/25">doi: 10.3390/pharmacy14010025</a></p>
	<p>Authors:
		Cristina Ioana Niculaș
		Sonia Bianca Blaj
		Marius Călin Cherecheș
		Raul Miron
		Daniela Cristina Valea
		Daniela Lucia Muntean
		</p>
	<p>(1) Background: Regulations governing food supplements vary considerably across countries, allowing products that are prohibited in one jurisdiction to be legally sold in another. Furthermore, online sales enable and facilitate this practice. Regarding pharmaceutical malpractice, the absence of a standardized European framework complicates the evaluation of pharmacist liability. As a result, the specific elements of the liability framework are defined by the national legislation of each Member State. The aim of our review is to map the global regulatory landscape of food supplements and to examine the pharmacist&amp;amp;rsquo;s professional responsibilities, including instances of malpractice related to this area. (2) Methods: A literature review covering publications from January 2020 to December 2024 was performed using four databases: Scopus, PubMed, Embase, and Web of Science. The search retrieved 8243 records, of which 77 studies fulfilled the eligibility criteria. The extracted data were organized into five main themes: pharmacist responsibility and malpractice, food supplement regulation, consumer safety, health claims, and pharmacist knowledge. (3) Results: The literature reviewed indicated a relatively low number of malpractice cases within the pharmacy profession compared to other professions. A higher incidence of cases is observed among male pharmacists and those practicing in the private sector. Notably, no cases have been identified addressing pharmacists&amp;amp;rsquo; responsibilities in the dispensing of food supplements. In the context of food supplement regulation, the reviewed literature highlights a lack of standardized terminology and harmonized legislation across different jurisdictions. Therefore, products may be classified differently across jurisdictions. Another observed barrier is the considerable variation in market access requirements across countries. Regarding consumer safety, several irregularities have been observed. Substantial non-compliance in both product composition and labeling has been observed, reflecting insufficient quality control measures. Concerning health claims, significant regulatory non-compliance with European Union regulations has been documented. In addition, widespread misleading advertising practices have been observed. With respect to pharmacists&amp;amp;rsquo; knowledge, the reviewed literature identifies several professional challenges within pharmacy practice, particularly those concerning the dispensing of food supplements. (4) Conclusions: This research offers a comprehensive analysis of the literature published over the past five years concerning pharmaceutical malpractice cases, as well as an examination of food supplement regulation and the professional responsibilities of pharmacists. A recurring barrier identified is the absence of unified regulatory frameworks worldwide. This results in uncertainty concerning the pharmacist&amp;amp;rsquo;s professional role and responsibilities.</p>
	]]></content:encoded>

	<dc:title>Regulation of Food Supplements and Pharmacists&amp;amp;rsquo; Responsibility in Professional Practice: A Review</dc:title>
			<dc:creator>Cristina Ioana Niculaș</dc:creator>
			<dc:creator>Sonia Bianca Blaj</dc:creator>
			<dc:creator>Marius Călin Cherecheș</dc:creator>
			<dc:creator>Raul Miron</dc:creator>
			<dc:creator>Daniela Cristina Valea</dc:creator>
			<dc:creator>Daniela Lucia Muntean</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010025</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>25</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010025</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/24">

	<title>Pharmacy, Vol. 14, Pages 24: Good Practices and Challenges in the Collaboration of Pharmacists with General Practitioners&amp;mdash;A Scoping Review</title>
	<link>https://www.mdpi.com/2226-4787/14/1/24</link>
	<description>Optimizing medication management and improving patient health outcomes depend primarily on the strength of primary healthcare services, where collaboration between general practitioners (GPs) and pharmacists plays a critical role. This scoping review aimed to identify the main facilitators and barriers influencing pharmacist&amp;amp;ndash;GP collaboration. The review was conducted in line with PRISMA-ScR guidelines. A comprehensive search of PubMed, Scopus, and Web of Science identified studies published in English between January 2019 and May 2025, of which twenty met the inclusion criteria. Key facilitators of collaboration included pharmacist co-location within GP practices, clearly defined professional responsibilities, access to shared electronic health records, and supportive government policies. Barriers most frequently reported were limited communication pathways, insufficient interprofessional training, and financial constraints. Overall, the findings suggest that effective pharmacist&amp;amp;ndash;GP collaboration relies on structural integration, professional trust, and policy initiatives that enable sustained cooperation. Long-term investment in collaborative infrastructure and workforce development will be essential to strengthen primary care, support patient outcomes, and ensure more efficient use of healthcare resources.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 24: Good Practices and Challenges in the Collaboration of Pharmacists with General Practitioners&amp;mdash;A Scoping Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/24">doi: 10.3390/pharmacy14010024</a></p>
	<p>Authors:
		Evelina Gavazova
		Kiril Atliev
		Daniela Kafalova
		</p>
	<p>Optimizing medication management and improving patient health outcomes depend primarily on the strength of primary healthcare services, where collaboration between general practitioners (GPs) and pharmacists plays a critical role. This scoping review aimed to identify the main facilitators and barriers influencing pharmacist&amp;amp;ndash;GP collaboration. The review was conducted in line with PRISMA-ScR guidelines. A comprehensive search of PubMed, Scopus, and Web of Science identified studies published in English between January 2019 and May 2025, of which twenty met the inclusion criteria. Key facilitators of collaboration included pharmacist co-location within GP practices, clearly defined professional responsibilities, access to shared electronic health records, and supportive government policies. Barriers most frequently reported were limited communication pathways, insufficient interprofessional training, and financial constraints. Overall, the findings suggest that effective pharmacist&amp;amp;ndash;GP collaboration relies on structural integration, professional trust, and policy initiatives that enable sustained cooperation. Long-term investment in collaborative infrastructure and workforce development will be essential to strengthen primary care, support patient outcomes, and ensure more efficient use of healthcare resources.</p>
	]]></content:encoded>

	<dc:title>Good Practices and Challenges in the Collaboration of Pharmacists with General Practitioners&amp;amp;mdash;A Scoping Review</dc:title>
			<dc:creator>Evelina Gavazova</dc:creator>
			<dc:creator>Kiril Atliev</dc:creator>
			<dc:creator>Daniela Kafalova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010024</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>24</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010024</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/23">

	<title>Pharmacy, Vol. 14, Pages 23: Healthcare Professionals&amp;rsquo; Perspectives on Barriers and Facilitators to Medication Adherence Post Myocardial Infarction: A Qualitative Study Using the Theoretical Domains Framework</title>
	<link>https://www.mdpi.com/2226-4787/14/1/23</link>
	<description>Medication adherence following myocardial infarction (MI) is essential for effective secondary prevention, yet adherence rates remain suboptimal. Healthcare professionals (HCPs) are central to promoting adherence through clinical decision-making, patient education, and ongoing behavioural support. Understanding how HCPs perceive and experience the factors&amp;amp;rsquo; influencing adherence is key to developing effective, context-specific interventions. This study explored HCPs&amp;amp;rsquo; perspectives on medication adherence post-MI and identified behavioural determinants influencing medication management across the care pathway. A qualitative descriptive study was conducted using semi-structured interviews with HCPs in the southwest of Ireland. Participants included hospital pharmacists, community pharmacists, general practitioners (GPs), cardiologists, and nurses, recruited through purposive, convenience, and snowball sampling. Interviews were recorded, transcribed verbatim, and analysed using directed content analysis guided by the Theoretical Domains Framework (TDF). Twelve HCPs (eight female) were interviewed between December 2024 and May 2025, including four pharmacists, two GPs, three cardiologists and three nurses. Interviews lasted 30&amp;amp;ndash;50 min (mean 41 min). Analysis identified 15 facilitators, 13 barriers, and 7 dual-role determinants across 10 TDF domains. Novel contributions include demonstrating how HCPs&amp;amp;rsquo; real-world experiences contextualise adherence issues in the distinct post-MI setting characterised by abrupt care transitions, polypharmacy, and emotional vulnerability and identifying where HCPs feel most constrained and where their expertise could directly inform targeted intervention design. HCPs&amp;amp;rsquo; insights reveal complex, context-specific behavioural determinants influencing post-MI medication adherence and highlight the need for multidisciplinary, tailored, and system-level solutions. Enhancing collaboration, supporting patient-centred communication, and addressing resource barriers could empower HCPs to deliver more effective, personalised adherence support and inform the development of targeted intervention strategies.</description>
	<pubDate>2026-02-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 23: Healthcare Professionals&amp;rsquo; Perspectives on Barriers and Facilitators to Medication Adherence Post Myocardial Infarction: A Qualitative Study Using the Theoretical Domains Framework</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/23">doi: 10.3390/pharmacy14010023</a></p>
	<p>Authors:
		Fatma El-Komy
		Michelle O’Driscoll
		Stephen Byrne
		Margaret Bermingham
		Laura J. Sahm
		</p>
	<p>Medication adherence following myocardial infarction (MI) is essential for effective secondary prevention, yet adherence rates remain suboptimal. Healthcare professionals (HCPs) are central to promoting adherence through clinical decision-making, patient education, and ongoing behavioural support. Understanding how HCPs perceive and experience the factors&amp;amp;rsquo; influencing adherence is key to developing effective, context-specific interventions. This study explored HCPs&amp;amp;rsquo; perspectives on medication adherence post-MI and identified behavioural determinants influencing medication management across the care pathway. A qualitative descriptive study was conducted using semi-structured interviews with HCPs in the southwest of Ireland. Participants included hospital pharmacists, community pharmacists, general practitioners (GPs), cardiologists, and nurses, recruited through purposive, convenience, and snowball sampling. Interviews were recorded, transcribed verbatim, and analysed using directed content analysis guided by the Theoretical Domains Framework (TDF). Twelve HCPs (eight female) were interviewed between December 2024 and May 2025, including four pharmacists, two GPs, three cardiologists and three nurses. Interviews lasted 30&amp;amp;ndash;50 min (mean 41 min). Analysis identified 15 facilitators, 13 barriers, and 7 dual-role determinants across 10 TDF domains. Novel contributions include demonstrating how HCPs&amp;amp;rsquo; real-world experiences contextualise adherence issues in the distinct post-MI setting characterised by abrupt care transitions, polypharmacy, and emotional vulnerability and identifying where HCPs feel most constrained and where their expertise could directly inform targeted intervention design. HCPs&amp;amp;rsquo; insights reveal complex, context-specific behavioural determinants influencing post-MI medication adherence and highlight the need for multidisciplinary, tailored, and system-level solutions. Enhancing collaboration, supporting patient-centred communication, and addressing resource barriers could empower HCPs to deliver more effective, personalised adherence support and inform the development of targeted intervention strategies.</p>
	]]></content:encoded>

	<dc:title>Healthcare Professionals&amp;amp;rsquo; Perspectives on Barriers and Facilitators to Medication Adherence Post Myocardial Infarction: A Qualitative Study Using the Theoretical Domains Framework</dc:title>
			<dc:creator>Fatma El-Komy</dc:creator>
			<dc:creator>Michelle O’Driscoll</dc:creator>
			<dc:creator>Stephen Byrne</dc:creator>
			<dc:creator>Margaret Bermingham</dc:creator>
			<dc:creator>Laura J. Sahm</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010023</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>23</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010023</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/22">

	<title>Pharmacy, Vol. 14, Pages 22: ACE Inhibitor/ARB Therapy and Other Risk Factors for COVID-19 Infection in Elderly Hypertensive Patients: Sub-Group Analysis Based on a Single-Center, Retrospective, Observational Study in Japan</title>
	<link>https://www.mdpi.com/2226-4787/14/1/22</link>
	<description>Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are often used in hypertensive patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, binds the ACE2 receptor on the cell surface. This study aimed to identify the risk factors influencing COVID-19 infection in hypertensive patients. Methods: This is a part of a single-center, retrospective, observational study investigating patients &amp;amp;ge; 20 years old at Kenwakai Hospital (Nagano, Japan). COVID-19 was diagnosed by polymerase chain reaction. All patients received antihypertensive drugs. Results: Among 316 patients (mean age, 75.0 &amp;amp;plusmn; 13.4 years; men, 55.1%), COVID-19 was diagnosed in 39 (12.3%). Multiple logistic regression analysis after adjustment for age, sex, and smoking status identified increased serum creatinine (Scr) as a significant risk factor for COVID-19 (odds ratio [OR] 1.10; 95% confidence interval [CI] 1.00&amp;amp;ndash;1.20; p = 0.046). Conversely, lower serum chloride was associated with COVID-19 (OR 0.92; 95% CI 0.85&amp;amp;ndash;0.99; p = 0.047). There was no significant association between COVID-19 and the use of ACEIs and ARBs. Conclusions: Scr was independently associated with COVID-19 risk, whereas ACEI/ARB use was not associated with COVID-19 risk in Japanese hypertensive patients, suggesting that these users need not discontinue or change their treatment. The study population included a very high proportion of patients with advanced chronic kidney disease, which makes the cohort substantially different from the general hypertensive population. However, our results can help guide targeted treatment strategies, improving patient outcomes in healthcare settings.</description>
	<pubDate>2026-02-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 22: ACE Inhibitor/ARB Therapy and Other Risk Factors for COVID-19 Infection in Elderly Hypertensive Patients: Sub-Group Analysis Based on a Single-Center, Retrospective, Observational Study in Japan</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/22">doi: 10.3390/pharmacy14010022</a></p>
	<p>Authors:
		Kazuhiro Furumachi
		Akari Higuchi
		Tatsuki Kagatsume
		Mariko Kozaru
		Tsutomu Nakamura
		Etsuko Kumagai
		Keiko Hosohata
		</p>
	<p>Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are often used in hypertensive patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, binds the ACE2 receptor on the cell surface. This study aimed to identify the risk factors influencing COVID-19 infection in hypertensive patients. Methods: This is a part of a single-center, retrospective, observational study investigating patients &amp;amp;ge; 20 years old at Kenwakai Hospital (Nagano, Japan). COVID-19 was diagnosed by polymerase chain reaction. All patients received antihypertensive drugs. Results: Among 316 patients (mean age, 75.0 &amp;amp;plusmn; 13.4 years; men, 55.1%), COVID-19 was diagnosed in 39 (12.3%). Multiple logistic regression analysis after adjustment for age, sex, and smoking status identified increased serum creatinine (Scr) as a significant risk factor for COVID-19 (odds ratio [OR] 1.10; 95% confidence interval [CI] 1.00&amp;amp;ndash;1.20; p = 0.046). Conversely, lower serum chloride was associated with COVID-19 (OR 0.92; 95% CI 0.85&amp;amp;ndash;0.99; p = 0.047). There was no significant association between COVID-19 and the use of ACEIs and ARBs. Conclusions: Scr was independently associated with COVID-19 risk, whereas ACEI/ARB use was not associated with COVID-19 risk in Japanese hypertensive patients, suggesting that these users need not discontinue or change their treatment. The study population included a very high proportion of patients with advanced chronic kidney disease, which makes the cohort substantially different from the general hypertensive population. However, our results can help guide targeted treatment strategies, improving patient outcomes in healthcare settings.</p>
	]]></content:encoded>

	<dc:title>ACE Inhibitor/ARB Therapy and Other Risk Factors for COVID-19 Infection in Elderly Hypertensive Patients: Sub-Group Analysis Based on a Single-Center, Retrospective, Observational Study in Japan</dc:title>
			<dc:creator>Kazuhiro Furumachi</dc:creator>
			<dc:creator>Akari Higuchi</dc:creator>
			<dc:creator>Tatsuki Kagatsume</dc:creator>
			<dc:creator>Mariko Kozaru</dc:creator>
			<dc:creator>Tsutomu Nakamura</dc:creator>
			<dc:creator>Etsuko Kumagai</dc:creator>
			<dc:creator>Keiko Hosohata</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010022</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>22</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010022</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/20">

	<title>Pharmacy, Vol. 14, Pages 20: An Exploratory Study of Over-the-Counter Medication Counseling Topics in Community Pharmacies and Alignment with Counseling Frameworks</title>
	<link>https://www.mdpi.com/2226-4787/14/1/20</link>
	<description>Community pharmacists can play an important role in patient safety by consulting patients on over-the-counter (OTC) medications. Several OTC counseling frameworks have been integrated into pharmacy education to guide pharmacists through these consultations, but limited work has been performed to examine how these frameworks are applied in real-world settings. The objective of this study was to identify the topics discussed during over-the-counter medication consultations and explore how they align with existing counseling frameworks. Participants were recruited from 10 community pharmacies. Participants were given hypothetical symptoms and asked to select OTCs for self-treatment. The selection process and potential interactions with pharmacy staff were recorded via Tobii Pro Glasses 2. Deductive and inductive content analysis of the recordings were used to compare participant&amp;amp;ndash;pharmacist consultations to existing OTC counseling frameworks. In total, 144 participants completed the study, with 32 (22%) having an OTC consultation with the pharmacist. Across all consultations, eight topic categories were identified. The consultations most frequently focused on discussions of product details and did not closely align with the OTC counseling frameworks. Future work should examine if and how this discordance contributes to OTC misuse among those interacting with pharmacists and potentially adapt or develop new frameworks to further support consultations and OTC safety.</description>
	<pubDate>2026-02-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 20: An Exploratory Study of Over-the-Counter Medication Counseling Topics in Community Pharmacies and Alignment with Counseling Frameworks</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/20">doi: 10.3390/pharmacy14010020</a></p>
	<p>Authors:
		Jason S. Chladek
		Leena Jaiswal
		Jamie A. Stone
		Aaron M. Gilson
		Taylor L. Watterson
		Elin C. Lehnbom
		Jukrin Moon
		Emily L. Hoffins
		Maria E. Berbakov
		Michelle A. Chui
		</p>
	<p>Community pharmacists can play an important role in patient safety by consulting patients on over-the-counter (OTC) medications. Several OTC counseling frameworks have been integrated into pharmacy education to guide pharmacists through these consultations, but limited work has been performed to examine how these frameworks are applied in real-world settings. The objective of this study was to identify the topics discussed during over-the-counter medication consultations and explore how they align with existing counseling frameworks. Participants were recruited from 10 community pharmacies. Participants were given hypothetical symptoms and asked to select OTCs for self-treatment. The selection process and potential interactions with pharmacy staff were recorded via Tobii Pro Glasses 2. Deductive and inductive content analysis of the recordings were used to compare participant&amp;amp;ndash;pharmacist consultations to existing OTC counseling frameworks. In total, 144 participants completed the study, with 32 (22%) having an OTC consultation with the pharmacist. Across all consultations, eight topic categories were identified. The consultations most frequently focused on discussions of product details and did not closely align with the OTC counseling frameworks. Future work should examine if and how this discordance contributes to OTC misuse among those interacting with pharmacists and potentially adapt or develop new frameworks to further support consultations and OTC safety.</p>
	]]></content:encoded>

	<dc:title>An Exploratory Study of Over-the-Counter Medication Counseling Topics in Community Pharmacies and Alignment with Counseling Frameworks</dc:title>
			<dc:creator>Jason S. Chladek</dc:creator>
			<dc:creator>Leena Jaiswal</dc:creator>
			<dc:creator>Jamie A. Stone</dc:creator>
			<dc:creator>Aaron M. Gilson</dc:creator>
			<dc:creator>Taylor L. Watterson</dc:creator>
			<dc:creator>Elin C. Lehnbom</dc:creator>
			<dc:creator>Jukrin Moon</dc:creator>
			<dc:creator>Emily L. Hoffins</dc:creator>
			<dc:creator>Maria E. Berbakov</dc:creator>
			<dc:creator>Michelle A. Chui</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010020</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010020</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/21">

	<title>Pharmacy, Vol. 14, Pages 21: Perspectives and Experiences of Doctors and Pharmacists on the Clinical Use of Direct Oral Anticoagulants in Saudi Arabia</title>
	<link>https://www.mdpi.com/2226-4787/14/1/21</link>
	<description>Background and objectives: Research into clinicians&amp;amp;rsquo; and pharmacists&amp;amp;rsquo; experiences and perspectives on direct oral anticoagulant (DOAC) use in Saudi Arabia and the broader Middle Eastern area is limited. Therefore, we aimed to evaluate the perspectives and experiences of physicians and pharmacists practicing in Saudi Arabia who prescribe DOACs and dispense DOAC therapy, respectively. Methods: A cross-sectional study was undertaken utilizing an online survey instrument. We collected data via Google Forms. Between June and July 2024, the study questionnaire was distributed to community pharmacists, general practitioners [GPs], cardiologists, residents in internal medicine, and hospital pharmacists (primary and secondary healthcare professionals) working in Saudi Arabia. Results: Comprising 146 doctors and 167 pharmacists, 313 total healthcare professionals participated in the study. Of the weekly DOAC prescriptions, cardiologists had the most at 35%; internal medicine residents came next at 16.3% and general practitioners at 17.5%. Among pharmacists, 16.7% of community pharmacists and 23.9% of hospital pharmacists dispensed DOACs weekly. The most often prescribed and dispensed medications were rivaroxaban, edoxaban, and apixaban. Across all categories, Lexicomp was the most often used tool. Most physicians (98%) said they lowered the DOAC dose when necessary. Especially in dosing, preoperative care, patient education, and medication interaction identification, internal medicine residents and hospital pharmacists expressed more confidence in managing DOACs. In these domains, community pharmacists expressed less trust. Conclusions: This study revealed that most participants preferred newer oral anticoagulants over warfarin and demonstrated a fairly good level of self-perceived knowledge regarding various aspects of the clinical use of DOACs. The study findings highlight the importance of focused training initiatives to standardize the use of DOACs, boost trust among community pharmacists and GPs, and ensure safe and effective patient care.</description>
	<pubDate>2026-02-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 21: Perspectives and Experiences of Doctors and Pharmacists on the Clinical Use of Direct Oral Anticoagulants in Saudi Arabia</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/21">doi: 10.3390/pharmacy14010021</a></p>
	<p>Authors:
		Dalal Salem Aldossari
		Komal Latif
		Amjad Nasser Alsadoni
		Orjuwan Hasan Alshehri
		Rakan Ibrahim Binjathlan
		Monirah Mutlaq Alenezy
		Taif Farhan Alshahrani
		Hana Ahmed Lubbad
		Rana Saeed Alshamasi
		Abdulmajead Khaled Alanazi
		Raed Ghazi Alotaibi
		Ghazi Ibrahim Arishi
		Sheraz Ali
		</p>
	<p>Background and objectives: Research into clinicians&amp;amp;rsquo; and pharmacists&amp;amp;rsquo; experiences and perspectives on direct oral anticoagulant (DOAC) use in Saudi Arabia and the broader Middle Eastern area is limited. Therefore, we aimed to evaluate the perspectives and experiences of physicians and pharmacists practicing in Saudi Arabia who prescribe DOACs and dispense DOAC therapy, respectively. Methods: A cross-sectional study was undertaken utilizing an online survey instrument. We collected data via Google Forms. Between June and July 2024, the study questionnaire was distributed to community pharmacists, general practitioners [GPs], cardiologists, residents in internal medicine, and hospital pharmacists (primary and secondary healthcare professionals) working in Saudi Arabia. Results: Comprising 146 doctors and 167 pharmacists, 313 total healthcare professionals participated in the study. Of the weekly DOAC prescriptions, cardiologists had the most at 35%; internal medicine residents came next at 16.3% and general practitioners at 17.5%. Among pharmacists, 16.7% of community pharmacists and 23.9% of hospital pharmacists dispensed DOACs weekly. The most often prescribed and dispensed medications were rivaroxaban, edoxaban, and apixaban. Across all categories, Lexicomp was the most often used tool. Most physicians (98%) said they lowered the DOAC dose when necessary. Especially in dosing, preoperative care, patient education, and medication interaction identification, internal medicine residents and hospital pharmacists expressed more confidence in managing DOACs. In these domains, community pharmacists expressed less trust. Conclusions: This study revealed that most participants preferred newer oral anticoagulants over warfarin and demonstrated a fairly good level of self-perceived knowledge regarding various aspects of the clinical use of DOACs. The study findings highlight the importance of focused training initiatives to standardize the use of DOACs, boost trust among community pharmacists and GPs, and ensure safe and effective patient care.</p>
	]]></content:encoded>

	<dc:title>Perspectives and Experiences of Doctors and Pharmacists on the Clinical Use of Direct Oral Anticoagulants in Saudi Arabia</dc:title>
			<dc:creator>Dalal Salem Aldossari</dc:creator>
			<dc:creator>Komal Latif</dc:creator>
			<dc:creator>Amjad Nasser Alsadoni</dc:creator>
			<dc:creator>Orjuwan Hasan Alshehri</dc:creator>
			<dc:creator>Rakan Ibrahim Binjathlan</dc:creator>
			<dc:creator>Monirah Mutlaq Alenezy</dc:creator>
			<dc:creator>Taif Farhan Alshahrani</dc:creator>
			<dc:creator>Hana Ahmed Lubbad</dc:creator>
			<dc:creator>Rana Saeed Alshamasi</dc:creator>
			<dc:creator>Abdulmajead Khaled Alanazi</dc:creator>
			<dc:creator>Raed Ghazi Alotaibi</dc:creator>
			<dc:creator>Ghazi Ibrahim Arishi</dc:creator>
			<dc:creator>Sheraz Ali</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010021</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-02-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-02-02</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>21</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010021</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/19">

	<title>Pharmacy, Vol. 14, Pages 19: Direct Oral Anti-Xa Anticoagulants and the Future of Factor XI/FXIa Inhibition: A New Paradigm in Thrombosis Prevention</title>
	<link>https://www.mdpi.com/2226-4787/14/1/19</link>
	<description>The introduction of direct oral anticoagulants (DOACs), particularly factor Xa (FXa) inhibitors, has transformed the prevention and treatment of thromboembolic events. These agents have largely replaced vitamin K antagonists across most indications due to their predictable pharmacokinetics, reduced rates of intracranial bleeding, and overall ease of use. Nevertheless, a substantial residual bleeding risk remains, particularly gastrointestinal bleeding and clinically relevant non-major bleeding in elderly, frail, or polymedicated patients. Furthermore, the management of patients with severe renal dysfunction, active cancer, especially gastrointestinal or genitourinary malignancies and those requiring complex pharmacological regimens, continues to pose significant challenges. These limitations have intensified interest in targeting earlier steps of the coagulation cascade, specifically factor XI (FXI) and its activated form (FXIa). FXI occupies a unique mechanistic position: it contributes substantially to pathological thrombosis while playing only a limited role in physiological hemostasis. Genetic, observational, and mechanistic evidence consistently demonstrates that FXI deficiency confers protection against venous thromboembolism and cardiovascular events while causing minimal spontaneous bleeding. This biological paradigm has catalyzed the development of novel FXI/FXIa inhibitors, including small-molecule agents (asundexian, milvexian) and biological therapies (abelacimab). Clinical trials such as AXIOMATIC-TKR, PACIFIC-AF, and OCEANIC-AF, and ongoing programmes including ASTER and MAGNOLIA suggest that FXI inhibition may preserve antithrombotic efficacy while substantially reducing bleeding risk. This review summarizes the current landscape of oral FXa inhibitors, outlines the biological rationale for FXI/FXIa inhibition, and discusses the evolving clinical evidence supporting what may represent the next major advance in anticoagulant therapy.</description>
	<pubDate>2026-01-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 19: Direct Oral Anti-Xa Anticoagulants and the Future of Factor XI/FXIa Inhibition: A New Paradigm in Thrombosis Prevention</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/19">doi: 10.3390/pharmacy14010019</a></p>
	<p>Authors:
		Francesca Futura Bernardi
		Dario Bianco
		Rosaria Lanzillo
		Natalia Diana
		Mario Scarpato
		Antonio Lalli
		Aniello Corallo
		Consiglia Riccardi
		Ugo Trama
		Alessandro Perrella
		Manuela Basaglia
		Ada Maffettone
		Pierpaolo Di Micco
		Carmine Siniscalchi
		</p>
	<p>The introduction of direct oral anticoagulants (DOACs), particularly factor Xa (FXa) inhibitors, has transformed the prevention and treatment of thromboembolic events. These agents have largely replaced vitamin K antagonists across most indications due to their predictable pharmacokinetics, reduced rates of intracranial bleeding, and overall ease of use. Nevertheless, a substantial residual bleeding risk remains, particularly gastrointestinal bleeding and clinically relevant non-major bleeding in elderly, frail, or polymedicated patients. Furthermore, the management of patients with severe renal dysfunction, active cancer, especially gastrointestinal or genitourinary malignancies and those requiring complex pharmacological regimens, continues to pose significant challenges. These limitations have intensified interest in targeting earlier steps of the coagulation cascade, specifically factor XI (FXI) and its activated form (FXIa). FXI occupies a unique mechanistic position: it contributes substantially to pathological thrombosis while playing only a limited role in physiological hemostasis. Genetic, observational, and mechanistic evidence consistently demonstrates that FXI deficiency confers protection against venous thromboembolism and cardiovascular events while causing minimal spontaneous bleeding. This biological paradigm has catalyzed the development of novel FXI/FXIa inhibitors, including small-molecule agents (asundexian, milvexian) and biological therapies (abelacimab). Clinical trials such as AXIOMATIC-TKR, PACIFIC-AF, and OCEANIC-AF, and ongoing programmes including ASTER and MAGNOLIA suggest that FXI inhibition may preserve antithrombotic efficacy while substantially reducing bleeding risk. This review summarizes the current landscape of oral FXa inhibitors, outlines the biological rationale for FXI/FXIa inhibition, and discusses the evolving clinical evidence supporting what may represent the next major advance in anticoagulant therapy.</p>
	]]></content:encoded>

	<dc:title>Direct Oral Anti-Xa Anticoagulants and the Future of Factor XI/FXIa Inhibition: A New Paradigm in Thrombosis Prevention</dc:title>
			<dc:creator>Francesca Futura Bernardi</dc:creator>
			<dc:creator>Dario Bianco</dc:creator>
			<dc:creator>Rosaria Lanzillo</dc:creator>
			<dc:creator>Natalia Diana</dc:creator>
			<dc:creator>Mario Scarpato</dc:creator>
			<dc:creator>Antonio Lalli</dc:creator>
			<dc:creator>Aniello Corallo</dc:creator>
			<dc:creator>Consiglia Riccardi</dc:creator>
			<dc:creator>Ugo Trama</dc:creator>
			<dc:creator>Alessandro Perrella</dc:creator>
			<dc:creator>Manuela Basaglia</dc:creator>
			<dc:creator>Ada Maffettone</dc:creator>
			<dc:creator>Pierpaolo Di Micco</dc:creator>
			<dc:creator>Carmine Siniscalchi</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010019</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-27</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-27</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010019</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/18">

	<title>Pharmacy, Vol. 14, Pages 18: Pharmacists&amp;rsquo; Work Experiences and Career Dynamics in Saudi Arabia: A Cross-Sector Study</title>
	<link>https://www.mdpi.com/2226-4787/14/1/18</link>
	<description>Background: Pharmacists in Saudi Arabia are assuming increasingly diverse and specialized roles amid rapid healthcare transformation. However, evolving expectations and expanding responsibilities may influence their job satisfaction, well-being, and career stability. This study aimed to assess job satisfaction, burnout, well-being, and career intentions among pharmacists across multiple practice sectors in Saudi Arabia. Method: A nationwide cross-sectional survey was conducted between December 2024 and January 2025 using an electronic questionnaire distributed to licensed pharmacists. The instrument assessed mental well-being, job satisfaction, burnout, workplace environment, and career mobility. Descriptive and inferential analyses were performed using SPSS version 20.0. Results: A total of 531 pharmacists completed the survey; 65% were male, and 89.3% were Saudi nationals. Sector distribution differed significantly by gender (p &amp;amp;lt; 0.001): females were more represented in clinical and hospital pharmacy, while males predominated in the pharmaceutical industry&amp;amp;ndash;related roles. Male pharmacists reported higher work environment scores (p = 0.028) and greater sector mobility (34.2% vs. 23.7%, p = 0.012). Approximately 30.5% of participants had changed their employment sector at least once. Community pharmacists reported the highest burnout levels, whereas those in regulatory and administrative roles demonstrated the greatest job satisfaction (both p &amp;amp;lt; 0.001). Participation in professional development showed strong positive associations with job satisfaction and intention to remain in the current role. Conclusions: Marked variations exist in pharmacists&amp;amp;rsquo; well-being, satisfaction, and career mobility across sectors in Saudi Arabia, with notable gender differences. Enhancing professional development, ensuring equitable work environments, and promoting sector-specific support strategies may help inform discussions on pharmacist engagement and retention within the evolving national healthcare system.</description>
	<pubDate>2026-01-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 18: Pharmacists&amp;rsquo; Work Experiences and Career Dynamics in Saudi Arabia: A Cross-Sector Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/18">doi: 10.3390/pharmacy14010018</a></p>
	<p>Authors:
		Mohammed Alnuhait
		Ayidh Alqarni
		Leena Alsharafi
		Arjwan Alshreef
		Renad Althebaiti
		Alaa Shahbar
		Foud Bahamdain
		Abdulhamid Althagafi
		Mohamed A. Albekery
		Abdullah F. Alharthi
		Abdulmalik S. Alotaibi
		</p>
	<p>Background: Pharmacists in Saudi Arabia are assuming increasingly diverse and specialized roles amid rapid healthcare transformation. However, evolving expectations and expanding responsibilities may influence their job satisfaction, well-being, and career stability. This study aimed to assess job satisfaction, burnout, well-being, and career intentions among pharmacists across multiple practice sectors in Saudi Arabia. Method: A nationwide cross-sectional survey was conducted between December 2024 and January 2025 using an electronic questionnaire distributed to licensed pharmacists. The instrument assessed mental well-being, job satisfaction, burnout, workplace environment, and career mobility. Descriptive and inferential analyses were performed using SPSS version 20.0. Results: A total of 531 pharmacists completed the survey; 65% were male, and 89.3% were Saudi nationals. Sector distribution differed significantly by gender (p &amp;amp;lt; 0.001): females were more represented in clinical and hospital pharmacy, while males predominated in the pharmaceutical industry&amp;amp;ndash;related roles. Male pharmacists reported higher work environment scores (p = 0.028) and greater sector mobility (34.2% vs. 23.7%, p = 0.012). Approximately 30.5% of participants had changed their employment sector at least once. Community pharmacists reported the highest burnout levels, whereas those in regulatory and administrative roles demonstrated the greatest job satisfaction (both p &amp;amp;lt; 0.001). Participation in professional development showed strong positive associations with job satisfaction and intention to remain in the current role. Conclusions: Marked variations exist in pharmacists&amp;amp;rsquo; well-being, satisfaction, and career mobility across sectors in Saudi Arabia, with notable gender differences. Enhancing professional development, ensuring equitable work environments, and promoting sector-specific support strategies may help inform discussions on pharmacist engagement and retention within the evolving national healthcare system.</p>
	]]></content:encoded>

	<dc:title>Pharmacists&amp;amp;rsquo; Work Experiences and Career Dynamics in Saudi Arabia: A Cross-Sector Study</dc:title>
			<dc:creator>Mohammed Alnuhait</dc:creator>
			<dc:creator>Ayidh Alqarni</dc:creator>
			<dc:creator>Leena Alsharafi</dc:creator>
			<dc:creator>Arjwan Alshreef</dc:creator>
			<dc:creator>Renad Althebaiti</dc:creator>
			<dc:creator>Alaa Shahbar</dc:creator>
			<dc:creator>Foud Bahamdain</dc:creator>
			<dc:creator>Abdulhamid Althagafi</dc:creator>
			<dc:creator>Mohamed A. Albekery</dc:creator>
			<dc:creator>Abdullah F. Alharthi</dc:creator>
			<dc:creator>Abdulmalik S. Alotaibi</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010018</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-27</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-27</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010018</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/17">

	<title>Pharmacy, Vol. 14, Pages 17: The Prevalence and Impact of Bacteremia Among Neonates Receiving Parenteral Nutrition: A Multicenter Retrospective Study from Saudi Arabia</title>
	<link>https://www.mdpi.com/2226-4787/14/1/17</link>
	<description>(1) Background: We aimed to determine rates of bacteremia and multidrug resistance (MDR) bacteremia and associated risk factors among neonates receiving parenteral nutrition (PN). (2) Methods: This is a multicenter study conducted in three neonatal intensive care units in Saudi Arabia, including 414 neonates who received PN. Associations were assessed using Chi-square or Fisher&amp;amp;rsquo;s Exact tests when applicable and logistic regression analyses were conducted to determine factors predicting outcomes. Odds ratios with their 95% confidence intervals were computed, and a p value &amp;amp;lt; 0.05 was considered statistically significant. (3) Results: PN was started within the first 10 days of life in 74.4% of cases. Fat emulsion was administered to 38.9% of the newborns. Blood cultures were positive in 24.9% of patients. Among the positive cultures, 4.9% were confirmed to have MDR bacteria. The mortality rate following bacteremia was 7.8%. The use of fat emulsion (p = 0.003), birth weight &amp;amp;lt; 700 g (p &amp;amp;lt; 0.001), and a gestational age within 27 weeks (p &amp;amp;lt; 0.001) predicted bacteremia. (4) Conclusions: There was an association between the PN and bacteremia. Significant predictors of bacteremia were the use of fat emulsion, birth weight &amp;amp;lt; 700 g, and a gestational age within 27 weeks.</description>
	<pubDate>2026-01-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 17: The Prevalence and Impact of Bacteremia Among Neonates Receiving Parenteral Nutrition: A Multicenter Retrospective Study from Saudi Arabia</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/17">doi: 10.3390/pharmacy14010017</a></p>
	<p>Authors:
		Shaker Althobaiti
		Aisha H. Alshehri
		Abeer K. Alorabi
		Alhussain Alzahrani
		Lama Marwan Fetyani
		Ebtihal Mohsin Fairaq
		Enas Ahmed Abukwaik
		Njood Abdulsalam Alharbi
		Abrar A. Alotaibi
		Safia Ghali Alotibi
		Shaimaa Alsulami
		Abdullah Althomali
		Ahmed Ibrahim Fathelrahman
		</p>
	<p>(1) Background: We aimed to determine rates of bacteremia and multidrug resistance (MDR) bacteremia and associated risk factors among neonates receiving parenteral nutrition (PN). (2) Methods: This is a multicenter study conducted in three neonatal intensive care units in Saudi Arabia, including 414 neonates who received PN. Associations were assessed using Chi-square or Fisher&amp;amp;rsquo;s Exact tests when applicable and logistic regression analyses were conducted to determine factors predicting outcomes. Odds ratios with their 95% confidence intervals were computed, and a p value &amp;amp;lt; 0.05 was considered statistically significant. (3) Results: PN was started within the first 10 days of life in 74.4% of cases. Fat emulsion was administered to 38.9% of the newborns. Blood cultures were positive in 24.9% of patients. Among the positive cultures, 4.9% were confirmed to have MDR bacteria. The mortality rate following bacteremia was 7.8%. The use of fat emulsion (p = 0.003), birth weight &amp;amp;lt; 700 g (p &amp;amp;lt; 0.001), and a gestational age within 27 weeks (p &amp;amp;lt; 0.001) predicted bacteremia. (4) Conclusions: There was an association between the PN and bacteremia. Significant predictors of bacteremia were the use of fat emulsion, birth weight &amp;amp;lt; 700 g, and a gestational age within 27 weeks.</p>
	]]></content:encoded>

	<dc:title>The Prevalence and Impact of Bacteremia Among Neonates Receiving Parenteral Nutrition: A Multicenter Retrospective Study from Saudi Arabia</dc:title>
			<dc:creator>Shaker Althobaiti</dc:creator>
			<dc:creator>Aisha H. Alshehri</dc:creator>
			<dc:creator>Abeer K. Alorabi</dc:creator>
			<dc:creator>Alhussain Alzahrani</dc:creator>
			<dc:creator>Lama Marwan Fetyani</dc:creator>
			<dc:creator>Ebtihal Mohsin Fairaq</dc:creator>
			<dc:creator>Enas Ahmed Abukwaik</dc:creator>
			<dc:creator>Njood Abdulsalam Alharbi</dc:creator>
			<dc:creator>Abrar A. Alotaibi</dc:creator>
			<dc:creator>Safia Ghali Alotibi</dc:creator>
			<dc:creator>Shaimaa Alsulami</dc:creator>
			<dc:creator>Abdullah Althomali</dc:creator>
			<dc:creator>Ahmed Ibrahim Fathelrahman</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010017</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-26</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-26</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010017</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/16">

	<title>Pharmacy, Vol. 14, Pages 16: Parenteral Nutrition Management from the Clinical Pharmacy Perspective: Insights and Recommendations from the Saudi Society of Clinical Pharmacy</title>
	<link>https://www.mdpi.com/2226-4787/14/1/16</link>
	<description>Parenteral nutrition (PN) is essential for patients who are unable to tolerate oral or enteral feeding, providing them with necessary nutrients intravenously, including dextrose, amino acids, electrolytes, vitamins, trace elements, and lipid emulsions. Clinical pharmacists (CPs) play a critical role in PN management by ensuring proper formulation, monitoring therapy, preventing complications, and optimizing patient outcomes. In Saudi Arabia, limited literature exists on CPs&amp;amp;rsquo; involvement in total parenteral nutrition (TPN) administration, health information management (HIM) systems, and pharmacist staffing ratios. This paper examines the evolving role of CPs in PN management, addressing key challenges such as the optimal patient-to-CP ratio, the impact of HIM systems on PN prescribing, and the advantages and limitations of centralized versus decentralized PN prescription models. It highlights the need for standardized staffing levels, structured pharmacist training, and improved HIM integration to enhance workflow efficiency and prescribing accuracy. Additionally, the study examines how the adoption of advanced HIM systems can streamline documentation, reduce prescribing errors, and enhance interdisciplinary collaboration. This paper provides a framework for optimizing PN delivery, enhancing healthcare quality, and strengthening CPs&amp;amp;rsquo; contributions to nutrition support by addressing these factors. Implementing these recommendations will improve patient outcomes and establish a more efficient PN management system in Saudi Arabia, reinforcing the vital role of CPs in multidisciplinary care.</description>
	<pubDate>2026-01-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 16: Parenteral Nutrition Management from the Clinical Pharmacy Perspective: Insights and Recommendations from the Saudi Society of Clinical Pharmacy</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/16">doi: 10.3390/pharmacy14010016</a></p>
	<p>Authors:
		Nora Albanyan
		Dana Altannir
		Osama Tabbara
		Abdullah M. Alrajhi
		Ahmed Aldemerdash
		Razan Orfali
		Ahmed Aljedai
		</p>
	<p>Parenteral nutrition (PN) is essential for patients who are unable to tolerate oral or enteral feeding, providing them with necessary nutrients intravenously, including dextrose, amino acids, electrolytes, vitamins, trace elements, and lipid emulsions. Clinical pharmacists (CPs) play a critical role in PN management by ensuring proper formulation, monitoring therapy, preventing complications, and optimizing patient outcomes. In Saudi Arabia, limited literature exists on CPs&amp;amp;rsquo; involvement in total parenteral nutrition (TPN) administration, health information management (HIM) systems, and pharmacist staffing ratios. This paper examines the evolving role of CPs in PN management, addressing key challenges such as the optimal patient-to-CP ratio, the impact of HIM systems on PN prescribing, and the advantages and limitations of centralized versus decentralized PN prescription models. It highlights the need for standardized staffing levels, structured pharmacist training, and improved HIM integration to enhance workflow efficiency and prescribing accuracy. Additionally, the study examines how the adoption of advanced HIM systems can streamline documentation, reduce prescribing errors, and enhance interdisciplinary collaboration. This paper provides a framework for optimizing PN delivery, enhancing healthcare quality, and strengthening CPs&amp;amp;rsquo; contributions to nutrition support by addressing these factors. Implementing these recommendations will improve patient outcomes and establish a more efficient PN management system in Saudi Arabia, reinforcing the vital role of CPs in multidisciplinary care.</p>
	]]></content:encoded>

	<dc:title>Parenteral Nutrition Management from the Clinical Pharmacy Perspective: Insights and Recommendations from the Saudi Society of Clinical Pharmacy</dc:title>
			<dc:creator>Nora Albanyan</dc:creator>
			<dc:creator>Dana Altannir</dc:creator>
			<dc:creator>Osama Tabbara</dc:creator>
			<dc:creator>Abdullah M. Alrajhi</dc:creator>
			<dc:creator>Ahmed Aldemerdash</dc:creator>
			<dc:creator>Razan Orfali</dc:creator>
			<dc:creator>Ahmed Aljedai</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010016</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-26</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-26</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010016</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/15">

	<title>Pharmacy, Vol. 14, Pages 15: Addressing Pharmacy Admissions Declines Through a Student-Led Pre-Health Advising and Leadership System (PAALS): An Implementation Evaluation</title>
	<link>https://www.mdpi.com/2226-4787/14/1/15</link>
	<description>To enhance PharmD student leadership and advocacy skills, combat the paucity of trained pre-health advisors for pharmacy admissions, augment community relationships, and increase pharmacy admissions volume, we designed, implemented, and assessed PAALS, a Pre-health Academic Advising and Leadership System. PAALS was grounded in Astin&amp;amp;rsquo;s Theory of Student Involvement and evaluated using the RE-AIM implementation science framework. RE-AIM measured outcomes across Reach, Effectiveness, Adoption, Implementation, and Maintenance as indicators of PAALS&amp;amp;rsquo;s scale, fidelity, sustainability, and institutional embedding. Analysis of PAALS using the RE-AIM framework demonstrated the following outcomes: (1) Reach: 42 P1-P3 PharmD students participated as mentors; external partnerships expanded from 2 to 8 regional high schools and community programs; and more than 25 mentored learners successfully matriculated into the PharmD program. (2) Effectiveness: students enacted sustained leadership, advocacy, and mentoring roles. (3) Adoption: voluntary uptake of mentoring and governance roles by PharmD students occurred with repeated engagement by external partner institutions. (4) Implementation: Core program components were delivered consistently using existing institutional resources. (5) Maintenance: PAALS remained operational across five academic years despite student turnover, with leadership succession and institutional embedding sustained across cohorts. Our findings demonstrate that student-led advising and advocacy ecosystems address critical gaps in pharmacy-specific pre-health advising models.</description>
	<pubDate>2026-01-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 15: Addressing Pharmacy Admissions Declines Through a Student-Led Pre-Health Advising and Leadership System (PAALS): An Implementation Evaluation</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/15">doi: 10.3390/pharmacy14010015</a></p>
	<p>Authors:
		Ashim Malhotra
		</p>
	<p>To enhance PharmD student leadership and advocacy skills, combat the paucity of trained pre-health advisors for pharmacy admissions, augment community relationships, and increase pharmacy admissions volume, we designed, implemented, and assessed PAALS, a Pre-health Academic Advising and Leadership System. PAALS was grounded in Astin&amp;amp;rsquo;s Theory of Student Involvement and evaluated using the RE-AIM implementation science framework. RE-AIM measured outcomes across Reach, Effectiveness, Adoption, Implementation, and Maintenance as indicators of PAALS&amp;amp;rsquo;s scale, fidelity, sustainability, and institutional embedding. Analysis of PAALS using the RE-AIM framework demonstrated the following outcomes: (1) Reach: 42 P1-P3 PharmD students participated as mentors; external partnerships expanded from 2 to 8 regional high schools and community programs; and more than 25 mentored learners successfully matriculated into the PharmD program. (2) Effectiveness: students enacted sustained leadership, advocacy, and mentoring roles. (3) Adoption: voluntary uptake of mentoring and governance roles by PharmD students occurred with repeated engagement by external partner institutions. (4) Implementation: Core program components were delivered consistently using existing institutional resources. (5) Maintenance: PAALS remained operational across five academic years despite student turnover, with leadership succession and institutional embedding sustained across cohorts. Our findings demonstrate that student-led advising and advocacy ecosystems address critical gaps in pharmacy-specific pre-health advising models.</p>
	]]></content:encoded>

	<dc:title>Addressing Pharmacy Admissions Declines Through a Student-Led Pre-Health Advising and Leadership System (PAALS): An Implementation Evaluation</dc:title>
			<dc:creator>Ashim Malhotra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010015</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-25</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-25</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010015</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/14">

	<title>Pharmacy, Vol. 14, Pages 14: Trends in Antipsychotic Drug Use in the United States, 2000&amp;ndash;2016</title>
	<link>https://www.mdpi.com/2226-4787/14/1/14</link>
	<description>This study evaluated long-term trends in the prevalence of use of atypical and typical antipsychotic drugs (APDs), both as classes of drugs and as individual drugs, among adult inpatients in the United States (US). The Health Facts&amp;amp;reg; database developed by Cerner Corporation was used to analyze the prevalence of APD use among adult inpatients aged 18 years or older who were administered at least one antipsychotic medication order during hospitalization between 1 January 2000 and 31 December 2016. The prevalence of APD use was standardized by age, sex, race, and census region. Typical and atypical antipsychotic treatment patterns in the US differed over this period. While the use of atypical APDs increased overall, the use of typical antipsychotic medications decreased, but remained more prevalent. Overall, haloperidol and prochlorperazine were the two most administered antipsychotic medications throughout the study period. From 2000 to 2011, prochlorperazine and haloperidol were the first- and second-most prescribed typical APDs, respectively; haloperidol became the most administered antipsychotic of this class as of 2012. Quetiapine was the most administered atypical antipsychotic medication, followed by risperidone and olanzapine until 2014, after which olanzapine was the second-most administered atypical APD. There was a notable decline in the use of atypical antipsychotics medications between 2005 and 2008, which may reflect the impact of the Food and Drug Administration&amp;amp;rsquo;s warnings and the American Diabetes Association&amp;amp;rsquo;s consensus position, but only for a short time. The usage patterns observed in this study support existing evidence of substantial off-label use of antipsychotic drugs in the US.</description>
	<pubDate>2026-01-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 14: Trends in Antipsychotic Drug Use in the United States, 2000&amp;ndash;2016</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/14">doi: 10.3390/pharmacy14010014</a></p>
	<p>Authors:
		Nisrine Haddad
		Nawal Farhat
		Jennifer Go
		Yue Chen
		Christopher A. Gravel
		Franco Momoli
		Donald R. Mattison
		Douglas McNair
		Abdallah Alami
		Daniel Krewski
		</p>
	<p>This study evaluated long-term trends in the prevalence of use of atypical and typical antipsychotic drugs (APDs), both as classes of drugs and as individual drugs, among adult inpatients in the United States (US). The Health Facts&amp;amp;reg; database developed by Cerner Corporation was used to analyze the prevalence of APD use among adult inpatients aged 18 years or older who were administered at least one antipsychotic medication order during hospitalization between 1 January 2000 and 31 December 2016. The prevalence of APD use was standardized by age, sex, race, and census region. Typical and atypical antipsychotic treatment patterns in the US differed over this period. While the use of atypical APDs increased overall, the use of typical antipsychotic medications decreased, but remained more prevalent. Overall, haloperidol and prochlorperazine were the two most administered antipsychotic medications throughout the study period. From 2000 to 2011, prochlorperazine and haloperidol were the first- and second-most prescribed typical APDs, respectively; haloperidol became the most administered antipsychotic of this class as of 2012. Quetiapine was the most administered atypical antipsychotic medication, followed by risperidone and olanzapine until 2014, after which olanzapine was the second-most administered atypical APD. There was a notable decline in the use of atypical antipsychotics medications between 2005 and 2008, which may reflect the impact of the Food and Drug Administration&amp;amp;rsquo;s warnings and the American Diabetes Association&amp;amp;rsquo;s consensus position, but only for a short time. The usage patterns observed in this study support existing evidence of substantial off-label use of antipsychotic drugs in the US.</p>
	]]></content:encoded>

	<dc:title>Trends in Antipsychotic Drug Use in the United States, 2000&amp;amp;ndash;2016</dc:title>
			<dc:creator>Nisrine Haddad</dc:creator>
			<dc:creator>Nawal Farhat</dc:creator>
			<dc:creator>Jennifer Go</dc:creator>
			<dc:creator>Yue Chen</dc:creator>
			<dc:creator>Christopher A. Gravel</dc:creator>
			<dc:creator>Franco Momoli</dc:creator>
			<dc:creator>Donald R. Mattison</dc:creator>
			<dc:creator>Douglas McNair</dc:creator>
			<dc:creator>Abdallah Alami</dc:creator>
			<dc:creator>Daniel Krewski</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010014</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-24</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-24</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010014</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/13">

	<title>Pharmacy, Vol. 14, Pages 13: Comparison of Subcutaneous Versus Intramuscular Estradiol Administration for Feminizing Gender-Affirming Hormone Therapy</title>
	<link>https://www.mdpi.com/2226-4787/14/1/13</link>
	<description>This single health system, retrospective cohort study compared subcutaneous (SC) versus intramuscular (IM) estradiol administration in 70 adult patients with a diagnosis of gender incongruence or gender dysphoria seen in an LGBTQ Specialty Clinic within a safety-net institution between October 2018 and December 2024. The primary endpoint was patients who reached therapeutic estradiol levels at 6 months. Secondary endpoints included the incidence of sub- and supra-therapeutic and actual estradiol levels at months 3, 6, 9, and 12 and patients who received pharmacist-led injection technique education. At 6 months, the proportion of patients achieving therapeutic estradiol levels did not differ between IM and SC administration. In exploratory analyses of continuous estradiol concentrations, IM administration was associated with higher measured estradiol levels.</description>
	<pubDate>2026-01-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 13: Comparison of Subcutaneous Versus Intramuscular Estradiol Administration for Feminizing Gender-Affirming Hormone Therapy</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/13">doi: 10.3390/pharmacy14010013</a></p>
	<p>Authors:
		Abby C. Poage
		Jordan M. Rowe
		Mary Beth A. Dameron
		Abigail M. Bavuso
		Andrew J. Smith
		</p>
	<p>This single health system, retrospective cohort study compared subcutaneous (SC) versus intramuscular (IM) estradiol administration in 70 adult patients with a diagnosis of gender incongruence or gender dysphoria seen in an LGBTQ Specialty Clinic within a safety-net institution between October 2018 and December 2024. The primary endpoint was patients who reached therapeutic estradiol levels at 6 months. Secondary endpoints included the incidence of sub- and supra-therapeutic and actual estradiol levels at months 3, 6, 9, and 12 and patients who received pharmacist-led injection technique education. At 6 months, the proportion of patients achieving therapeutic estradiol levels did not differ between IM and SC administration. In exploratory analyses of continuous estradiol concentrations, IM administration was associated with higher measured estradiol levels.</p>
	]]></content:encoded>

	<dc:title>Comparison of Subcutaneous Versus Intramuscular Estradiol Administration for Feminizing Gender-Affirming Hormone Therapy</dc:title>
			<dc:creator>Abby C. Poage</dc:creator>
			<dc:creator>Jordan M. Rowe</dc:creator>
			<dc:creator>Mary Beth A. Dameron</dc:creator>
			<dc:creator>Abigail M. Bavuso</dc:creator>
			<dc:creator>Andrew J. Smith</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010013</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-23</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-23</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010013</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/12">

	<title>Pharmacy, Vol. 14, Pages 12: Drug-Drug Interaction Knowledge, Practices, and Barriers in Community Pharmacies: A Cross-Sectional Study from Jazan Region, Saudi Arabia</title>
	<link>https://www.mdpi.com/2226-4787/14/1/12</link>
	<description>(1) Background: Drug&amp;amp;ndash;drug interactions (DDIs) are a frequent cause of medication-related harm, particularly in ambulatory care. Community pharmacists are uniquely positioned to identify and manage these risks. This study assessed DDI knowledge, practices, and barriers among community pharmacists in the Jazan Region, Saudi Arabia. (2) Methods: A structured, self-administered questionnaire was distributed to community pharmacists. The survey assessed DDI knowledge using 26 clinically relevant drug pairings and included questions on professional behavior, training exposure, software use, and educational needs. Descriptive and inferential statistics were applied to identify associations between knowledge scores and demographic or practice-related variables. (3) Results: A total of 219 pharmacists participated in the study. The mean knowledge score was (9.63 &amp;amp;plusmn; 4.58) out of 26, reflecting suboptimal to moderate awareness. Female pharmacists demonstrated significantly higher DDI knowledge scores than males (10.74 &amp;amp;plusmn; 5.4 vs. 9.08 &amp;amp;plusmn; 4.2; p = 0.016). Knowledge scores also differed significantly by academic qualification (p &amp;amp;lt; 0.001), with PharmD holders scoring higher than B. Pharm and postgraduate degree holders. Pharmacists with less than 10 years of experience had significantly higher scores compared with those with longer practice duration (p = 0.002). Additionally, pharmacists who graduated from Saudi institutions scored higher than those trained outside Saudi Arabia (10.22 &amp;amp;plusmn; 4.7 vs. 8.44 &amp;amp;plusmn; 4.2; p = 0.005). Pharmacists who had received professional development training and those who attended workshops regularly also scored significantly higher. Familiarity with guidelines showed a positive trend. Reported barriers to effective DDI counseling included time constraints, limited patient understanding, and poor collaboration with prescribers. Self-rated awareness of DDIs was positively associated with actual knowledge scores. Pharmacists expressed strong preferences for workshops, online courses, and webinars as future training formats. (4) Conclusions: Pharmacists in the Jazan Region demonstrate moderate awareness of DDIs, with variation influenced by training, experience, and qualifications. Enhancing access to structured professional development and integrating clinical decision support tools could strengthen pharmacists&amp;amp;rsquo; role in preventing DDIs in community practice.</description>
	<pubDate>2026-01-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 12: Drug-Drug Interaction Knowledge, Practices, and Barriers in Community Pharmacies: A Cross-Sectional Study from Jazan Region, Saudi Arabia</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/12">doi: 10.3390/pharmacy14010012</a></p>
	<p>Authors:
		Moaddey Alfarhan
		Muath F. Haqwi
		Abdulrahman H. Musayyikh
		Jala Ashqar
		Lama Y. Suwidi
		Amal H. Fageh
		Enas A. Alajam
		Hadi Almansour
		Thamir M. Alshammari
		Saeed Al-Qahtani
		</p>
	<p>(1) Background: Drug&amp;amp;ndash;drug interactions (DDIs) are a frequent cause of medication-related harm, particularly in ambulatory care. Community pharmacists are uniquely positioned to identify and manage these risks. This study assessed DDI knowledge, practices, and barriers among community pharmacists in the Jazan Region, Saudi Arabia. (2) Methods: A structured, self-administered questionnaire was distributed to community pharmacists. The survey assessed DDI knowledge using 26 clinically relevant drug pairings and included questions on professional behavior, training exposure, software use, and educational needs. Descriptive and inferential statistics were applied to identify associations between knowledge scores and demographic or practice-related variables. (3) Results: A total of 219 pharmacists participated in the study. The mean knowledge score was (9.63 &amp;amp;plusmn; 4.58) out of 26, reflecting suboptimal to moderate awareness. Female pharmacists demonstrated significantly higher DDI knowledge scores than males (10.74 &amp;amp;plusmn; 5.4 vs. 9.08 &amp;amp;plusmn; 4.2; p = 0.016). Knowledge scores also differed significantly by academic qualification (p &amp;amp;lt; 0.001), with PharmD holders scoring higher than B. Pharm and postgraduate degree holders. Pharmacists with less than 10 years of experience had significantly higher scores compared with those with longer practice duration (p = 0.002). Additionally, pharmacists who graduated from Saudi institutions scored higher than those trained outside Saudi Arabia (10.22 &amp;amp;plusmn; 4.7 vs. 8.44 &amp;amp;plusmn; 4.2; p = 0.005). Pharmacists who had received professional development training and those who attended workshops regularly also scored significantly higher. Familiarity with guidelines showed a positive trend. Reported barriers to effective DDI counseling included time constraints, limited patient understanding, and poor collaboration with prescribers. Self-rated awareness of DDIs was positively associated with actual knowledge scores. Pharmacists expressed strong preferences for workshops, online courses, and webinars as future training formats. (4) Conclusions: Pharmacists in the Jazan Region demonstrate moderate awareness of DDIs, with variation influenced by training, experience, and qualifications. Enhancing access to structured professional development and integrating clinical decision support tools could strengthen pharmacists&amp;amp;rsquo; role in preventing DDIs in community practice.</p>
	]]></content:encoded>

	<dc:title>Drug-Drug Interaction Knowledge, Practices, and Barriers in Community Pharmacies: A Cross-Sectional Study from Jazan Region, Saudi Arabia</dc:title>
			<dc:creator>Moaddey Alfarhan</dc:creator>
			<dc:creator>Muath F. Haqwi</dc:creator>
			<dc:creator>Abdulrahman H. Musayyikh</dc:creator>
			<dc:creator>Jala Ashqar</dc:creator>
			<dc:creator>Lama Y. Suwidi</dc:creator>
			<dc:creator>Amal H. Fageh</dc:creator>
			<dc:creator>Enas A. Alajam</dc:creator>
			<dc:creator>Hadi Almansour</dc:creator>
			<dc:creator>Thamir M. Alshammari</dc:creator>
			<dc:creator>Saeed Al-Qahtani</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010012</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-23</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-23</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010012</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/11">

	<title>Pharmacy, Vol. 14, Pages 11: Medication Regimen Complexity and Patient-Reported Adverse Drug Events in Korean Community Pharmacies: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2226-4787/14/1/11</link>
	<description>Evidence linking medication regimen complexity to patient-reported adverse drug events (ADEs) is limited. This study examined the association between regimen complexity and patient-reported ADEs among adults using community pharmacy services. A cross-sectional survey was conducted among adults with prescription experience at community pharmacies in Korea (14 January&amp;amp;ndash;24 February 2025). Data included MRCI-K scores, medication adherence, ADE reports, comorbidities, polypharmacy status, and demographics. Prescription records verified medication counts and drug-related risks. Determinants of regimen complexity were assessed using multivariable linear regression, and predictors of ADE reporting were examined using multivariable logistic regression. Among 201 participants, 101 (50.2%) reported at least one ADE in the past month. Polypharmacy, comorbidities, and multidose dispensing service use were independently associated with higher regimen complexity, whereas higher income, college education, and older age were associated with lower complexity. Higher MRCI-K scores (OR = 0.95, 95% CI 0.91&amp;amp;ndash;0.99) and older age (OR = 0.98, 95% CI 0.96&amp;amp;ndash;0.99) were associated with lower odds of ADE reporting. Higher medication regimen complexity and older age were associated with reduced reporting of ADEs, suggesting possible under-recognition among these populations. Patient-centered strategies are needed to enhance ADE identification in individuals with complex medication regimens.</description>
	<pubDate>2026-01-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 11: Medication Regimen Complexity and Patient-Reported Adverse Drug Events in Korean Community Pharmacies: A Cross-Sectional Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/11">doi: 10.3390/pharmacy14010011</a></p>
	<p>Authors:
		Sunmin Lee
		Kyung sun Oh
		</p>
	<p>Evidence linking medication regimen complexity to patient-reported adverse drug events (ADEs) is limited. This study examined the association between regimen complexity and patient-reported ADEs among adults using community pharmacy services. A cross-sectional survey was conducted among adults with prescription experience at community pharmacies in Korea (14 January&amp;amp;ndash;24 February 2025). Data included MRCI-K scores, medication adherence, ADE reports, comorbidities, polypharmacy status, and demographics. Prescription records verified medication counts and drug-related risks. Determinants of regimen complexity were assessed using multivariable linear regression, and predictors of ADE reporting were examined using multivariable logistic regression. Among 201 participants, 101 (50.2%) reported at least one ADE in the past month. Polypharmacy, comorbidities, and multidose dispensing service use were independently associated with higher regimen complexity, whereas higher income, college education, and older age were associated with lower complexity. Higher MRCI-K scores (OR = 0.95, 95% CI 0.91&amp;amp;ndash;0.99) and older age (OR = 0.98, 95% CI 0.96&amp;amp;ndash;0.99) were associated with lower odds of ADE reporting. Higher medication regimen complexity and older age were associated with reduced reporting of ADEs, suggesting possible under-recognition among these populations. Patient-centered strategies are needed to enhance ADE identification in individuals with complex medication regimens.</p>
	]]></content:encoded>

	<dc:title>Medication Regimen Complexity and Patient-Reported Adverse Drug Events in Korean Community Pharmacies: A Cross-Sectional Study</dc:title>
			<dc:creator>Sunmin Lee</dc:creator>
			<dc:creator>Kyung sun Oh</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010011</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-22</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-22</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010011</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/10">

	<title>Pharmacy, Vol. 14, Pages 10: AI-Enabled Sacramento Public Health (SACPH) App: A Reproducible AI-Based Method for Population-to-Practice Reasoning in Foundational Sciences in Pharmacy Education</title>
	<link>https://www.mdpi.com/2226-4787/14/1/10</link>
	<description>Foundational biomedical sciences are commonly taught without routine integration of local population health contexts, limiting students&amp;amp;rsquo; ability to connect mechanisms to community disease burden and practice responsibilities. In this method paper, we developed and piloted an AI-enabled &amp;amp;ldquo;Sacramento County Public Health (SACPH)&amp;amp;rdquo; AI workflow and app prototype, a structured, faculty-authored prompt sequence designed to guide population-to-practice reasoning using publicly available data. The workflow was implemented during a TBL session with first-year PharmD students in an immunology course. Using splenectomy and risk of overwhelming post-splenectomy infection (OPSI) as an illustrative use case, students executed a standardized prompt sequence addressing data source identification, coding logic (diagnosis vs. procedure codes), population-level estimation with uncertainty framing, and translation to pharmacist-relevant prevention and counseling implications. Feasibility was defined by conceptual convergence. The validated reasoning workflow was subsequently translated into a prototype, app-style interface using generative design prompts. Across student teams, outputs converged on similar categories, consistent recognition of coding frameworks and verification steps, and directionally similar interpretations of local burden and pharmacist responsibilities. The prototype demonstrated successful externalization of the reasoning workflow into a modular, reproducible artifact. SACPH demonstrates a feasible, reproducible method for using generative AI to integrate foundational science instruction with local population health context and pharmacist practice reasoning, while supporting AI literacy competencies.</description>
	<pubDate>2026-01-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 10: AI-Enabled Sacramento Public Health (SACPH) App: A Reproducible AI-Based Method for Population-to-Practice Reasoning in Foundational Sciences in Pharmacy Education</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/10">doi: 10.3390/pharmacy14010010</a></p>
	<p>Authors:
		Ashim Malhotra
		</p>
	<p>Foundational biomedical sciences are commonly taught without routine integration of local population health contexts, limiting students&amp;amp;rsquo; ability to connect mechanisms to community disease burden and practice responsibilities. In this method paper, we developed and piloted an AI-enabled &amp;amp;ldquo;Sacramento County Public Health (SACPH)&amp;amp;rdquo; AI workflow and app prototype, a structured, faculty-authored prompt sequence designed to guide population-to-practice reasoning using publicly available data. The workflow was implemented during a TBL session with first-year PharmD students in an immunology course. Using splenectomy and risk of overwhelming post-splenectomy infection (OPSI) as an illustrative use case, students executed a standardized prompt sequence addressing data source identification, coding logic (diagnosis vs. procedure codes), population-level estimation with uncertainty framing, and translation to pharmacist-relevant prevention and counseling implications. Feasibility was defined by conceptual convergence. The validated reasoning workflow was subsequently translated into a prototype, app-style interface using generative design prompts. Across student teams, outputs converged on similar categories, consistent recognition of coding frameworks and verification steps, and directionally similar interpretations of local burden and pharmacist responsibilities. The prototype demonstrated successful externalization of the reasoning workflow into a modular, reproducible artifact. SACPH demonstrates a feasible, reproducible method for using generative AI to integrate foundational science instruction with local population health context and pharmacist practice reasoning, while supporting AI literacy competencies.</p>
	]]></content:encoded>

	<dc:title>AI-Enabled Sacramento Public Health (SACPH) App: A Reproducible AI-Based Method for Population-to-Practice Reasoning in Foundational Sciences in Pharmacy Education</dc:title>
			<dc:creator>Ashim Malhotra</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010010</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-16</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-16</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010010</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/9">

	<title>Pharmacy, Vol. 14, Pages 9: Irisin as a Neuroprotective Agent in Parkinson&amp;rsquo;s Disease: The Role of Physical Exercise in Modulating Dopaminergic Neurons</title>
	<link>https://www.mdpi.com/2226-4787/14/1/9</link>
	<description>Exercise-induced myokines have emerged as crucial mediators of the beneficial effects of physical activity on neurodegenerative diseases through complex molecular mechanisms involving oxidative stress reduction, neuroinflammation suppression, and synaptic plasticity enhancement. Among these myokines, irisin, encoded by the FNDC5 gene, has gained significant attention as a potential therapeutic target in neurodegenerative conditions due to its ability to cross the blood&amp;amp;ndash;brain barrier and exert pleiotropic neuroprotective effects. This review synthesizes current evidence from both preclinical and clinical studies examining the role of exercise-induced irisin in neurodegeneration, with particular emphasis on translational potential and therapeutic applications. A comprehensive search was conducted across PubMed, Web of Science, Scopus, and EMBASE databases (spanning January 2015 to December 2024) to identify peer-reviewed articles investigating irisin&amp;amp;rsquo;s neuroprotective mechanisms in neurodegenerative diseases. Ten studies met the inclusion criteria (five rodent/primate model studies and five human clinical investigations), which were analyzed for methodological rigor, intervention protocols, biomarker quantification methods, and reported outcomes. Reviewed studies consistently demonstrated that exercise-induced endogenous irisin elevation correlates with improved cognitive function, reduced neuroinflammatory markers, enhanced synaptic plasticity, and modulation of neurodegenerative pathways, with exogenous irisin administration reproducing several neuroprotective benefits observed with exercise training in animal models. However, substantial heterogeneity exists regarding exercise prescription parameters (intensity, duration, frequency, modality), training-induced irisin quantification methodologies (ELISA versus mass spectrometry), and study designs (ranging from uncontrolled human observations to randomized controlled trials in animal models). Critical appraisal reveals that human studies lack adequate control for confounding variables including baseline physical fitness, comorbidities, concurrent medications, and potential sources of bias, while biochemical studies indicate distinct pharmacokinetics between endogenous training-induced irisin and exogenous bolus dosing, necessitating careful interpretation of therapeutic applicability. The translational potential of irisin as a therapeutic agent or drug target depends on resolving methodological standardization in biomarker measurement, conducting well-designed clinical trials with rigorous control for confounders, and integrating findings from molecular/biochemical studies to elucidate mechanisms linking irisin to disease modification. Future research should prioritize establishing clinical trial frameworks that harmonize exercise prescriptions, employ robust biomarker quantification (mass spectrometry), and stratify participants based on disease stage, comorbidities, and genetic predisposition to clarify irisin&amp;amp;rsquo;s role as a potential therapeutic intervention in neurodegenerative disease management.</description>
	<pubDate>2026-01-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 9: Irisin as a Neuroprotective Agent in Parkinson&amp;rsquo;s Disease: The Role of Physical Exercise in Modulating Dopaminergic Neurons</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/9">doi: 10.3390/pharmacy14010009</a></p>
	<p>Authors:
		José Garcia de Brito-Neto
		Paulo Leonardo de Góis Morais
		José Rodolfo Lopes de Paiva Cavalcanti
		Francisco Irochima Pinheiro
		Fausto Pierdoná Guzen
		Ricardo Ney Cobucci
		</p>
	<p>Exercise-induced myokines have emerged as crucial mediators of the beneficial effects of physical activity on neurodegenerative diseases through complex molecular mechanisms involving oxidative stress reduction, neuroinflammation suppression, and synaptic plasticity enhancement. Among these myokines, irisin, encoded by the FNDC5 gene, has gained significant attention as a potential therapeutic target in neurodegenerative conditions due to its ability to cross the blood&amp;amp;ndash;brain barrier and exert pleiotropic neuroprotective effects. This review synthesizes current evidence from both preclinical and clinical studies examining the role of exercise-induced irisin in neurodegeneration, with particular emphasis on translational potential and therapeutic applications. A comprehensive search was conducted across PubMed, Web of Science, Scopus, and EMBASE databases (spanning January 2015 to December 2024) to identify peer-reviewed articles investigating irisin&amp;amp;rsquo;s neuroprotective mechanisms in neurodegenerative diseases. Ten studies met the inclusion criteria (five rodent/primate model studies and five human clinical investigations), which were analyzed for methodological rigor, intervention protocols, biomarker quantification methods, and reported outcomes. Reviewed studies consistently demonstrated that exercise-induced endogenous irisin elevation correlates with improved cognitive function, reduced neuroinflammatory markers, enhanced synaptic plasticity, and modulation of neurodegenerative pathways, with exogenous irisin administration reproducing several neuroprotective benefits observed with exercise training in animal models. However, substantial heterogeneity exists regarding exercise prescription parameters (intensity, duration, frequency, modality), training-induced irisin quantification methodologies (ELISA versus mass spectrometry), and study designs (ranging from uncontrolled human observations to randomized controlled trials in animal models). Critical appraisal reveals that human studies lack adequate control for confounding variables including baseline physical fitness, comorbidities, concurrent medications, and potential sources of bias, while biochemical studies indicate distinct pharmacokinetics between endogenous training-induced irisin and exogenous bolus dosing, necessitating careful interpretation of therapeutic applicability. The translational potential of irisin as a therapeutic agent or drug target depends on resolving methodological standardization in biomarker measurement, conducting well-designed clinical trials with rigorous control for confounders, and integrating findings from molecular/biochemical studies to elucidate mechanisms linking irisin to disease modification. Future research should prioritize establishing clinical trial frameworks that harmonize exercise prescriptions, employ robust biomarker quantification (mass spectrometry), and stratify participants based on disease stage, comorbidities, and genetic predisposition to clarify irisin&amp;amp;rsquo;s role as a potential therapeutic intervention in neurodegenerative disease management.</p>
	]]></content:encoded>

	<dc:title>Irisin as a Neuroprotective Agent in Parkinson&amp;amp;rsquo;s Disease: The Role of Physical Exercise in Modulating Dopaminergic Neurons</dc:title>
			<dc:creator>José Garcia de Brito-Neto</dc:creator>
			<dc:creator>Paulo Leonardo de Góis Morais</dc:creator>
			<dc:creator>José Rodolfo Lopes de Paiva Cavalcanti</dc:creator>
			<dc:creator>Francisco Irochima Pinheiro</dc:creator>
			<dc:creator>Fausto Pierdoná Guzen</dc:creator>
			<dc:creator>Ricardo Ney Cobucci</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010009</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-13</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-13</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010009</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/8">

	<title>Pharmacy, Vol. 14, Pages 8: Patient and Physician Perspectives on Pharmacotherapy in Parkinson&amp;rsquo;s Disease Psychosis: A Mixed-Methods Exploratory Study</title>
	<link>https://www.mdpi.com/2226-4787/14/1/8</link>
	<description>Psychosis is a frequent and disabling non-motor complication of Parkinson&amp;amp;rsquo;s disease (PD). Clozapine and quetiapine are widely used in the treatment of Parkinson&amp;amp;rsquo;s disease psychosis (PDP). We conducted an exploratory study to compare patient experiences with physician prescribing practices. Patients with PDP hospitalized at a university center completed semi-structured interviews on perceived efficacy, adverse effects, and daily functioning. Neurologists and geriatricians attending training sessions completed a structured questionnaire on prescribing patterns, attitudes toward clozapine, and perceived treatment burden. Data were analyzed thematically and triangulated across cohorts. Eleven patients (mean age 81 years; nine treated with quetiapine, two with clozapine) were included. Most quetiapine-treated patients reported persistent hallucinations, sedation, dizziness, and reduced autonomy. Fourteen physicians completed the survey and most preferred quetiapine, citing monitoring logistics and agranulocytosis risk as barriers to clozapine. Overall, patient priorities centered on symptom control and independence, whereas physician decisions emphasized feasibility and safety. Facilitating clozapine monitoring and incorporating patient-reported outcomes into routine care may improve patient-centered PDP management.</description>
	<pubDate>2026-01-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 8: Patient and Physician Perspectives on Pharmacotherapy in Parkinson&amp;rsquo;s Disease Psychosis: A Mixed-Methods Exploratory Study</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/8">doi: 10.3390/pharmacy14010008</a></p>
	<p>Authors:
		Olaf Rose
		Tobias Hinteregger
		Eugen Trinka
		Bernhard Iglseder
		Johanna Pachmayr
		Stephanie Clemens
		</p>
	<p>Psychosis is a frequent and disabling non-motor complication of Parkinson&amp;amp;rsquo;s disease (PD). Clozapine and quetiapine are widely used in the treatment of Parkinson&amp;amp;rsquo;s disease psychosis (PDP). We conducted an exploratory study to compare patient experiences with physician prescribing practices. Patients with PDP hospitalized at a university center completed semi-structured interviews on perceived efficacy, adverse effects, and daily functioning. Neurologists and geriatricians attending training sessions completed a structured questionnaire on prescribing patterns, attitudes toward clozapine, and perceived treatment burden. Data were analyzed thematically and triangulated across cohorts. Eleven patients (mean age 81 years; nine treated with quetiapine, two with clozapine) were included. Most quetiapine-treated patients reported persistent hallucinations, sedation, dizziness, and reduced autonomy. Fourteen physicians completed the survey and most preferred quetiapine, citing monitoring logistics and agranulocytosis risk as barriers to clozapine. Overall, patient priorities centered on symptom control and independence, whereas physician decisions emphasized feasibility and safety. Facilitating clozapine monitoring and incorporating patient-reported outcomes into routine care may improve patient-centered PDP management.</p>
	]]></content:encoded>

	<dc:title>Patient and Physician Perspectives on Pharmacotherapy in Parkinson&amp;amp;rsquo;s Disease Psychosis: A Mixed-Methods Exploratory Study</dc:title>
			<dc:creator>Olaf Rose</dc:creator>
			<dc:creator>Tobias Hinteregger</dc:creator>
			<dc:creator>Eugen Trinka</dc:creator>
			<dc:creator>Bernhard Iglseder</dc:creator>
			<dc:creator>Johanna Pachmayr</dc:creator>
			<dc:creator>Stephanie Clemens</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010008</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-13</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-13</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010008</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/7">

	<title>Pharmacy, Vol. 14, Pages 7: Leveraging Artificial Intelligence-Based Applications to Remove Disruptive Factors from Pharmaceutical Care: A Quantitative Study in Eastern Romania</title>
	<link>https://www.mdpi.com/2226-4787/14/1/7</link>
	<description>Artificial Intelligence (AI) has increasingly contributed to advancements in pharmaceutical practice, particularly by enhancing the pharmacist&amp;amp;ndash;patient relationship and improving medication adherence. This quantitative, descriptive, cross-sectional study investigated Eastern Romanian pharmacists&amp;amp;rsquo; perception of AI-based applications as effective optimization tools, correlating it with disruptive communication factors. An anonymous and online questionnaire was distributed to community pharmacists, examining sociodemographic characteristics, awareness of disruptive factors, and the perceived usefulness of AI. The sample included 437 respondents: pharmacists (55.6%), mostly female (83.8%), and aged between 25 and 44 (52.6%). Data analysis involved descriptive statistics and independent t-tests. The statistical analysis revealed a significantly positive perception (p &amp;amp;lt; 0.001) of AI on pharmacist&amp;amp;ndash;patient communication. Respondents viewed AI as a valuable tool for reducing medication errors and optimizing counseling time, though they maintain a strong emphasis on genuine human interaction. Significant correlations were found between disruptive factors&amp;amp;mdash;such as noise and high patient volume&amp;amp;mdash;and the quality of communication. Participants also expressed an increased interest in applications like automatic prescription scheduling and the use of chatbots. The study concludes that a balanced implementation of AI technologies is necessary, one that runs parallel with the continuous development of pharmacists&amp;amp;rsquo; communication skills. Future research should focus on validating AI&amp;amp;rsquo;s impact on clinical outcomes and establishing clear ethical guidelines regarding the use of patient data.</description>
	<pubDate>2026-01-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 7: Leveraging Artificial Intelligence-Based Applications to Remove Disruptive Factors from Pharmaceutical Care: A Quantitative Study in Eastern Romania</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/7">doi: 10.3390/pharmacy14010007</a></p>
	<p>Authors:
		Ionela Daniela Ferțu
		Alina Mihaela Elisei
		Mariana Lupoae
		Alexandra Burlacu
		Claudia Simona Ștefan
		Luminița Enache
		Andrei Vlad Brădeanu
		Loredana Sabina Pascu
		Iulia Chiscop
		Mădălina Nicoleta Matei
		Aurel Nechita
		Ancuța Iacob
		</p>
	<p>Artificial Intelligence (AI) has increasingly contributed to advancements in pharmaceutical practice, particularly by enhancing the pharmacist&amp;amp;ndash;patient relationship and improving medication adherence. This quantitative, descriptive, cross-sectional study investigated Eastern Romanian pharmacists&amp;amp;rsquo; perception of AI-based applications as effective optimization tools, correlating it with disruptive communication factors. An anonymous and online questionnaire was distributed to community pharmacists, examining sociodemographic characteristics, awareness of disruptive factors, and the perceived usefulness of AI. The sample included 437 respondents: pharmacists (55.6%), mostly female (83.8%), and aged between 25 and 44 (52.6%). Data analysis involved descriptive statistics and independent t-tests. The statistical analysis revealed a significantly positive perception (p &amp;amp;lt; 0.001) of AI on pharmacist&amp;amp;ndash;patient communication. Respondents viewed AI as a valuable tool for reducing medication errors and optimizing counseling time, though they maintain a strong emphasis on genuine human interaction. Significant correlations were found between disruptive factors&amp;amp;mdash;such as noise and high patient volume&amp;amp;mdash;and the quality of communication. Participants also expressed an increased interest in applications like automatic prescription scheduling and the use of chatbots. The study concludes that a balanced implementation of AI technologies is necessary, one that runs parallel with the continuous development of pharmacists&amp;amp;rsquo; communication skills. Future research should focus on validating AI&amp;amp;rsquo;s impact on clinical outcomes and establishing clear ethical guidelines regarding the use of patient data.</p>
	]]></content:encoded>

	<dc:title>Leveraging Artificial Intelligence-Based Applications to Remove Disruptive Factors from Pharmaceutical Care: A Quantitative Study in Eastern Romania</dc:title>
			<dc:creator>Ionela Daniela Ferțu</dc:creator>
			<dc:creator>Alina Mihaela Elisei</dc:creator>
			<dc:creator>Mariana Lupoae</dc:creator>
			<dc:creator>Alexandra Burlacu</dc:creator>
			<dc:creator>Claudia Simona Ștefan</dc:creator>
			<dc:creator>Luminița Enache</dc:creator>
			<dc:creator>Andrei Vlad Brădeanu</dc:creator>
			<dc:creator>Loredana Sabina Pascu</dc:creator>
			<dc:creator>Iulia Chiscop</dc:creator>
			<dc:creator>Mădălina Nicoleta Matei</dc:creator>
			<dc:creator>Aurel Nechita</dc:creator>
			<dc:creator>Ancuța Iacob</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010007</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-09</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-09</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010007</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/6">

	<title>Pharmacy, Vol. 14, Pages 6: Epidemiological Assessment of Benzodiazepine Dependence via Pharmacist-Led EMR Review in Pain and Palliative Care Institution</title>
	<link>https://www.mdpi.com/2226-4787/14/1/6</link>
	<description>Background/Objectives: Benzodiazepines (BZDs) are used routinely in cases requiring sedation for anxiety, insomnia, and procedures that require pain management, and daily use of these agents may extend over several months; therefore, monitoring patients is essential to reduce the risk of developing dependence. However, the high patient volume in pain and palliative-care settings often limits physicians&amp;amp;rsquo; ability to both conduct consultations and perform comprehensive evaluations. In this context, the pharmacist plays a key role in supporting patient care by contributing professional activities that enhance patient well-being, such as conducting systematic reviews of electronic medical records. This pharmacist-led EMR assessment enables the identification of benzodiazepine dependence patterns and supports a more robust epidemiological evaluation within the institution. Methods: A descriptive observational study (January 2022&amp;amp;ndash;May 2025) using electronic medical records and prescription data was conducted. Consecutive adults with an active BZD prescription and a documented BDEPQ-MX (Benzodiazepine Dependence Questionnaire, Mexican version) were included. Outcomes were BDEPQ-MX categories (No dependence; Pleasurable effects; Perceived need; Dependence) and a binary endpoint was stablished as &amp;amp;ldquo;any dependence&amp;amp;rdquo; (either scored in Perceived need or Dependence category) vs. No dependence (either scored as No dependence or Pleasurable effects categories). Group comparisons used &amp;amp;chi;2, Student&amp;amp;rsquo;s t, and one-way ANOVA. A logistic regression modeled any dependence; a general linear model (GLM) examined the BDEPQ-MX total score. Results: Of 181 complete cases, BDEPQ-MX categories were No dependence 33.2% (60/181), Pleasurable effects 7.2% (13/181), Perceived need 17.1% (31/181), and Dependence 42.5% (77/181); hence, 59.7% met &amp;amp;ldquo;any dependence.&amp;amp;rdquo; Women comprised 67.4% overall. Compared with No dependence, the any-dependence group had higher comorbidity (83.3% vs. 65.8%, p = 0.006) and markedly greater duration of BZD use (months) (22.6 &amp;amp;plusmn; 11.5 vs. 5.9 &amp;amp;plusmn; 4.9, p &amp;amp;lt; 0.001), with no difference in daily dose (p = 0.6). Benzodiazepine medications shifted toward alprazolam in dependence (38.9% vs. 20.5%, p = 0.009) and away from clonazepam (43.5% vs. 58.9%, p = 0.042). In the adjusted model, the male sex was associated with lower odds of any dependence (aOR 0.29, 95% CI 0.11&amp;amp;ndash;0.76; p = 0.013), while the duration of BZD use (per month) increased the odds (aOR 1.32, 1.20&amp;amp;ndash;1.45; p &amp;amp;lt; 0.001). In the GLM, the duration showed the largest effect on BDEPQ-MX total (F = 203.26; p &amp;amp;lt; 0.001; partial &amp;amp;eta;2 = 0.545). Conclusions: In this outpatient pain and palliative-care population, benzodiazepine-related dependence phenomena were common: 59.7% of patients met the criteria for dependence based on the pharmacist-led EMR review. The involvement of the pharmacist was essential, as this systematic evaluation would have been difficult to perform within routine medical consultations. The pharmacist&amp;amp;rsquo;s contribution enabled a detailed epidemiological characterization, revealing that the exposure duration&amp;amp;mdash;more than daily dose&amp;amp;mdash;was the principal, modifiable correlate of dependence, and that alprazolam was disproportionately represented in the higher-dependence categories. These findings underscore the value of pharmacist-supported surveillance to identify and measure BZD dependance.</description>
	<pubDate>2026-01-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 6: Epidemiological Assessment of Benzodiazepine Dependence via Pharmacist-Led EMR Review in Pain and Palliative Care Institution</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/6">doi: 10.3390/pharmacy14010006</a></p>
	<p>Authors:
		Carlos Eduardo Estrada-De La Rosa
		Felipe Alexis Avalos-Salgado
		Daniel Osmar Suárez-Rico
		Martin Zermeño-Ruiz
		César Ricardo Cortez-Álvarez
		Raymundo Escutia-Gutiérrez
		</p>
	<p>Background/Objectives: Benzodiazepines (BZDs) are used routinely in cases requiring sedation for anxiety, insomnia, and procedures that require pain management, and daily use of these agents may extend over several months; therefore, monitoring patients is essential to reduce the risk of developing dependence. However, the high patient volume in pain and palliative-care settings often limits physicians&amp;amp;rsquo; ability to both conduct consultations and perform comprehensive evaluations. In this context, the pharmacist plays a key role in supporting patient care by contributing professional activities that enhance patient well-being, such as conducting systematic reviews of electronic medical records. This pharmacist-led EMR assessment enables the identification of benzodiazepine dependence patterns and supports a more robust epidemiological evaluation within the institution. Methods: A descriptive observational study (January 2022&amp;amp;ndash;May 2025) using electronic medical records and prescription data was conducted. Consecutive adults with an active BZD prescription and a documented BDEPQ-MX (Benzodiazepine Dependence Questionnaire, Mexican version) were included. Outcomes were BDEPQ-MX categories (No dependence; Pleasurable effects; Perceived need; Dependence) and a binary endpoint was stablished as &amp;amp;ldquo;any dependence&amp;amp;rdquo; (either scored in Perceived need or Dependence category) vs. No dependence (either scored as No dependence or Pleasurable effects categories). Group comparisons used &amp;amp;chi;2, Student&amp;amp;rsquo;s t, and one-way ANOVA. A logistic regression modeled any dependence; a general linear model (GLM) examined the BDEPQ-MX total score. Results: Of 181 complete cases, BDEPQ-MX categories were No dependence 33.2% (60/181), Pleasurable effects 7.2% (13/181), Perceived need 17.1% (31/181), and Dependence 42.5% (77/181); hence, 59.7% met &amp;amp;ldquo;any dependence.&amp;amp;rdquo; Women comprised 67.4% overall. Compared with No dependence, the any-dependence group had higher comorbidity (83.3% vs. 65.8%, p = 0.006) and markedly greater duration of BZD use (months) (22.6 &amp;amp;plusmn; 11.5 vs. 5.9 &amp;amp;plusmn; 4.9, p &amp;amp;lt; 0.001), with no difference in daily dose (p = 0.6). Benzodiazepine medications shifted toward alprazolam in dependence (38.9% vs. 20.5%, p = 0.009) and away from clonazepam (43.5% vs. 58.9%, p = 0.042). In the adjusted model, the male sex was associated with lower odds of any dependence (aOR 0.29, 95% CI 0.11&amp;amp;ndash;0.76; p = 0.013), while the duration of BZD use (per month) increased the odds (aOR 1.32, 1.20&amp;amp;ndash;1.45; p &amp;amp;lt; 0.001). In the GLM, the duration showed the largest effect on BDEPQ-MX total (F = 203.26; p &amp;amp;lt; 0.001; partial &amp;amp;eta;2 = 0.545). Conclusions: In this outpatient pain and palliative-care population, benzodiazepine-related dependence phenomena were common: 59.7% of patients met the criteria for dependence based on the pharmacist-led EMR review. The involvement of the pharmacist was essential, as this systematic evaluation would have been difficult to perform within routine medical consultations. The pharmacist&amp;amp;rsquo;s contribution enabled a detailed epidemiological characterization, revealing that the exposure duration&amp;amp;mdash;more than daily dose&amp;amp;mdash;was the principal, modifiable correlate of dependence, and that alprazolam was disproportionately represented in the higher-dependence categories. These findings underscore the value of pharmacist-supported surveillance to identify and measure BZD dependance.</p>
	]]></content:encoded>

	<dc:title>Epidemiological Assessment of Benzodiazepine Dependence via Pharmacist-Led EMR Review in Pain and Palliative Care Institution</dc:title>
			<dc:creator>Carlos Eduardo Estrada-De La Rosa</dc:creator>
			<dc:creator>Felipe Alexis Avalos-Salgado</dc:creator>
			<dc:creator>Daniel Osmar Suárez-Rico</dc:creator>
			<dc:creator>Martin Zermeño-Ruiz</dc:creator>
			<dc:creator>César Ricardo Cortez-Álvarez</dc:creator>
			<dc:creator>Raymundo Escutia-Gutiérrez</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010006</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-07</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-07</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010006</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/5">

	<title>Pharmacy, Vol. 14, Pages 5: Structured Medication Review and Shared Decision-Making in Patients with Mild Intellectual Disabilities Who Use Psychotropic Medication</title>
	<link>https://www.mdpi.com/2226-4787/14/1/5</link>
	<description>People with intellectual disabilities frequently use psychotropic and other medications, sometimes inappropriately. To promote shared decision-making, they require accessible information about their medication. This study combined data from two similar intervention studies, conducted in two different settings, to assess the appropriateness of medication use and the shared decision-making process among adults with mild intellectual disabilities who used psychotropic medication. The intervention consisted of a structured, multidisciplinary medication review, including the provision of accessible psychotropic medication leaflets, and a discussion of the pharmacotherapeutic treatment plan with the patient by either a pharmacist or physician, depending on the setting. Outcomes included medication use, pharmacotherapeutic problems, implementation of recommendations, and perceived shared decision-making, measured with the Shared Decision-Making Questionnaire Q9. The 15 included participants used an average of nearly seven medications, which were mainly neurotropic, gastrointestinal, cardiovascular, and respiratory agents. On average, two pharmacotherapeutic problems were identified; the most common were overtreatment, side effects, and administration difficulties. Recommendations often involved dose reduction or tapering, and about 75% were fully or partially implemented. Both participants and clinicians reported high satisfaction with shared decision-making. Multidisciplinary, structured medication reviews, incorporating accessible medication leaflets, may enhance appropriate medication use and shared decision-making, but more research is needed.</description>
	<pubDate>2026-01-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 5: Structured Medication Review and Shared Decision-Making in Patients with Mild Intellectual Disabilities Who Use Psychotropic Medication</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/5">doi: 10.3390/pharmacy14010005</a></p>
	<p>Authors:
		Gerda de Kuijper
		Josien Jonker
		Rien Hoge
		</p>
	<p>People with intellectual disabilities frequently use psychotropic and other medications, sometimes inappropriately. To promote shared decision-making, they require accessible information about their medication. This study combined data from two similar intervention studies, conducted in two different settings, to assess the appropriateness of medication use and the shared decision-making process among adults with mild intellectual disabilities who used psychotropic medication. The intervention consisted of a structured, multidisciplinary medication review, including the provision of accessible psychotropic medication leaflets, and a discussion of the pharmacotherapeutic treatment plan with the patient by either a pharmacist or physician, depending on the setting. Outcomes included medication use, pharmacotherapeutic problems, implementation of recommendations, and perceived shared decision-making, measured with the Shared Decision-Making Questionnaire Q9. The 15 included participants used an average of nearly seven medications, which were mainly neurotropic, gastrointestinal, cardiovascular, and respiratory agents. On average, two pharmacotherapeutic problems were identified; the most common were overtreatment, side effects, and administration difficulties. Recommendations often involved dose reduction or tapering, and about 75% were fully or partially implemented. Both participants and clinicians reported high satisfaction with shared decision-making. Multidisciplinary, structured medication reviews, incorporating accessible medication leaflets, may enhance appropriate medication use and shared decision-making, but more research is needed.</p>
	]]></content:encoded>

	<dc:title>Structured Medication Review and Shared Decision-Making in Patients with Mild Intellectual Disabilities Who Use Psychotropic Medication</dc:title>
			<dc:creator>Gerda de Kuijper</dc:creator>
			<dc:creator>Josien Jonker</dc:creator>
			<dc:creator>Rien Hoge</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010005</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-06</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-06</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010005</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/4">

	<title>Pharmacy, Vol. 14, Pages 4: Beyond Addiction: Burden of Polypharmacy and Risk in Frail Patients with Substance Use Disorder</title>
	<link>https://www.mdpi.com/2226-4787/14/1/4</link>
	<description>Substance use disorder (SUD) is a chronic and clinically complex condition, frequently complicated by significant organic and psychiatric comorbidities. Most patients are polymedicated and require opioid substitution programs (OSPs). This complexity is further exacerbated by drug&amp;amp;ndash;drug interactions, therapeutic duplication, and fragmentation of the healthcare system. This retrospective observational study analyses the prevalence of polypharmacy and associated pharmacotherapeutic risks in a cohort of 1050 patients with SUD treated at Drug Care Units (DCUs) in Tenerife (Canary Islands, Spain). Prescriptions were dominated by methadone (62%), antidepressants, and antipsychotics, often in combination with benzodiazepines. Significant polypharmacy (&amp;amp;gt;10 active prescriptions) was observed in 2.3% of patients, while 8.1% received 6&amp;amp;ndash;10 medications and 37.2% were using 2&amp;amp;ndash;5 medications. Women showed a higher pharmacological burden, with 3.5% experiencing significant polypharmacy (&amp;amp;gt;10 different prescriptions) compared with 1.1% of men. Overall, 31% of patients received antidepressants, 31% were treated with antipsychotics&amp;amp;mdash;frequently with concurrent use of multiple agents&amp;amp;mdash;and 6.4% received opioids outside the OSP. Therapeutic duplication was observed in 15.6% of patients for psycholeptics, 14.2% for psychoanaleptics, and 3.2% for antiepileptics. Additionally, 25.2% of patients reported self-medication, predominantly with benzodiazepines. These findings underscore the need for integrated pharmaceutical care programs incorporating individualized therapeutic review and deprescribing strategies to enhance the safety and efficacy of SUD treatment.</description>
	<pubDate>2026-01-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 4: Beyond Addiction: Burden of Polypharmacy and Risk in Frail Patients with Substance Use Disorder</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/4">doi: 10.3390/pharmacy14010004</a></p>
	<p>Authors:
		L. Goretti Santiago Gutiérrez
		Daida Alberto Armas
		Verónica Hernández García
		Juan Ramón Santana Ayala
		Roberto García Sánchez
		Soraya Paz Montelongo
		Ángel J. Gutiérrez
		Arturo Hardisson de la Torre
		Carmen Rubio Armendáriz
		</p>
	<p>Substance use disorder (SUD) is a chronic and clinically complex condition, frequently complicated by significant organic and psychiatric comorbidities. Most patients are polymedicated and require opioid substitution programs (OSPs). This complexity is further exacerbated by drug&amp;amp;ndash;drug interactions, therapeutic duplication, and fragmentation of the healthcare system. This retrospective observational study analyses the prevalence of polypharmacy and associated pharmacotherapeutic risks in a cohort of 1050 patients with SUD treated at Drug Care Units (DCUs) in Tenerife (Canary Islands, Spain). Prescriptions were dominated by methadone (62%), antidepressants, and antipsychotics, often in combination with benzodiazepines. Significant polypharmacy (&amp;amp;gt;10 active prescriptions) was observed in 2.3% of patients, while 8.1% received 6&amp;amp;ndash;10 medications and 37.2% were using 2&amp;amp;ndash;5 medications. Women showed a higher pharmacological burden, with 3.5% experiencing significant polypharmacy (&amp;amp;gt;10 different prescriptions) compared with 1.1% of men. Overall, 31% of patients received antidepressants, 31% were treated with antipsychotics&amp;amp;mdash;frequently with concurrent use of multiple agents&amp;amp;mdash;and 6.4% received opioids outside the OSP. Therapeutic duplication was observed in 15.6% of patients for psycholeptics, 14.2% for psychoanaleptics, and 3.2% for antiepileptics. Additionally, 25.2% of patients reported self-medication, predominantly with benzodiazepines. These findings underscore the need for integrated pharmaceutical care programs incorporating individualized therapeutic review and deprescribing strategies to enhance the safety and efficacy of SUD treatment.</p>
	]]></content:encoded>

	<dc:title>Beyond Addiction: Burden of Polypharmacy and Risk in Frail Patients with Substance Use Disorder</dc:title>
			<dc:creator>L. Goretti Santiago Gutiérrez</dc:creator>
			<dc:creator>Daida Alberto Armas</dc:creator>
			<dc:creator>Verónica Hernández García</dc:creator>
			<dc:creator>Juan Ramón Santana Ayala</dc:creator>
			<dc:creator>Roberto García Sánchez</dc:creator>
			<dc:creator>Soraya Paz Montelongo</dc:creator>
			<dc:creator>Ángel J. Gutiérrez</dc:creator>
			<dc:creator>Arturo Hardisson de la Torre</dc:creator>
			<dc:creator>Carmen Rubio Armendáriz</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010004</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2026-01-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2026-01-01</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010004</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/3">

	<title>Pharmacy, Vol. 14, Pages 3: &amp;ldquo;Let&amp;rsquo;s Talk Stigma&amp;rdquo;: A Pharmacy-Based Program for Opioid Use Disorder Anti-Stigma Education in Pennsylvania</title>
	<link>https://www.mdpi.com/2226-4787/14/1/3</link>
	<description>Opioid overdoses in the United States remain a significant public health concern. Opioid use disorder (OUD) is stigmatized, exacerbating negative health outcomes. Reducing stigma in healthcare, including in pharmacies, is critical. The &amp;amp;ldquo;Let&amp;amp;rsquo;s Talk Stigma&amp;amp;rdquo; program was collaboratively developed with two schools of pharmacy, a local health department, and individuals with lived drug use experience. It aimed to reduce OUD-related stigma among pharmacists, pharmacy technicians, student pharmacists, and other allied health professionals. The program included six core components: a podcast, continuing education, a standardized curriculum for student pharmacists, training for pharmacy technicians and medical assistants, pharmacy outreach by student pharmacists, and partnerships with chain pharmacies. The anti-stigma podcast reached a global audience with nearly 22,000 listens, while local sessions engaged over 5000 individuals. These initiatives were integrated into Doctor of Pharmacy curricula, with student pharmacists distributing stigma-reduction kits in local pharmacies. A mixed-methods approach, incorporating qualitative data from participant reflections and quantitative data from surveys, podcast analytics, and attendance records, was used for program evaluation. Participants reported increased awareness of stigma, improved attitudes, and greater professional responsibility to reduce stigma. The program successfully leveraged partnerships, flexible delivery methods, and inclusion of people with lived drug use experience in its design.</description>
	<pubDate>2025-12-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 3: &amp;ldquo;Let&amp;rsquo;s Talk Stigma&amp;rdquo;: A Pharmacy-Based Program for Opioid Use Disorder Anti-Stigma Education in Pennsylvania</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/3">doi: 10.3390/pharmacy14010003</a></p>
	<p>Authors:
		Joni C. Carroll
		Sophia M. C. Herbert
		Kim C. Coley
		Thai Q. Nguyen
		Melissa A. Somma McGivney
		Kelsey L. Hake
		Jennifer Padden Elliott
		Elizabeth Bunk Barton
		</p>
	<p>Opioid overdoses in the United States remain a significant public health concern. Opioid use disorder (OUD) is stigmatized, exacerbating negative health outcomes. Reducing stigma in healthcare, including in pharmacies, is critical. The &amp;amp;ldquo;Let&amp;amp;rsquo;s Talk Stigma&amp;amp;rdquo; program was collaboratively developed with two schools of pharmacy, a local health department, and individuals with lived drug use experience. It aimed to reduce OUD-related stigma among pharmacists, pharmacy technicians, student pharmacists, and other allied health professionals. The program included six core components: a podcast, continuing education, a standardized curriculum for student pharmacists, training for pharmacy technicians and medical assistants, pharmacy outreach by student pharmacists, and partnerships with chain pharmacies. The anti-stigma podcast reached a global audience with nearly 22,000 listens, while local sessions engaged over 5000 individuals. These initiatives were integrated into Doctor of Pharmacy curricula, with student pharmacists distributing stigma-reduction kits in local pharmacies. A mixed-methods approach, incorporating qualitative data from participant reflections and quantitative data from surveys, podcast analytics, and attendance records, was used for program evaluation. Participants reported increased awareness of stigma, improved attitudes, and greater professional responsibility to reduce stigma. The program successfully leveraged partnerships, flexible delivery methods, and inclusion of people with lived drug use experience in its design.</p>
	]]></content:encoded>

	<dc:title>&amp;amp;ldquo;Let&amp;amp;rsquo;s Talk Stigma&amp;amp;rdquo;: A Pharmacy-Based Program for Opioid Use Disorder Anti-Stigma Education in Pennsylvania</dc:title>
			<dc:creator>Joni C. Carroll</dc:creator>
			<dc:creator>Sophia M. C. Herbert</dc:creator>
			<dc:creator>Kim C. Coley</dc:creator>
			<dc:creator>Thai Q. Nguyen</dc:creator>
			<dc:creator>Melissa A. Somma McGivney</dc:creator>
			<dc:creator>Kelsey L. Hake</dc:creator>
			<dc:creator>Jennifer Padden Elliott</dc:creator>
			<dc:creator>Elizabeth Bunk Barton</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010003</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-24</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-24</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010003</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/2">

	<title>Pharmacy, Vol. 14, Pages 2: Drug Manipulation in Pediatric Care: A Scoping Review of a Widespread Practice Signaling Systemic Gaps in Pharmaceutical Provision</title>
	<link>https://www.mdpi.com/2226-4787/14/1/2</link>
	<description>Background: Pediatric patients often receive medicines manipulated from adult formulations due to a lack of age-appropriate products. While such practices are clinically routine, they may reflect deeper systemic deficiencies in pediatric pharmacotherapy. Objective: This scoping review aimed to map the prevalence, definitions, and types of pediatric drug manipulation and to conceptualize manipulation as an indicator of structural gaps in formulation science, regulation, and access. Methods: A systematic search of PubMed (January 2014&amp;amp;ndash;July 2024) included 10 studies reporting the frequency of drug manipulation in children aged &amp;amp;le;18 years. Eligible studies were synthesized narratively according to PRISMA-ScR guidelines. Results: Ten studies from nine countries were included, reporting manipulation frequencies ranging from 6.4% to 62% of all drug administrations and up to 60% at the patient level. Manipulated formulations most commonly included oral solid doses, altered through dispersing, splitting, or crushing. Definitions and methodologies varied considerably. The findings revealed five recurring structural gaps: limited pediatric formulations, inconsistent regulatory implementation, lack of standardized definitions and guidance, insufficient evidence on manipulation safety, and inequitable access across regions. Conclusion: Manipulation of finished dosage forms for use in children is a widespread, measurable phenomenon reflecting systemic inadequacies in formulation development, regulation, and access. Recognizing manipulation as a structural indicator may guide policy, innovation, and equitable pediatric pharmacotherapy worldwide.</description>
	<pubDate>2025-12-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 2: Drug Manipulation in Pediatric Care: A Scoping Review of a Widespread Practice Signaling Systemic Gaps in Pharmaceutical Provision</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/2">doi: 10.3390/pharmacy14010002</a></p>
	<p>Authors:
		Charlotte Vermehren
		Laura Giraldi
		Sarah Al-Rubai
		Ida M. Heerfordt
		Yasmine Merimi
		Rene Mathiasen
		Anette Müllertz
		Jon Trærup Andersen
		Susanne Kaae
		Christina Gade
		</p>
	<p>Background: Pediatric patients often receive medicines manipulated from adult formulations due to a lack of age-appropriate products. While such practices are clinically routine, they may reflect deeper systemic deficiencies in pediatric pharmacotherapy. Objective: This scoping review aimed to map the prevalence, definitions, and types of pediatric drug manipulation and to conceptualize manipulation as an indicator of structural gaps in formulation science, regulation, and access. Methods: A systematic search of PubMed (January 2014&amp;amp;ndash;July 2024) included 10 studies reporting the frequency of drug manipulation in children aged &amp;amp;le;18 years. Eligible studies were synthesized narratively according to PRISMA-ScR guidelines. Results: Ten studies from nine countries were included, reporting manipulation frequencies ranging from 6.4% to 62% of all drug administrations and up to 60% at the patient level. Manipulated formulations most commonly included oral solid doses, altered through dispersing, splitting, or crushing. Definitions and methodologies varied considerably. The findings revealed five recurring structural gaps: limited pediatric formulations, inconsistent regulatory implementation, lack of standardized definitions and guidance, insufficient evidence on manipulation safety, and inequitable access across regions. Conclusion: Manipulation of finished dosage forms for use in children is a widespread, measurable phenomenon reflecting systemic inadequacies in formulation development, regulation, and access. Recognizing manipulation as a structural indicator may guide policy, innovation, and equitable pediatric pharmacotherapy worldwide.</p>
	]]></content:encoded>

	<dc:title>Drug Manipulation in Pediatric Care: A Scoping Review of a Widespread Practice Signaling Systemic Gaps in Pharmaceutical Provision</dc:title>
			<dc:creator>Charlotte Vermehren</dc:creator>
			<dc:creator>Laura Giraldi</dc:creator>
			<dc:creator>Sarah Al-Rubai</dc:creator>
			<dc:creator>Ida M. Heerfordt</dc:creator>
			<dc:creator>Yasmine Merimi</dc:creator>
			<dc:creator>Rene Mathiasen</dc:creator>
			<dc:creator>Anette Müllertz</dc:creator>
			<dc:creator>Jon Trærup Andersen</dc:creator>
			<dc:creator>Susanne Kaae</dc:creator>
			<dc:creator>Christina Gade</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010002</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-24</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-24</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010002</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/14/1/1">

	<title>Pharmacy, Vol. 14, Pages 1: Evaluating the Accuracy and Educational Potential of Generative AI Models in Pharmacy Education: A Comparative Analysis of ChatGPT and Gemini Across Bloom&amp;rsquo;s Taxonomy</title>
	<link>https://www.mdpi.com/2226-4787/14/1/1</link>
	<description>This study evaluated the accuracy and educational potential of three generative AI models, ChatGPT 3.5, ChatGPT 4o, and Gemini 2.5, by addressing pharmacy-related content across three key areas: biostatistics, pharmaceutical calculations, and therapeutics. A total of 120 exam-style questions, categorized by Bloom&amp;amp;rsquo;s Taxonomy levels (Remember, Understand, Apply, and Analyze), were administered to each model. Overall, the AI models achieved a combined accuracy rate of 77.5%, with ChatGPT 4o consistently outperforming ChatGPT 3.5 and Gemini 2.5. The highest accuracy was observed in therapeutics (83.3%), followed by biostatistics (81.7%) and calculations (67.5%). Performance was strongest at lower Bloom levels, reflecting proficiency in recall and conceptual understanding, but declined at higher levels requiring analytical reasoning. These findings suggest that generative AI tools can serve as effective supplementary aids for pharmacy education, particularly for conceptual learning and review. However, their limitations in quantitative and higher-order reasoning highlight the need for guided use and faculty oversight. Future research should expand to additional subject areas and assess longitudinal learning outcomes to better understand AI&amp;amp;rsquo;s role in improving critical thinking and professional competence among pharmacy students.</description>
	<pubDate>2025-12-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 14, Pages 1: Evaluating the Accuracy and Educational Potential of Generative AI Models in Pharmacy Education: A Comparative Analysis of ChatGPT and Gemini Across Bloom&amp;rsquo;s Taxonomy</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/14/1/1">doi: 10.3390/pharmacy14010001</a></p>
	<p>Authors:
		Tuan Tran
		Uyen Le
		Victor Phan
		</p>
	<p>This study evaluated the accuracy and educational potential of three generative AI models, ChatGPT 3.5, ChatGPT 4o, and Gemini 2.5, by addressing pharmacy-related content across three key areas: biostatistics, pharmaceutical calculations, and therapeutics. A total of 120 exam-style questions, categorized by Bloom&amp;amp;rsquo;s Taxonomy levels (Remember, Understand, Apply, and Analyze), were administered to each model. Overall, the AI models achieved a combined accuracy rate of 77.5%, with ChatGPT 4o consistently outperforming ChatGPT 3.5 and Gemini 2.5. The highest accuracy was observed in therapeutics (83.3%), followed by biostatistics (81.7%) and calculations (67.5%). Performance was strongest at lower Bloom levels, reflecting proficiency in recall and conceptual understanding, but declined at higher levels requiring analytical reasoning. These findings suggest that generative AI tools can serve as effective supplementary aids for pharmacy education, particularly for conceptual learning and review. However, their limitations in quantitative and higher-order reasoning highlight the need for guided use and faculty oversight. Future research should expand to additional subject areas and assess longitudinal learning outcomes to better understand AI&amp;amp;rsquo;s role in improving critical thinking and professional competence among pharmacy students.</p>
	]]></content:encoded>

	<dc:title>Evaluating the Accuracy and Educational Potential of Generative AI Models in Pharmacy Education: A Comparative Analysis of ChatGPT and Gemini Across Bloom&amp;amp;rsquo;s Taxonomy</dc:title>
			<dc:creator>Tuan Tran</dc:creator>
			<dc:creator>Uyen Le</dc:creator>
			<dc:creator>Victor Phan</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy14010001</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-23</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-23</prism:publicationDate>
	<prism:volume>14</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/pharmacy14010001</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/14/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/185">

	<title>Pharmacy, Vol. 13, Pages 185: Intrathecal Drug Delivery Systems for Chronic Pain Management: A Narrative Review of Pharmacologic Agents, Clinical Applications, and Considerations</title>
	<link>https://www.mdpi.com/2226-4787/13/6/185</link>
	<description>This narrative review seeks to delve into the different on and off-label medications commonly used with intrathecal drug delivery systems (IDDS) and their clinical applications specifically in pain management settings. This review utilizes a variety of studies including reviews, retrospective chart analyses, and more to analyze the current effectiveness of various pharmacological agents on reducing chronic pain through IDDS. The initial results of intrathecal delivery of these medications have provided benefit in pain reduction and overall patient satisfaction; however, this review will seek to analyze the current data and understanding and suggest areas of strength and improvement within the field and our current understanding.</description>
	<pubDate>2025-12-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 185: Intrathecal Drug Delivery Systems for Chronic Pain Management: A Narrative Review of Pharmacologic Agents, Clinical Applications, and Considerations</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/185">doi: 10.3390/pharmacy13060185</a></p>
	<p>Authors:
		Milan Patel
		Alison J. Deng
		Madelyn Reilly
		Mariam Morcus
		Alyssa McKenzie
		Lukas Henjum
		Alan D. Kaye
		Alaa Abd-Elsayed
		</p>
	<p>This narrative review seeks to delve into the different on and off-label medications commonly used with intrathecal drug delivery systems (IDDS) and their clinical applications specifically in pain management settings. This review utilizes a variety of studies including reviews, retrospective chart analyses, and more to analyze the current effectiveness of various pharmacological agents on reducing chronic pain through IDDS. The initial results of intrathecal delivery of these medications have provided benefit in pain reduction and overall patient satisfaction; however, this review will seek to analyze the current data and understanding and suggest areas of strength and improvement within the field and our current understanding.</p>
	]]></content:encoded>

	<dc:title>Intrathecal Drug Delivery Systems for Chronic Pain Management: A Narrative Review of Pharmacologic Agents, Clinical Applications, and Considerations</dc:title>
			<dc:creator>Milan Patel</dc:creator>
			<dc:creator>Alison J. Deng</dc:creator>
			<dc:creator>Madelyn Reilly</dc:creator>
			<dc:creator>Mariam Morcus</dc:creator>
			<dc:creator>Alyssa McKenzie</dc:creator>
			<dc:creator>Lukas Henjum</dc:creator>
			<dc:creator>Alan D. Kaye</dc:creator>
			<dc:creator>Alaa Abd-Elsayed</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060185</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-16</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-16</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>185</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060185</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/185</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/184">

	<title>Pharmacy, Vol. 13, Pages 184: Prevalence of Potentially Inappropriate Medications in Drug Dispensing Data of Older Adults Living in Northwest Italy</title>
	<link>https://www.mdpi.com/2226-4787/13/6/184</link>
	<description>The increasing use of multiple medications among older adults raises concerns about potentially inappropriate medications (PIMs), which are associated with adverse health outcomes and increased healthcare costs. This study aimed to assess the prevalence and types of PIMs dispensed to older adults living in Northwest Italy using real-world pharmacy claims data. An observational, retrospective analysis was conducted on anonymized drug dispensing datasets from two local health authorities, covering individuals aged 65 years or older between 2018 and 2021. PIMs were identified according to the 2019 American Geriatrics Society Beers Criteria, focusing on drugs that are inappropriate or should be used with caution in older adults or have anticholinergic properties. Over half of older adults who received medications during the study period were dispensed at least one PIM, with stable or slight increased prevalence over time with no differences by sex or region. Proton-pump inhibitors used for more than 8 weeks and paroxetine were the most common PIMs, while furosemide and sulfonylureas were also frequently reported PIMs. These findings indicate a persistently high burden of inappropriate prescribing in older adults and highlight the need for coordinated deprescribing interventions and prescriber education to promote safer, evidence-based pharmacotherapy in aging populations.</description>
	<pubDate>2025-12-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 184: Prevalence of Potentially Inappropriate Medications in Drug Dispensing Data of Older Adults Living in Northwest Italy</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/184">doi: 10.3390/pharmacy13060184</a></p>
	<p>Authors:
		Lucrezia Greta Armando
		Jacopo Luboz
		Abdoulaye Diarassouba
		Gianluca Miglio
		Clara Cena
		</p>
	<p>The increasing use of multiple medications among older adults raises concerns about potentially inappropriate medications (PIMs), which are associated with adverse health outcomes and increased healthcare costs. This study aimed to assess the prevalence and types of PIMs dispensed to older adults living in Northwest Italy using real-world pharmacy claims data. An observational, retrospective analysis was conducted on anonymized drug dispensing datasets from two local health authorities, covering individuals aged 65 years or older between 2018 and 2021. PIMs were identified according to the 2019 American Geriatrics Society Beers Criteria, focusing on drugs that are inappropriate or should be used with caution in older adults or have anticholinergic properties. Over half of older adults who received medications during the study period were dispensed at least one PIM, with stable or slight increased prevalence over time with no differences by sex or region. Proton-pump inhibitors used for more than 8 weeks and paroxetine were the most common PIMs, while furosemide and sulfonylureas were also frequently reported PIMs. These findings indicate a persistently high burden of inappropriate prescribing in older adults and highlight the need for coordinated deprescribing interventions and prescriber education to promote safer, evidence-based pharmacotherapy in aging populations.</p>
	]]></content:encoded>

	<dc:title>Prevalence of Potentially Inappropriate Medications in Drug Dispensing Data of Older Adults Living in Northwest Italy</dc:title>
			<dc:creator>Lucrezia Greta Armando</dc:creator>
			<dc:creator>Jacopo Luboz</dc:creator>
			<dc:creator>Abdoulaye Diarassouba</dc:creator>
			<dc:creator>Gianluca Miglio</dc:creator>
			<dc:creator>Clara Cena</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060184</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-15</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-15</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>184</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060184</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/184</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/183">

	<title>Pharmacy, Vol. 13, Pages 183: Pharmacy Students&amp;rsquo; Perspectives on Integrating Generative AI into Pharmacy Education</title>
	<link>https://www.mdpi.com/2226-4787/13/6/183</link>
	<description>Objective: This study aims to evaluate pharmacy students&amp;amp;rsquo; perceptions regarding the integration of generative artificial intelligence (GenAI) into pharmacy curricula, providing evidence to inform future curriculum development. Methods: A cross-sectional survey of Doctor of Pharmacy (PharmD) students at a single U.S. College of Pharmacy was conducted in April 2025. Students from all four professional years (P1&amp;amp;ndash;P4) were invited to participate. The 10-item survey assessed four domains: (1) General GenAI Use, (2) Knowledge and Experience with GenAI Tools, (3) Learning Preferences with GenAI, and (4) Perspectives on GenAI in the curriculum. Results: A total of 110 students responded (response rate = 12.4%). Most were P1 students (56/110, 50.9%). Many reported using GenAI tools for personal (65/110, 59.1%) and school-related purposes (64/110, 58.1%) sometimes, often, or frequently. ChatGPT was the most used tool. While 40% (40/99) agreed or strongly agreed that GenAI could enhance their learning, 62.6% (62/99) preferred traditional teaching methods. Open-ended responses (n = 25) reflected a mix of positive, neutral, and negative views on GenAI in education. Conclusions: Many pharmacy students in this cohort reported using GenAI tools and demonstrated a basic understanding of GenAI functions, yet students also reported that they preferred traditional learning methods and expressed mixed views on incorporating GenAI into teaching. These findings provide valuable insights for faculty and schools of pharmacy as they develop strategies to integrate GenAI into pharmacy education.</description>
	<pubDate>2025-12-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 183: Pharmacy Students&amp;rsquo; Perspectives on Integrating Generative AI into Pharmacy Education</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/183">doi: 10.3390/pharmacy13060183</a></p>
	<p>Authors:
		Kaitlin M. Alexander
		Eli O. Jorgensen
		Casey Rowe
		Khoa Nguyen
		</p>
	<p>Objective: This study aims to evaluate pharmacy students&amp;amp;rsquo; perceptions regarding the integration of generative artificial intelligence (GenAI) into pharmacy curricula, providing evidence to inform future curriculum development. Methods: A cross-sectional survey of Doctor of Pharmacy (PharmD) students at a single U.S. College of Pharmacy was conducted in April 2025. Students from all four professional years (P1&amp;amp;ndash;P4) were invited to participate. The 10-item survey assessed four domains: (1) General GenAI Use, (2) Knowledge and Experience with GenAI Tools, (3) Learning Preferences with GenAI, and (4) Perspectives on GenAI in the curriculum. Results: A total of 110 students responded (response rate = 12.4%). Most were P1 students (56/110, 50.9%). Many reported using GenAI tools for personal (65/110, 59.1%) and school-related purposes (64/110, 58.1%) sometimes, often, or frequently. ChatGPT was the most used tool. While 40% (40/99) agreed or strongly agreed that GenAI could enhance their learning, 62.6% (62/99) preferred traditional teaching methods. Open-ended responses (n = 25) reflected a mix of positive, neutral, and negative views on GenAI in education. Conclusions: Many pharmacy students in this cohort reported using GenAI tools and demonstrated a basic understanding of GenAI functions, yet students also reported that they preferred traditional learning methods and expressed mixed views on incorporating GenAI into teaching. These findings provide valuable insights for faculty and schools of pharmacy as they develop strategies to integrate GenAI into pharmacy education.</p>
	]]></content:encoded>

	<dc:title>Pharmacy Students&amp;amp;rsquo; Perspectives on Integrating Generative AI into Pharmacy Education</dc:title>
			<dc:creator>Kaitlin M. Alexander</dc:creator>
			<dc:creator>Eli O. Jorgensen</dc:creator>
			<dc:creator>Casey Rowe</dc:creator>
			<dc:creator>Khoa Nguyen</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060183</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-15</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-15</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>183</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060183</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/183</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/182">

	<title>Pharmacy, Vol. 13, Pages 182: Impacts of Outsourcing Medication Repackaging in Nursing Homes: Quality and Areas of Pharmacy&amp;ndash;Nursing Collaboration</title>
	<link>https://www.mdpi.com/2226-4787/13/6/182</link>
	<description>The task of repackaging resident&amp;amp;rsquo;s medication into medication organizers is increasingly outsourced from nursing homes to pharmacies, presenting an opportunity to redefine the interaction between nursing and pharmaceutical staff. This study investigated whether outsourcing medication repackaging changes the quality and subjects of collaboration between the two professions. A cross-sectional survey was developed targeting heads of nursing in German nursing homes. A simple random sample of 1415 nursing homes was contacted by phone. Respondents participated either by phone or by online survey. Quality of collaboration was measured using Kenaszchuk&amp;amp;rsquo;s Interprofessional Collaboration Scale (ICS) with its subscales Communication, Accommodation and Isolation. Topics of interaction were ascertained using items along a medication management phase model. Differences in response frequencies were analyzed using Fisher&amp;amp;rsquo;s exact test. A total of 268 nursing homes participated (response: 18.9%). Of these, 132 (49.3%) had outsourced repackaging. Respondents at nursing homes with in-house medication repackaging rated the subscale Accommodation more favorably (p = 0.008), while Communication and Isolation showed no difference. Of the 13 individual ICS items, &amp;amp;ldquo;passing on information&amp;amp;rdquo; (Communication) was rated better by respondents at homes with outsourced repackaging (p = 0.019) and &amp;amp;ldquo;consideration of convenience&amp;amp;rdquo; (Accommodation) more favorably by respondents at homes with in-house repackaging (p = 0.042). Nursing staff at homes with outsourced medication repackaging interacted with pharmaceutical staff more frequently on medication changes (p &amp;amp;lt; 0.001), but less frequently on tablet splitting (p = 0.035). In conclusion, outsourcing medication repackaging has a limited impact on the quality of interprofessional collaboration between the two professions but may have the potential to reduce ambiguities regarding splitting tablets.</description>
	<pubDate>2025-12-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 182: Impacts of Outsourcing Medication Repackaging in Nursing Homes: Quality and Areas of Pharmacy&amp;ndash;Nursing Collaboration</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/182">doi: 10.3390/pharmacy13060182</a></p>
	<p>Authors:
		Thomas Schmid
		Falk Hoffmann
		Michael Dörks
		Kathrin Jobski
		</p>
	<p>The task of repackaging resident&amp;amp;rsquo;s medication into medication organizers is increasingly outsourced from nursing homes to pharmacies, presenting an opportunity to redefine the interaction between nursing and pharmaceutical staff. This study investigated whether outsourcing medication repackaging changes the quality and subjects of collaboration between the two professions. A cross-sectional survey was developed targeting heads of nursing in German nursing homes. A simple random sample of 1415 nursing homes was contacted by phone. Respondents participated either by phone or by online survey. Quality of collaboration was measured using Kenaszchuk&amp;amp;rsquo;s Interprofessional Collaboration Scale (ICS) with its subscales Communication, Accommodation and Isolation. Topics of interaction were ascertained using items along a medication management phase model. Differences in response frequencies were analyzed using Fisher&amp;amp;rsquo;s exact test. A total of 268 nursing homes participated (response: 18.9%). Of these, 132 (49.3%) had outsourced repackaging. Respondents at nursing homes with in-house medication repackaging rated the subscale Accommodation more favorably (p = 0.008), while Communication and Isolation showed no difference. Of the 13 individual ICS items, &amp;amp;ldquo;passing on information&amp;amp;rdquo; (Communication) was rated better by respondents at homes with outsourced repackaging (p = 0.019) and &amp;amp;ldquo;consideration of convenience&amp;amp;rdquo; (Accommodation) more favorably by respondents at homes with in-house repackaging (p = 0.042). Nursing staff at homes with outsourced medication repackaging interacted with pharmaceutical staff more frequently on medication changes (p &amp;amp;lt; 0.001), but less frequently on tablet splitting (p = 0.035). In conclusion, outsourcing medication repackaging has a limited impact on the quality of interprofessional collaboration between the two professions but may have the potential to reduce ambiguities regarding splitting tablets.</p>
	]]></content:encoded>

	<dc:title>Impacts of Outsourcing Medication Repackaging in Nursing Homes: Quality and Areas of Pharmacy&amp;amp;ndash;Nursing Collaboration</dc:title>
			<dc:creator>Thomas Schmid</dc:creator>
			<dc:creator>Falk Hoffmann</dc:creator>
			<dc:creator>Michael Dörks</dc:creator>
			<dc:creator>Kathrin Jobski</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060182</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-13</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-13</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>182</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060182</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/182</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/181">

	<title>Pharmacy, Vol. 13, Pages 181: Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions</title>
	<link>https://www.mdpi.com/2226-4787/13/6/181</link>
	<description>Introduction: During pharmaceutical care, community pharmacists play a crucial role by carrying out interventions aimed at preventing, detecting, and resolving drug-related problems (DRPs) and negative outcomes associated with medication (NOM), simultaneously enhancing patients&amp;amp;rsquo; knowledge about their treatments. The chronic use of Benzodiazepines (BZDs) is known to be associated with risks such as tolerance, dependence, and cognitive impairment. Furthermore, the combined use of BZDs with other medications or alcohol may expose patients to significant drug interactions. Objectives: This study aimed to characterize and describe the clinical profile of patients using BZDs, to evaluate the extent of polypharmacy and potential drug interactions, to investigate their level of knowledge regarding BZD treatment, and ultimately, to propose evidence-based interventions from the community pharmacy to contribute to improving patient safety and minimizing risks associated with BZD use. Method: A cross-sectional, descriptive study was conducted in a single community pharmacy in Gran Canaria (Canary Islands, Spain). The study population comprised 125 adult patients with active BZD prescriptions. Data collection was performed through pharmacist&amp;amp;ndash;patient structured interviews using a questionnaire that included sociodemographic, clinical, and BZD knowledge variables. Results: Lormetazepam and alprazolam were the BZDs most frequently prescribed and dispensed. Potential drug interactions with other medications were detected in 38.4% of BZD users. Notably, 61.5% of patients using BZDs also reported the concurrent use of opioid analgesics, with tramadol being the most common opioid (48.1% of BZD users were also treated with tramadol). Statistically significant differences were observed between patients with and without BZD and other drug interactions in several adverse outcome variables, including the risk of falls (p = 0.003), cognitive impairment (p = 0.047), and urinary incontinence (p = 0.016). Existing BZD dependence is detected in 25% and 22.1% of cases, respectively. Patients&amp;amp;rsquo; knowledge of their BZD treatment revealed critical gaps, which are identified as a challenge and a clear opportunity for intervention through pharmaceutical care services. Conclusions: The findings underscore the essential and proactive role of community pharmacists in identifying and managing drug interactions, as well as in supporting deprescribing strategies through collaborative and interprofessional care models.</description>
	<pubDate>2025-12-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 181: Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/181">doi: 10.3390/pharmacy13060181</a></p>
	<p>Authors:
		Juan Ramón Santana Ayala
		Daida Alberto Armas
		Veronica Hernández García
		Armando Aguirre-Jaime
		Ángel J. Gutiérrez
		Soraya Paz-Montelongo
		Arturo Hardisson de la Torre
		Carmen Rubio Armendáriz
		</p>
	<p>Introduction: During pharmaceutical care, community pharmacists play a crucial role by carrying out interventions aimed at preventing, detecting, and resolving drug-related problems (DRPs) and negative outcomes associated with medication (NOM), simultaneously enhancing patients&amp;amp;rsquo; knowledge about their treatments. The chronic use of Benzodiazepines (BZDs) is known to be associated with risks such as tolerance, dependence, and cognitive impairment. Furthermore, the combined use of BZDs with other medications or alcohol may expose patients to significant drug interactions. Objectives: This study aimed to characterize and describe the clinical profile of patients using BZDs, to evaluate the extent of polypharmacy and potential drug interactions, to investigate their level of knowledge regarding BZD treatment, and ultimately, to propose evidence-based interventions from the community pharmacy to contribute to improving patient safety and minimizing risks associated with BZD use. Method: A cross-sectional, descriptive study was conducted in a single community pharmacy in Gran Canaria (Canary Islands, Spain). The study population comprised 125 adult patients with active BZD prescriptions. Data collection was performed through pharmacist&amp;amp;ndash;patient structured interviews using a questionnaire that included sociodemographic, clinical, and BZD knowledge variables. Results: Lormetazepam and alprazolam were the BZDs most frequently prescribed and dispensed. Potential drug interactions with other medications were detected in 38.4% of BZD users. Notably, 61.5% of patients using BZDs also reported the concurrent use of opioid analgesics, with tramadol being the most common opioid (48.1% of BZD users were also treated with tramadol). Statistically significant differences were observed between patients with and without BZD and other drug interactions in several adverse outcome variables, including the risk of falls (p = 0.003), cognitive impairment (p = 0.047), and urinary incontinence (p = 0.016). Existing BZD dependence is detected in 25% and 22.1% of cases, respectively. Patients&amp;amp;rsquo; knowledge of their BZD treatment revealed critical gaps, which are identified as a challenge and a clear opportunity for intervention through pharmaceutical care services. Conclusions: The findings underscore the essential and proactive role of community pharmacists in identifying and managing drug interactions, as well as in supporting deprescribing strategies through collaborative and interprofessional care models.</p>
	]]></content:encoded>

	<dc:title>Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions</dc:title>
			<dc:creator>Juan Ramón Santana Ayala</dc:creator>
			<dc:creator>Daida Alberto Armas</dc:creator>
			<dc:creator>Veronica Hernández García</dc:creator>
			<dc:creator>Armando Aguirre-Jaime</dc:creator>
			<dc:creator>Ángel J. Gutiérrez</dc:creator>
			<dc:creator>Soraya Paz-Montelongo</dc:creator>
			<dc:creator>Arturo Hardisson de la Torre</dc:creator>
			<dc:creator>Carmen Rubio Armendáriz</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060181</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-11</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-11</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>181</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060181</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/181</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/180">

	<title>Pharmacy, Vol. 13, Pages 180: Advances in Drug and Vaccine Delivery for Low- and Middle-Income Healthcare Programs&amp;mdash;The Case for Replacing Multi-Dose Vials with Prefilled Single-Dose Delivery Systems</title>
	<link>https://www.mdpi.com/2226-4787/13/6/180</link>
	<description>The transition toward wide-scale use of single-dose administration systems such as prefilled syringes has primarily occurred in high-income countries due to economic considerations. This has resulted in a disparity of access to such technologies in low- and middle-income countries, which continue to utilize multi-dose vial-based presentations and syringes for parenteral delivery. Single-dose innovations currently available or in the product development pipeline represent the promise of enhanced access globally and the potential for public health impact. This perspective article discusses the reported benefits of pre-filled single-dose delivery systems compared to multi-dose vials, as well as the higher standards of infection control regulations and practices that resulted in the increasing use of and benefit from single-dose administration systems in high-income countries. We evaluated how these benefits and standards could enhance health initiatives in low- and middle-income countries. Finally, we explored the potential for making pre-filled single-dose delivery methods both accessible and affordable in low- and middle-income countries.</description>
	<pubDate>2025-12-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 180: Advances in Drug and Vaccine Delivery for Low- and Middle-Income Healthcare Programs&amp;mdash;The Case for Replacing Multi-Dose Vials with Prefilled Single-Dose Delivery Systems</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/180">doi: 10.3390/pharmacy13060180</a></p>
	<p>Authors:
		Darin Zehrung
		Michael J. Free
		</p>
	<p>The transition toward wide-scale use of single-dose administration systems such as prefilled syringes has primarily occurred in high-income countries due to economic considerations. This has resulted in a disparity of access to such technologies in low- and middle-income countries, which continue to utilize multi-dose vial-based presentations and syringes for parenteral delivery. Single-dose innovations currently available or in the product development pipeline represent the promise of enhanced access globally and the potential for public health impact. This perspective article discusses the reported benefits of pre-filled single-dose delivery systems compared to multi-dose vials, as well as the higher standards of infection control regulations and practices that resulted in the increasing use of and benefit from single-dose administration systems in high-income countries. We evaluated how these benefits and standards could enhance health initiatives in low- and middle-income countries. Finally, we explored the potential for making pre-filled single-dose delivery methods both accessible and affordable in low- and middle-income countries.</p>
	]]></content:encoded>

	<dc:title>Advances in Drug and Vaccine Delivery for Low- and Middle-Income Healthcare Programs&amp;amp;mdash;The Case for Replacing Multi-Dose Vials with Prefilled Single-Dose Delivery Systems</dc:title>
			<dc:creator>Darin Zehrung</dc:creator>
			<dc:creator>Michael J. Free</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060180</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-10</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-10</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>180</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060180</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/180</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/179">

	<title>Pharmacy, Vol. 13, Pages 179: Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency&amp;rsquo;s Response to the Pandemic</title>
	<link>https://www.mdpi.com/2226-4787/13/6/179</link>
	<description>As one of the biggest challenges for healthcare in the 21st century, COVID-19 placed a sustained and intense demand on the European Medicines Agency&amp;amp;rsquo;s resources and required constant adaptation and mobilization of different regulatory processes. In this situation, drug repurposing appeared as a promising potential approach in quickly emerging health crises due to its main advantage of reducing the time and cost for addition of new indications since it uses products proven to be of high quality, safe, and effective. We performed an analysis of European Public Assessment Reports for medicinal products authorized for the SARS-CoV-2 infection by the European Medicines Agency, showing a total of eight products with this indication, three (37.5%) of which used repurposing as a mechanism for development (remdesivir, tocilizumab, and anakinra). The application of this mechanism by these medicines highlights the importance of the life cycle stage at which repositioning is undertaken, which resulted in different volumes of data submitted in the respective European Public Assessment Reports. The participation of organizations other than the marketing authorization holder in key stages in the drug development process of repurposed products was once again confirmed, which emphasizes the need to regulate this interaction.</description>
	<pubDate>2025-12-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 179: Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency&amp;rsquo;s Response to the Pandemic</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/179">doi: 10.3390/pharmacy13060179</a></p>
	<p>Authors:
		Antonio Ivanov
		Violeta Getova-Kolarova
		Ines Hababa-Ivanova
		</p>
	<p>As one of the biggest challenges for healthcare in the 21st century, COVID-19 placed a sustained and intense demand on the European Medicines Agency&amp;amp;rsquo;s resources and required constant adaptation and mobilization of different regulatory processes. In this situation, drug repurposing appeared as a promising potential approach in quickly emerging health crises due to its main advantage of reducing the time and cost for addition of new indications since it uses products proven to be of high quality, safe, and effective. We performed an analysis of European Public Assessment Reports for medicinal products authorized for the SARS-CoV-2 infection by the European Medicines Agency, showing a total of eight products with this indication, three (37.5%) of which used repurposing as a mechanism for development (remdesivir, tocilizumab, and anakinra). The application of this mechanism by these medicines highlights the importance of the life cycle stage at which repositioning is undertaken, which resulted in different volumes of data submitted in the respective European Public Assessment Reports. The participation of organizations other than the marketing authorization holder in key stages in the drug development process of repurposed products was once again confirmed, which emphasizes the need to regulate this interaction.</p>
	]]></content:encoded>

	<dc:title>Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency&amp;amp;rsquo;s Response to the Pandemic</dc:title>
			<dc:creator>Antonio Ivanov</dc:creator>
			<dc:creator>Violeta Getova-Kolarova</dc:creator>
			<dc:creator>Ines Hababa-Ivanova</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060179</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-10</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-10</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>179</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060179</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/179</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/178">

	<title>Pharmacy, Vol. 13, Pages 178: Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS</title>
	<link>https://www.mdpi.com/2226-4787/13/6/178</link>
	<description>Chronic obstructive pulmonary disease (COPD) is a major global health burden. The fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) triple therapy provides new treatment, but its long-term real-world safety lacks evidence. A post-marketing analysis used the FAERS database to identify adverse event (AE) signals for FF/UMEC/VI. Disproportionality methods including reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM), were applied to detect AE signals, focusing on reports from third quarter (Q3) 2019 to Q3 2024. Among 16,238 reports listing FF/UMEC/VI as primary suspect, significant AE signals occurred in &amp;amp;lsquo;injury, poisoning and procedural complications&amp;amp;rsquo; (n = 9067, ROR 2.46, PRR 2.08, IC 1.06, EBGM 2.08), and &amp;amp;lsquo;respiratory, thoracic and mediastinal disorders&amp;amp;rsquo; (n = 6567, ROR 4.87, PRR 4.15, IC 2.05, EBGM 4.13). A total of 196 significantly disproportionate preferred terms (PTs) were identified, including previously undocumented AEs such as chronic eosinophilic rhinosinusitis, dysphonia, and vocal cord dysfunction. This post-marketing safety study revealed significant signals for dysphonia and vocal cord dysfunction associated with FF/UMEC/VI, suggesting that clinicians should remain vigilant for these events.</description>
	<pubDate>2025-12-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 178: Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/178">doi: 10.3390/pharmacy13060178</a></p>
	<p>Authors:
		Jiajun Chen
		Ying Qiao
		Gaoxing Qiao
		Xiaocan Jia
		Jicun Zhu
		</p>
	<p>Chronic obstructive pulmonary disease (COPD) is a major global health burden. The fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) triple therapy provides new treatment, but its long-term real-world safety lacks evidence. A post-marketing analysis used the FAERS database to identify adverse event (AE) signals for FF/UMEC/VI. Disproportionality methods including reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM), were applied to detect AE signals, focusing on reports from third quarter (Q3) 2019 to Q3 2024. Among 16,238 reports listing FF/UMEC/VI as primary suspect, significant AE signals occurred in &amp;amp;lsquo;injury, poisoning and procedural complications&amp;amp;rsquo; (n = 9067, ROR 2.46, PRR 2.08, IC 1.06, EBGM 2.08), and &amp;amp;lsquo;respiratory, thoracic and mediastinal disorders&amp;amp;rsquo; (n = 6567, ROR 4.87, PRR 4.15, IC 2.05, EBGM 4.13). A total of 196 significantly disproportionate preferred terms (PTs) were identified, including previously undocumented AEs such as chronic eosinophilic rhinosinusitis, dysphonia, and vocal cord dysfunction. This post-marketing safety study revealed significant signals for dysphonia and vocal cord dysfunction associated with FF/UMEC/VI, suggesting that clinicians should remain vigilant for these events.</p>
	]]></content:encoded>

	<dc:title>Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS</dc:title>
			<dc:creator>Jiajun Chen</dc:creator>
			<dc:creator>Ying Qiao</dc:creator>
			<dc:creator>Gaoxing Qiao</dc:creator>
			<dc:creator>Xiaocan Jia</dc:creator>
			<dc:creator>Jicun Zhu</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060178</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-10</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-10</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>178</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060178</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/178</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/177">

	<title>Pharmacy, Vol. 13, Pages 177: Telepharmacy Consultations (TPCs) in Local Pharmacies&amp;mdash;A Bi-Centric Survey of Customer Opinions</title>
	<link>https://www.mdpi.com/2226-4787/13/6/177</link>
	<description>Background: Telepharmacy consultations (TPCs) became a routine element of pharmacy operations. However, there is limited data available on local pharmacy customer feedback related to TPC. Methods: A customer survey was developed seeking feedback on TPC. The pharmacy customers were invited to complete the survey in two local pharmacies in Germany. The survey and corresponding informed consent form were approved by the Ethics Committee. Results: In total, 178 pharmacy customers were enrolled (median age 41&amp;amp;ndash;50 years). From those, 37% agreed when asked whether they were generally interested in TPC. A total of 37% had the nearest pharmacy 5&amp;amp;ndash;15 min from their home. A total of 42% visited their pharmacy quarterly. A total of 36% used technical devices in median 1&amp;amp;ndash;2 h per days. A total of 33% classified their own digital skills at least as sufficient. A total of 59% would use their smartphone as a potential device for TPC. A total of 83% rated it as (slightly) important that the pharmacist providing TPC can be heard clearly. A total of 76% each (strongly) agreed that an argument for TPC would include limited mobility or pandemic/quarantine. A total of 33% (strongly) agreed that a key argument against TPC were technical requirements. A total of 75% considered situations of immobility to be the most important future perspective for TPC. Conclusions: Many pharmacy customers see TPC as an opportunity, e.g., in cases of limited mobility or during pandemic or quarantine. However, the use of appropriate technology can be a limiting factor.</description>
	<pubDate>2025-12-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 177: Telepharmacy Consultations (TPCs) in Local Pharmacies&amp;mdash;A Bi-Centric Survey of Customer Opinions</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/177">doi: 10.3390/pharmacy13060177</a></p>
	<p>Authors:
		Nathalie Floch
		Philipp Harand
		Chris Graichen
		Thilo Bertsche
		</p>
	<p>Background: Telepharmacy consultations (TPCs) became a routine element of pharmacy operations. However, there is limited data available on local pharmacy customer feedback related to TPC. Methods: A customer survey was developed seeking feedback on TPC. The pharmacy customers were invited to complete the survey in two local pharmacies in Germany. The survey and corresponding informed consent form were approved by the Ethics Committee. Results: In total, 178 pharmacy customers were enrolled (median age 41&amp;amp;ndash;50 years). From those, 37% agreed when asked whether they were generally interested in TPC. A total of 37% had the nearest pharmacy 5&amp;amp;ndash;15 min from their home. A total of 42% visited their pharmacy quarterly. A total of 36% used technical devices in median 1&amp;amp;ndash;2 h per days. A total of 33% classified their own digital skills at least as sufficient. A total of 59% would use their smartphone as a potential device for TPC. A total of 83% rated it as (slightly) important that the pharmacist providing TPC can be heard clearly. A total of 76% each (strongly) agreed that an argument for TPC would include limited mobility or pandemic/quarantine. A total of 33% (strongly) agreed that a key argument against TPC were technical requirements. A total of 75% considered situations of immobility to be the most important future perspective for TPC. Conclusions: Many pharmacy customers see TPC as an opportunity, e.g., in cases of limited mobility or during pandemic or quarantine. However, the use of appropriate technology can be a limiting factor.</p>
	]]></content:encoded>

	<dc:title>Telepharmacy Consultations (TPCs) in Local Pharmacies&amp;amp;mdash;A Bi-Centric Survey of Customer Opinions</dc:title>
			<dc:creator>Nathalie Floch</dc:creator>
			<dc:creator>Philipp Harand</dc:creator>
			<dc:creator>Chris Graichen</dc:creator>
			<dc:creator>Thilo Bertsche</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060177</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-08</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-08</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>177</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060177</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/177</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/176">

	<title>Pharmacy, Vol. 13, Pages 176: Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning</title>
	<link>https://www.mdpi.com/2226-4787/13/6/176</link>
	<description>Preventable medication harm in oncology is often driven by drug-related adverse events (AEs) that trigger order changes such as holds, dose reductions, delays, rechallenges, and enhanced monitoring. Much of the evidence needed to make these decisions lives in unstructured clinical texts, where large language models (LLMs), a type of artificial intelligence (AI), now offer extraction and reasoning capabilities. In this narrative review, we synthesize empirical studies evaluating LLMs and related NLP systems applied to clinical text for oncology AEs, focusing on three decision-linked tasks: (i) AE detection from clinical documentation, (ii) Common Terminology Criteria for Adverse Events (CTCAE) grade assignment, and (iii) grade-aligned actions. We also consider how these findings can inform pharmacist-facing recommendations for order-level safety. We conducted a narrative review of English-language studies indexed in PubMed, Ovid MEDLINE, and Embase. Eligible studies used LLMs on clinical narratives and/or authoritative guidance as model inputs or reference standards; non-text modalities and non-empirical articles were excluded. Nineteen studies met inclusion criteria. LLMs showed the potential to detect oncology AEs from routine notes and often outperformed diagnosis codes for surveillance and cohort construction. CTCAE grading was feasible but less stable than detection; performance improved when outputs were constrained to CTCAE terms/grades, temporally anchored, and aggregated at the patient level. Direct evaluation of grade-aligned actions was uncommon; most studies reported proxies (e.g., steroid initiation or drug discontinuation) rather than formal grade-to-action correctness. While prospective, real-world impact reporting remained sparse, several studies quantified scale advantages and time savings, supporting an initial role as high-recall triage with pharmacist adjudication. Overall, the evidence supports near-term, pharmacist-in-the-loop use of AI for AE surveillance and review, with CTCAE-structured, citation-backed outputs delivered into the pharmacist&amp;amp;rsquo;s electronic health record order-verification workspace as reviewable artifacts. Future work must standardize reporting and CTCAE/version usage, and measure grade-to-action correctness prospectively, to advance toward order-level decision support.</description>
	<pubDate>2025-12-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 176: Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/176">doi: 10.3390/pharmacy13060176</a></p>
	<p>Authors:
		Md Muntasir Zitu
		Ashish Manne
		Yuxi Zhu
		Wasimul Bari Rahat
		Samar Binkheder
		</p>
	<p>Preventable medication harm in oncology is often driven by drug-related adverse events (AEs) that trigger order changes such as holds, dose reductions, delays, rechallenges, and enhanced monitoring. Much of the evidence needed to make these decisions lives in unstructured clinical texts, where large language models (LLMs), a type of artificial intelligence (AI), now offer extraction and reasoning capabilities. In this narrative review, we synthesize empirical studies evaluating LLMs and related NLP systems applied to clinical text for oncology AEs, focusing on three decision-linked tasks: (i) AE detection from clinical documentation, (ii) Common Terminology Criteria for Adverse Events (CTCAE) grade assignment, and (iii) grade-aligned actions. We also consider how these findings can inform pharmacist-facing recommendations for order-level safety. We conducted a narrative review of English-language studies indexed in PubMed, Ovid MEDLINE, and Embase. Eligible studies used LLMs on clinical narratives and/or authoritative guidance as model inputs or reference standards; non-text modalities and non-empirical articles were excluded. Nineteen studies met inclusion criteria. LLMs showed the potential to detect oncology AEs from routine notes and often outperformed diagnosis codes for surveillance and cohort construction. CTCAE grading was feasible but less stable than detection; performance improved when outputs were constrained to CTCAE terms/grades, temporally anchored, and aggregated at the patient level. Direct evaluation of grade-aligned actions was uncommon; most studies reported proxies (e.g., steroid initiation or drug discontinuation) rather than formal grade-to-action correctness. While prospective, real-world impact reporting remained sparse, several studies quantified scale advantages and time savings, supporting an initial role as high-recall triage with pharmacist adjudication. Overall, the evidence supports near-term, pharmacist-in-the-loop use of AI for AE surveillance and review, with CTCAE-structured, citation-backed outputs delivered into the pharmacist&amp;amp;rsquo;s electronic health record order-verification workspace as reviewable artifacts. Future work must standardize reporting and CTCAE/version usage, and measure grade-to-action correctness prospectively, to advance toward order-level decision support.</p>
	]]></content:encoded>

	<dc:title>Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning</dc:title>
			<dc:creator>Md Muntasir Zitu</dc:creator>
			<dc:creator>Ashish Manne</dc:creator>
			<dc:creator>Yuxi Zhu</dc:creator>
			<dc:creator>Wasimul Bari Rahat</dc:creator>
			<dc:creator>Samar Binkheder</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060176</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-03</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>176</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060176</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/176</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/175">

	<title>Pharmacy, Vol. 13, Pages 175: Cost Analysis of Multidose Drug Dispensing (MDD) System Implementation in a Community Pharmacy in Portugal</title>
	<link>https://www.mdpi.com/2226-4787/13/6/175</link>
	<description>Background: Community pharmacies are increasingly delivering structured services to support chronic disease management, such as Multidose Drug Dispensing (MDD). This strategy can improve adherence and safety, but evidence of its economic feasibility in Portuguese pharmacies remains limited. Objective: To estimate the cost of implementing and operating an MDD system in a community pharmacy, informing reimbursement models and policy. Methods: A micro-costing approach assessed fixed and variable expenses for serving polymedicated elderly patients. Costs were calculated in euros (2024/2025) and expressed per working day based on 253 annual preparation days. Results: First-year costs totaled &amp;amp;euro;70,985.68, including &amp;amp;euro;8184.00 for setup, &amp;amp;euro;21,579.00 for supplies, and &amp;amp;euro;41,222.68 for staff salaries. The daily operating cost was &amp;amp;euro;280.58, with labour representing the major expense. A break-even analysis indicated sustainability with around 700 users at &amp;amp;euro;10/month. Conclusion: Although requiring significant initial investment, MDD can become financially viable through scaling, workflow efficiency, and supportive reimbursement strategies.</description>
	<pubDate>2025-12-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 175: Cost Analysis of Multidose Drug Dispensing (MDD) System Implementation in a Community Pharmacy in Portugal</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/175">doi: 10.3390/pharmacy13060175</a></p>
	<p>Authors:
		Ana Reis
		Ângelo Jesus
		Maria Luisa Martín
		</p>
	<p>Background: Community pharmacies are increasingly delivering structured services to support chronic disease management, such as Multidose Drug Dispensing (MDD). This strategy can improve adherence and safety, but evidence of its economic feasibility in Portuguese pharmacies remains limited. Objective: To estimate the cost of implementing and operating an MDD system in a community pharmacy, informing reimbursement models and policy. Methods: A micro-costing approach assessed fixed and variable expenses for serving polymedicated elderly patients. Costs were calculated in euros (2024/2025) and expressed per working day based on 253 annual preparation days. Results: First-year costs totaled &amp;amp;euro;70,985.68, including &amp;amp;euro;8184.00 for setup, &amp;amp;euro;21,579.00 for supplies, and &amp;amp;euro;41,222.68 for staff salaries. The daily operating cost was &amp;amp;euro;280.58, with labour representing the major expense. A break-even analysis indicated sustainability with around 700 users at &amp;amp;euro;10/month. Conclusion: Although requiring significant initial investment, MDD can become financially viable through scaling, workflow efficiency, and supportive reimbursement strategies.</p>
	]]></content:encoded>

	<dc:title>Cost Analysis of Multidose Drug Dispensing (MDD) System Implementation in a Community Pharmacy in Portugal</dc:title>
			<dc:creator>Ana Reis</dc:creator>
			<dc:creator>Ângelo Jesus</dc:creator>
			<dc:creator>Maria Luisa Martín</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060175</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>175</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060175</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/175</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/174">

	<title>Pharmacy, Vol. 13, Pages 174: &amp;ldquo;But Will It Last?&amp;rdquo;: Examining How Pharmacy Staff Perceptions Influence Beliefs About the Sustainability of a Pharmacy-Based Intervention Targeting Older Adult Over-the-Counter (OTC) Medication Misuse</title>
	<link>https://www.mdpi.com/2226-4787/13/6/174</link>
	<description>Sustaining a well-designed healthcare intervention justifies the resources allocated during its conceptualization and implementation and maximizes its clinical benefits, but staff influences on sustainment have been studied insufficiently. This study evaluates the effects of pharmacy staff (i.e., pharmacists/technicians) perceptions about the sustainability of Senior SafeTM, a U.S. pharmacy-based intervention to reduce older adult over-the-counter (OTC) medication misuse. Three months after introducing Senior Safe into 67 pharmacies in a large Midwestern health-system, all pharmacy staff (N = 279) received a survey invitation. Fifty-nine pharmacists and 94 technicians completed the survey. Using logistic regression modeling for the 14 belief-based survey items, and staff roles (pharmacist or technician), the final factors significantly predicting staff views that Senior Safe was sustainable were as follows: perceiving Senior Safe as well-integrated into leadership operations (OR = 5.606, p &amp;amp;lt; 0.001) and believing the intervention reduced OTC misuse (OR = 8.217, p &amp;amp;lt; 0.001). Also, technicians were more confident than pharmacists about Senior Safe&amp;amp;rsquo;s sustainment and its OTC misuse reduction success. Overall, an intervention&amp;amp;rsquo;s sustainability relies on those using it. Since the principal predictor of maintaining Senior Safe was its perceived effectiveness, increasing staff buy-in and awareness of an intervention&amp;amp;rsquo;s benefits may be central to its long-term viability. With an aging U.S. population, sustainable solutions to older adult medication misuse remain critical.</description>
	<pubDate>2025-12-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 174: &amp;ldquo;But Will It Last?&amp;rdquo;: Examining How Pharmacy Staff Perceptions Influence Beliefs About the Sustainability of a Pharmacy-Based Intervention Targeting Older Adult Over-the-Counter (OTC) Medication Misuse</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/174">doi: 10.3390/pharmacy13060174</a></p>
	<p>Authors:
		Aaron M. Gilson
		Katherine G. Moore
		Stephanie M. Resendiz
		Emily L. Hoffins
		Shiying Mai
		Jamie A. Stone
		Michelle A. Chui
		</p>
	<p>Sustaining a well-designed healthcare intervention justifies the resources allocated during its conceptualization and implementation and maximizes its clinical benefits, but staff influences on sustainment have been studied insufficiently. This study evaluates the effects of pharmacy staff (i.e., pharmacists/technicians) perceptions about the sustainability of Senior SafeTM, a U.S. pharmacy-based intervention to reduce older adult over-the-counter (OTC) medication misuse. Three months after introducing Senior Safe into 67 pharmacies in a large Midwestern health-system, all pharmacy staff (N = 279) received a survey invitation. Fifty-nine pharmacists and 94 technicians completed the survey. Using logistic regression modeling for the 14 belief-based survey items, and staff roles (pharmacist or technician), the final factors significantly predicting staff views that Senior Safe was sustainable were as follows: perceiving Senior Safe as well-integrated into leadership operations (OR = 5.606, p &amp;amp;lt; 0.001) and believing the intervention reduced OTC misuse (OR = 8.217, p &amp;amp;lt; 0.001). Also, technicians were more confident than pharmacists about Senior Safe&amp;amp;rsquo;s sustainment and its OTC misuse reduction success. Overall, an intervention&amp;amp;rsquo;s sustainability relies on those using it. Since the principal predictor of maintaining Senior Safe was its perceived effectiveness, increasing staff buy-in and awareness of an intervention&amp;amp;rsquo;s benefits may be central to its long-term viability. With an aging U.S. population, sustainable solutions to older adult medication misuse remain critical.</p>
	]]></content:encoded>

	<dc:title>&amp;amp;ldquo;But Will It Last?&amp;amp;rdquo;: Examining How Pharmacy Staff Perceptions Influence Beliefs About the Sustainability of a Pharmacy-Based Intervention Targeting Older Adult Over-the-Counter (OTC) Medication Misuse</dc:title>
			<dc:creator>Aaron M. Gilson</dc:creator>
			<dc:creator>Katherine G. Moore</dc:creator>
			<dc:creator>Stephanie M. Resendiz</dc:creator>
			<dc:creator>Emily L. Hoffins</dc:creator>
			<dc:creator>Shiying Mai</dc:creator>
			<dc:creator>Jamie A. Stone</dc:creator>
			<dc:creator>Michelle A. Chui</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060174</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>174</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060174</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/174</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/173">

	<title>Pharmacy, Vol. 13, Pages 173: Barriers and Opportunities in Cancer Pain Management: A Qualitative Study on Pharmacists&amp;rsquo; Role</title>
	<link>https://www.mdpi.com/2226-4787/13/6/173</link>
	<description>Introduction: Cancer pain remains a critical issue for patients&amp;amp;rsquo; quality of life, affecting their physiology, psychology, and social relationships. Despite the widely recognized role of pharmacists in pain management, their involvement in palliative care in Greece remains limited. This study focuses on exploring the perceptions and experiences of pharmacists regarding their role in cancer pain management, identifying barriers, required skills, and proposing strategies for their integration in the multidisciplinary team. &amp;amp;Mu;aterials and &amp;amp;Mu;ethods: Qualitative research was conducted through semi-structured interviews with seven pharmacists in the Attica region. The interviews were recorded, transcribed, and thematically analyzed. Results: The analysis revealed four main themes: (1) limited access to medical records and challenges in pharmaceutical decision-making, (2) lack of institutional frameworks and a culture of collaboration, (3) need for specialized education and continuous training, and (4) understaffing and bureaucracy, faced by pharmacists. Discussion: This study highlights the underutilized role of pharmacists in cancer pain management in Greece. Barriers such as restricted access to patient records, weak interdisciplinary collaboration, insufficient training, and bureaucratic constraints limit their contribution. Structured frameworks and collaborative cultures can enhance pharmacists&amp;amp;rsquo; involvement, while education and continuous training are essential to strengthen their legitimacy within care teams. Digital tools can improve access to patient information and support evidence-based decisions. Conclusions: Pharmacists&amp;amp;rsquo; integration in the patient&amp;amp;rsquo;s management team has significant benefits for the patient&amp;amp;rsquo;s quality of life. Strengthening pharmacists&amp;amp;rsquo; involvement in cancer pain management requires the establishment of collaborations, continuous education, bureaucratic simplification, and the integration of digital tools. The development of practical resources, such as educational guides, can play a pivotal role in enhancing the quality of care provided.</description>
	<pubDate>2025-12-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 173: Barriers and Opportunities in Cancer Pain Management: A Qualitative Study on Pharmacists&amp;rsquo; Role</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/173">doi: 10.3390/pharmacy13060173</a></p>
	<p>Authors:
		Evangelos Aliferis
		George Koulierakis
		Christina Dalla
		Tina Garani-Papadatos
		</p>
	<p>Introduction: Cancer pain remains a critical issue for patients&amp;amp;rsquo; quality of life, affecting their physiology, psychology, and social relationships. Despite the widely recognized role of pharmacists in pain management, their involvement in palliative care in Greece remains limited. This study focuses on exploring the perceptions and experiences of pharmacists regarding their role in cancer pain management, identifying barriers, required skills, and proposing strategies for their integration in the multidisciplinary team. &amp;amp;Mu;aterials and &amp;amp;Mu;ethods: Qualitative research was conducted through semi-structured interviews with seven pharmacists in the Attica region. The interviews were recorded, transcribed, and thematically analyzed. Results: The analysis revealed four main themes: (1) limited access to medical records and challenges in pharmaceutical decision-making, (2) lack of institutional frameworks and a culture of collaboration, (3) need for specialized education and continuous training, and (4) understaffing and bureaucracy, faced by pharmacists. Discussion: This study highlights the underutilized role of pharmacists in cancer pain management in Greece. Barriers such as restricted access to patient records, weak interdisciplinary collaboration, insufficient training, and bureaucratic constraints limit their contribution. Structured frameworks and collaborative cultures can enhance pharmacists&amp;amp;rsquo; involvement, while education and continuous training are essential to strengthen their legitimacy within care teams. Digital tools can improve access to patient information and support evidence-based decisions. Conclusions: Pharmacists&amp;amp;rsquo; integration in the patient&amp;amp;rsquo;s management team has significant benefits for the patient&amp;amp;rsquo;s quality of life. Strengthening pharmacists&amp;amp;rsquo; involvement in cancer pain management requires the establishment of collaborations, continuous education, bureaucratic simplification, and the integration of digital tools. The development of practical resources, such as educational guides, can play a pivotal role in enhancing the quality of care provided.</p>
	]]></content:encoded>

	<dc:title>Barriers and Opportunities in Cancer Pain Management: A Qualitative Study on Pharmacists&amp;amp;rsquo; Role</dc:title>
			<dc:creator>Evangelos Aliferis</dc:creator>
			<dc:creator>George Koulierakis</dc:creator>
			<dc:creator>Christina Dalla</dc:creator>
			<dc:creator>Tina Garani-Papadatos</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060173</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-12-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-12-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>173</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060173</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/173</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/172">

	<title>Pharmacy, Vol. 13, Pages 172: Capturing Value: How Health-System Specialty Pharmacies Define and Document Pharmacist Interventions</title>
	<link>https://www.mdpi.com/2226-4787/13/6/172</link>
	<description>Standardized pharmacist intervention practices and documentation among health-system specialty pharmacies could improve understanding of the pharmacists&amp;amp;rsquo; role and value in this setting. This study describes current health-system specialty pharmacies&amp;amp;rsquo; intervention practices. A survey developed by a volunteer committee subgroup was distributed to two health-system specialty pharmacy group email distribution lists. The survey evaluated the types of tasks considered to be clinical or non-clinical interventions; who could perform interventions; where and how they were documented; data elements included in documentation; and how intervention data were classified, used, reviewed, and shared with internal or external stakeholders. Twenty-four institutions responded to the survey. Tasks within medication management, adverse drug events/monitoring, and education domains were more commonly considered clinical interventions; tasks in the health maintenance and coordination of care domains were more frequently considered non-clinical interventions or not considered to be interventions. Interventions were completed by pharmacists (at 100% of sites) and were mostly documented in the electronic health record (92%). Intervention data were primarily collected to meet accreditation purposes (96%) or for quality auditing and review (88%). No respondents shared intervention data with patients. Results demonstrate areas of alignment and variance in intervention definition and documentation among health-system specialty pharmacies.</description>
	<pubDate>2025-11-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 172: Capturing Value: How Health-System Specialty Pharmacies Define and Document Pharmacist Interventions</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/172">doi: 10.3390/pharmacy13060172</a></p>
	<p>Authors:
		Autumn D. Zuckerman
		Karen C. Thomas
		Erica Diamantides
		Shannan Takhar
		Rushabh Shah
		Kelsi Conant
		Thom Platt
		Christian Rhudy
		</p>
	<p>Standardized pharmacist intervention practices and documentation among health-system specialty pharmacies could improve understanding of the pharmacists&amp;amp;rsquo; role and value in this setting. This study describes current health-system specialty pharmacies&amp;amp;rsquo; intervention practices. A survey developed by a volunteer committee subgroup was distributed to two health-system specialty pharmacy group email distribution lists. The survey evaluated the types of tasks considered to be clinical or non-clinical interventions; who could perform interventions; where and how they were documented; data elements included in documentation; and how intervention data were classified, used, reviewed, and shared with internal or external stakeholders. Twenty-four institutions responded to the survey. Tasks within medication management, adverse drug events/monitoring, and education domains were more commonly considered clinical interventions; tasks in the health maintenance and coordination of care domains were more frequently considered non-clinical interventions or not considered to be interventions. Interventions were completed by pharmacists (at 100% of sites) and were mostly documented in the electronic health record (92%). Intervention data were primarily collected to meet accreditation purposes (96%) or for quality auditing and review (88%). No respondents shared intervention data with patients. Results demonstrate areas of alignment and variance in intervention definition and documentation among health-system specialty pharmacies.</p>
	]]></content:encoded>

	<dc:title>Capturing Value: How Health-System Specialty Pharmacies Define and Document Pharmacist Interventions</dc:title>
			<dc:creator>Autumn D. Zuckerman</dc:creator>
			<dc:creator>Karen C. Thomas</dc:creator>
			<dc:creator>Erica Diamantides</dc:creator>
			<dc:creator>Shannan Takhar</dc:creator>
			<dc:creator>Rushabh Shah</dc:creator>
			<dc:creator>Kelsi Conant</dc:creator>
			<dc:creator>Thom Platt</dc:creator>
			<dc:creator>Christian Rhudy</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060172</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-26</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-26</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>172</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060172</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/172</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/171">

	<title>Pharmacy, Vol. 13, Pages 171: Job Satisfaction Among Pharmacists Graduating from a University in Northern Sweden: A Comparative Analysis</title>
	<link>https://www.mdpi.com/2226-4787/13/6/171</link>
	<description>Job satisfaction plays a critical role in shaping professional outcomes, as it has been positively associated with enhanced performance and greater motivation. Conversely, insufficient job satisfaction may contribute to higher rates of staff turnover, professional burnout, and intentions to leave the profession. The objective was to investigate job satisfaction among pharmacists educated at Ume&amp;amp;aring; University in Sweden over time and to explore factors affecting job satisfaction. A survey was distributed to pharmacy graduates who had completed web-based pharmacy programs at Ume&amp;amp;aring; University between 2019 and 2023. Questions regarding job satisfaction and factors related to it were included. The response rate was 38%. The results were compared with results from a previous investigation (graduation years 2015&amp;amp;ndash;2018) to enable comparisons over time. Compared to findings from the previous survey, job satisfaction was lower in the present study (76.4% vs. 91.4%, p = 0.004). Both greater opportunities for continuing professional development (CPD) and the perception that the knowledge and skills gained during education are beneficial in the current job were associated with high job satisfaction (OR: 5.360; 95% CI: 1.896&amp;amp;ndash;15.156 and OR: 3.983; 95% CI: 1.255&amp;amp;ndash;12.642, respectively). Understanding factors contributing to job satisfaction can help employers improve retention and work environment.</description>
	<pubDate>2025-11-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 171: Job Satisfaction Among Pharmacists Graduating from a University in Northern Sweden: A Comparative Analysis</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/171">doi: 10.3390/pharmacy13060171</a></p>
	<p>Authors:
		Maria Gustafsson
		Helena Norberg
		Sofia Mattsson
		</p>
	<p>Job satisfaction plays a critical role in shaping professional outcomes, as it has been positively associated with enhanced performance and greater motivation. Conversely, insufficient job satisfaction may contribute to higher rates of staff turnover, professional burnout, and intentions to leave the profession. The objective was to investigate job satisfaction among pharmacists educated at Ume&amp;amp;aring; University in Sweden over time and to explore factors affecting job satisfaction. A survey was distributed to pharmacy graduates who had completed web-based pharmacy programs at Ume&amp;amp;aring; University between 2019 and 2023. Questions regarding job satisfaction and factors related to it were included. The response rate was 38%. The results were compared with results from a previous investigation (graduation years 2015&amp;amp;ndash;2018) to enable comparisons over time. Compared to findings from the previous survey, job satisfaction was lower in the present study (76.4% vs. 91.4%, p = 0.004). Both greater opportunities for continuing professional development (CPD) and the perception that the knowledge and skills gained during education are beneficial in the current job were associated with high job satisfaction (OR: 5.360; 95% CI: 1.896&amp;amp;ndash;15.156 and OR: 3.983; 95% CI: 1.255&amp;amp;ndash;12.642, respectively). Understanding factors contributing to job satisfaction can help employers improve retention and work environment.</p>
	]]></content:encoded>

	<dc:title>Job Satisfaction Among Pharmacists Graduating from a University in Northern Sweden: A Comparative Analysis</dc:title>
			<dc:creator>Maria Gustafsson</dc:creator>
			<dc:creator>Helena Norberg</dc:creator>
			<dc:creator>Sofia Mattsson</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060171</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-22</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-22</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>171</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060171</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/171</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/170">

	<title>Pharmacy, Vol. 13, Pages 170: Medication Use by Older Adults with Frailty: A Scoping Review</title>
	<link>https://www.mdpi.com/2226-4787/13/6/170</link>
	<description>Frailty among older adults heightens their risk of negative health outcomes, and medication use plays a major role in this increased vulnerability. Various aspects of medication use elevate the risk of poor outcomes in individuals with frailty. The current scoping review was designed to explore medication use in older adults with frailty in primary care, focusing on the prevalence of potentially inappropriate medications (PIMs), polypharmacy, medication adherence, and their role in contributing to adverse drug events. This scoping review was conducted using the Arksey and O&amp;amp;rsquo;Malley, supplemented by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews (PRISMA-ScR) guidelines. A search of the literature was conducted from inception to November 2023 in Ovid EMBASE, PubMed (MEDLINE), Scopus, EBSCOhost CINAHL, and Ovid International Pharmaceutical Abstracts. Studies which met the eligibility criteria included older adults with frailty (&amp;amp;ge;65 years) living at home, defined frailty criteria, and assessment of medication use. Out of the 4726 studies screened, 223 were included, conducted across 39 countries. Frailty prevalence varied widely from 0.9% to 89.2%. Polypharmacy (5&amp;amp;ndash;9 medications) and hyper-polypharmacy (&amp;amp;ge;10 medications) were notably more common among individuals with frailty, with polypharmacy rates ranging from 1.3% to 96.4%. Twelve studies reported PIM prevalence among individuals with varying levels of frailty, ranging from 2.4% to 95.9%. This scoping review highlights the challenges and complexities involved in understanding the relationship between medication use and frailty in older adults.</description>
	<pubDate>2025-11-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 170: Medication Use by Older Adults with Frailty: A Scoping Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/170">doi: 10.3390/pharmacy13060170</a></p>
	<p>Authors:
		Rishabh Sharma
		Tanaya Sharma
		Brent McCready-Branch
		Arshia Chauhan
		Caitlin Carter
		SooMin Park
		Imra Hudani
		Prapti Choudhuri
		Tejal Patel
		</p>
	<p>Frailty among older adults heightens their risk of negative health outcomes, and medication use plays a major role in this increased vulnerability. Various aspects of medication use elevate the risk of poor outcomes in individuals with frailty. The current scoping review was designed to explore medication use in older adults with frailty in primary care, focusing on the prevalence of potentially inappropriate medications (PIMs), polypharmacy, medication adherence, and their role in contributing to adverse drug events. This scoping review was conducted using the Arksey and O&amp;amp;rsquo;Malley, supplemented by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews (PRISMA-ScR) guidelines. A search of the literature was conducted from inception to November 2023 in Ovid EMBASE, PubMed (MEDLINE), Scopus, EBSCOhost CINAHL, and Ovid International Pharmaceutical Abstracts. Studies which met the eligibility criteria included older adults with frailty (&amp;amp;ge;65 years) living at home, defined frailty criteria, and assessment of medication use. Out of the 4726 studies screened, 223 were included, conducted across 39 countries. Frailty prevalence varied widely from 0.9% to 89.2%. Polypharmacy (5&amp;amp;ndash;9 medications) and hyper-polypharmacy (&amp;amp;ge;10 medications) were notably more common among individuals with frailty, with polypharmacy rates ranging from 1.3% to 96.4%. Twelve studies reported PIM prevalence among individuals with varying levels of frailty, ranging from 2.4% to 95.9%. This scoping review highlights the challenges and complexities involved in understanding the relationship between medication use and frailty in older adults.</p>
	]]></content:encoded>

	<dc:title>Medication Use by Older Adults with Frailty: A Scoping Review</dc:title>
			<dc:creator>Rishabh Sharma</dc:creator>
			<dc:creator>Tanaya Sharma</dc:creator>
			<dc:creator>Brent McCready-Branch</dc:creator>
			<dc:creator>Arshia Chauhan</dc:creator>
			<dc:creator>Caitlin Carter</dc:creator>
			<dc:creator>SooMin Park</dc:creator>
			<dc:creator>Imra Hudani</dc:creator>
			<dc:creator>Prapti Choudhuri</dc:creator>
			<dc:creator>Tejal Patel</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060170</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-21</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-21</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>170</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060170</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/170</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/169">

	<title>Pharmacy, Vol. 13, Pages 169: Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know</title>
	<link>https://www.mdpi.com/2226-4787/13/6/169</link>
	<description>Monoclonal antibodies (mAbs) are an important medical innovation in modern medicine. They are an effective therapy for several subtypes of leukaemia but may have undesirable effects, which may be minimised through the provision of interdisciplinary care including a pharmacist. The goals of this narrative review were twofold: first, to summarise the literature on the side effects of mAbs and the challenges of their preparation, and to provide recommendations for the safe preparation of mAb drug formulations for clinicians. Second, to suggest clinical roles for pharmacists to improve patient safety and clinical outcomes for leukaemia patients receiving mAb therapy. The review covers data from 178 scientific and official sources of information on the types of targeted immunobiological drugs for the treatment of various types of leukaemia. The results are a detailed description of the possible side effects from mAb therapy and a list of suggested actions that can be taken to prevent them. Pharmaceutical aspects of the use of mAbs, such as pharmacoeconomics, compounding and stability, are also discussed. The discussion is organised according to the current classification of leukaemia. The drugs considered include blinatumomab, inotuzumab ozogamicin, gemtuzumab ozogamicin, rituximab, ofatumumab, obinutuzumab, and alemtuzumab. The review offers a comprehensive resource to equip pharmacists and other clinicians to optimise mAb therapy and promote the safe use of these novel therapies.</description>
	<pubDate>2025-11-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 169: Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/169">doi: 10.3390/pharmacy13060169</a></p>
	<p>Authors:
		Anastasiia Ryzhuk
		Sergiy M. Kovalenko
		Marine Georgiyants
		Kateryna Vysotska
		Victoriya Georgiyants
		</p>
	<p>Monoclonal antibodies (mAbs) are an important medical innovation in modern medicine. They are an effective therapy for several subtypes of leukaemia but may have undesirable effects, which may be minimised through the provision of interdisciplinary care including a pharmacist. The goals of this narrative review were twofold: first, to summarise the literature on the side effects of mAbs and the challenges of their preparation, and to provide recommendations for the safe preparation of mAb drug formulations for clinicians. Second, to suggest clinical roles for pharmacists to improve patient safety and clinical outcomes for leukaemia patients receiving mAb therapy. The review covers data from 178 scientific and official sources of information on the types of targeted immunobiological drugs for the treatment of various types of leukaemia. The results are a detailed description of the possible side effects from mAb therapy and a list of suggested actions that can be taken to prevent them. Pharmaceutical aspects of the use of mAbs, such as pharmacoeconomics, compounding and stability, are also discussed. The discussion is organised according to the current classification of leukaemia. The drugs considered include blinatumomab, inotuzumab ozogamicin, gemtuzumab ozogamicin, rituximab, ofatumumab, obinutuzumab, and alemtuzumab. The review offers a comprehensive resource to equip pharmacists and other clinicians to optimise mAb therapy and promote the safe use of these novel therapies.</p>
	]]></content:encoded>

	<dc:title>Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know</dc:title>
			<dc:creator>Anastasiia Ryzhuk</dc:creator>
			<dc:creator>Sergiy M. Kovalenko</dc:creator>
			<dc:creator>Marine Georgiyants</dc:creator>
			<dc:creator>Kateryna Vysotska</dc:creator>
			<dc:creator>Victoriya Georgiyants</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060169</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-20</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-20</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>169</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060169</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/169</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/168">

	<title>Pharmacy, Vol. 13, Pages 168: Effects of Modifying Supportive Care Medications in Combination Therapy with Pertuzumab, Trastuzumab, and Taxane Anticancer Drugs</title>
	<link>https://www.mdpi.com/2226-4787/13/6/168</link>
	<description>Chemotherapy for breast cancer includes pertuzumab and trastuzumab regimens with docetaxel (PHD) or paclitaxel (PHP). Current approaches for using supportive care drugs to manage the side effects of PHD and PHP are unclear. Here, we investigated the occurrence of side effects before and after supportive care medications were modified by discontinuing antipyretic analgesics. We retrospectively analyzed adverse events that occurred within 24 h of treating 76 patients with PHD or PHP. The frequencies of adverse effects in the groups before and after modification did not differ significantly (45.5% [15/33] and 44.2% [19/43], respectively). Severity also did not significantly differ between the groups. Therefore, discontinuing antipyretic analgesics as supportive care drugs had little effect on the frequency of side effects. Symptoms of feeling hot, pyrexic, and flushed were frequent, and their severity increased in the group after the support drugs were modified. Discontinuation of supportive care medications, including antipyretic analgesics, might affect the severity of certain symptoms and lead to the development of side effects that require medical intervention. Overall, our findings indicate the need to consider premedication with antipyretic analgesics, including further analysis of the risk factors that can predict symptoms.</description>
	<pubDate>2025-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 168: Effects of Modifying Supportive Care Medications in Combination Therapy with Pertuzumab, Trastuzumab, and Taxane Anticancer Drugs</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/168">doi: 10.3390/pharmacy13060168</a></p>
	<p>Authors:
		Mina Takagi
		Shinichiro Maeda
		Makiko Maeda
		Yasushi Fujio
		Sachiko Hirobe
		</p>
	<p>Chemotherapy for breast cancer includes pertuzumab and trastuzumab regimens with docetaxel (PHD) or paclitaxel (PHP). Current approaches for using supportive care drugs to manage the side effects of PHD and PHP are unclear. Here, we investigated the occurrence of side effects before and after supportive care medications were modified by discontinuing antipyretic analgesics. We retrospectively analyzed adverse events that occurred within 24 h of treating 76 patients with PHD or PHP. The frequencies of adverse effects in the groups before and after modification did not differ significantly (45.5% [15/33] and 44.2% [19/43], respectively). Severity also did not significantly differ between the groups. Therefore, discontinuing antipyretic analgesics as supportive care drugs had little effect on the frequency of side effects. Symptoms of feeling hot, pyrexic, and flushed were frequent, and their severity increased in the group after the support drugs were modified. Discontinuation of supportive care medications, including antipyretic analgesics, might affect the severity of certain symptoms and lead to the development of side effects that require medical intervention. Overall, our findings indicate the need to consider premedication with antipyretic analgesics, including further analysis of the risk factors that can predict symptoms.</p>
	]]></content:encoded>

	<dc:title>Effects of Modifying Supportive Care Medications in Combination Therapy with Pertuzumab, Trastuzumab, and Taxane Anticancer Drugs</dc:title>
			<dc:creator>Mina Takagi</dc:creator>
			<dc:creator>Shinichiro Maeda</dc:creator>
			<dc:creator>Makiko Maeda</dc:creator>
			<dc:creator>Yasushi Fujio</dc:creator>
			<dc:creator>Sachiko Hirobe</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060168</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-17</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-17</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>168</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060168</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/168</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/167">

	<title>Pharmacy, Vol. 13, Pages 167: Pharmacist Intervention Models in Drug&amp;ndash;Drug Interaction Management in Prescribed Pharmacotherapy</title>
	<link>https://www.mdpi.com/2226-4787/13/6/167</link>
	<description>Drug&amp;amp;ndash;drug interactions (DDIs) are one of the most common problems related to drug administration which represent a risk for patient safety. Considering their position in the healthcare system, pharmacists should be more proactively involved in DDI management. The paper shows representation of DDI intervention models in each DDI category. This research enrolled outpatients prescribed pharmacotherapies from 40 randomly selected community pharmacies. DDIs were analyzed using Lexicomp&amp;amp;reg; Lexi-InteractTM Online (Lexi-Comp, Inc., Hudson, NY, USA) software. Clinical pharmacists&amp;amp;rsquo; panel, according to the necessary interventions, determined an independent model of pharmacist interventions (category 1) and models that require cooperation with physicians (category 2) for DDI management. In total, 4107 patients were enrolled in the study. Mean patient age was 67.5; they were mostly women (56.5%) and had on average of 3.4 diagnosis and 5.5 prescription drugs. Overall, 14,175 potential clinically significant DDIs were identified: 83.3% of C, 15.4% of D, and 1.3% of X category. At least one potential DDI was found in 78.6% of patients. Models of pharmacist DDI interventions in collaboration with a physician (category 2) were more prevalent than independent models (category 1): 57.5% vs. 42.5% in C category DDIs, 97.8% vs. 2.2% in D category, and 100% vs. 0% in category X DDIs. This research aimed to gain an insight into the distribution of interventions in DDI management models between physicians and pharmacists, which can contribute to more efficient pharmaceutical care and visibility.</description>
	<pubDate>2025-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 167: Pharmacist Intervention Models in Drug&amp;ndash;Drug Interaction Management in Prescribed Pharmacotherapy</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/167">doi: 10.3390/pharmacy13060167</a></p>
	<p>Authors:
		Ivana Samardžić
		Ivana Marinović
		Iva Marović
		Nikolina Kuča
		Vesna Bačić Vrca
		</p>
	<p>Drug&amp;amp;ndash;drug interactions (DDIs) are one of the most common problems related to drug administration which represent a risk for patient safety. Considering their position in the healthcare system, pharmacists should be more proactively involved in DDI management. The paper shows representation of DDI intervention models in each DDI category. This research enrolled outpatients prescribed pharmacotherapies from 40 randomly selected community pharmacies. DDIs were analyzed using Lexicomp&amp;amp;reg; Lexi-InteractTM Online (Lexi-Comp, Inc., Hudson, NY, USA) software. Clinical pharmacists&amp;amp;rsquo; panel, according to the necessary interventions, determined an independent model of pharmacist interventions (category 1) and models that require cooperation with physicians (category 2) for DDI management. In total, 4107 patients were enrolled in the study. Mean patient age was 67.5; they were mostly women (56.5%) and had on average of 3.4 diagnosis and 5.5 prescription drugs. Overall, 14,175 potential clinically significant DDIs were identified: 83.3% of C, 15.4% of D, and 1.3% of X category. At least one potential DDI was found in 78.6% of patients. Models of pharmacist DDI interventions in collaboration with a physician (category 2) were more prevalent than independent models (category 1): 57.5% vs. 42.5% in C category DDIs, 97.8% vs. 2.2% in D category, and 100% vs. 0% in category X DDIs. This research aimed to gain an insight into the distribution of interventions in DDI management models between physicians and pharmacists, which can contribute to more efficient pharmaceutical care and visibility.</p>
	]]></content:encoded>

	<dc:title>Pharmacist Intervention Models in Drug&amp;amp;ndash;Drug Interaction Management in Prescribed Pharmacotherapy</dc:title>
			<dc:creator>Ivana Samardžić</dc:creator>
			<dc:creator>Ivana Marinović</dc:creator>
			<dc:creator>Iva Marović</dc:creator>
			<dc:creator>Nikolina Kuča</dc:creator>
			<dc:creator>Vesna Bačić Vrca</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060167</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-17</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-17</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>167</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060167</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/167</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/166">

	<title>Pharmacy, Vol. 13, Pages 166: Experiences Reported by People with Epilepsy During Antiseizure Medication Shortages in the UK: A Cross-Sectional Survey</title>
	<link>https://www.mdpi.com/2226-4787/13/6/166</link>
	<description>(1) Background: Medication shortages have become increasingly common in the UK. However, there is limited evidence regarding the experiences of people with epilepsy and their caregivers during these shortages. The aim of this study is to explore the extent and impact of ASM shortages on people with epilepsy and their caregivers across the UK. (2) Methods: A cross-sectional online survey was distributed between January and April, 2024 by epilepsy charities. Participants included people with epilepsy and caregivers. The survey collected demographic information, types of ASM respondents were prescribed, experiences of shortages, and the impact of shortages. Data were analysed descriptively, and subgroup analyses were conducted by medication type. (3) Results: A total of 1549 responded, of whom 1312 were people with epilepsy and their carers who were included in the analysis with a mean age of 43 years. A total of 941 respondents (71.7%) reported difficulty obtaining their prescribed ASM in the past year. Shortages were most frequently reported for sodium valproate (60.8%), lamotrigine (65.2%), carbamazepine (92.6%), clobazam (82.6%), topiramate (81.5%), zonisamide (74.0%), levetiracetam (62.8%), lacosamide (71.0%), and brivaracetam (70.5%). A total of 529 (40.4%) of the participants reported that stress and/or anxiety caused by medication shortages was associated with recurrent seizures. We did not ask whether patients missed medications because of these difficulties. (4) Conclusions: ASM shortages are a widespread issue for people with epilepsy in the UK, leading to treatment disruptions and psychological distress. Addressing supply change limitations and identifying effective approaches to preventing the substitution of ASMs brands by clinicians may potentially reduce this problem.</description>
	<pubDate>2025-11-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 166: Experiences Reported by People with Epilepsy During Antiseizure Medication Shortages in the UK: A Cross-Sectional Survey</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/166">doi: 10.3390/pharmacy13060166</a></p>
	<p>Authors:
		Eric Amankona Abrefa Kyeremaa
		Tom Shillito
		Caroline Smith
		Charlotte Lawthom
		Sion Scott
		David Wright
		</p>
	<p>(1) Background: Medication shortages have become increasingly common in the UK. However, there is limited evidence regarding the experiences of people with epilepsy and their caregivers during these shortages. The aim of this study is to explore the extent and impact of ASM shortages on people with epilepsy and their caregivers across the UK. (2) Methods: A cross-sectional online survey was distributed between January and April, 2024 by epilepsy charities. Participants included people with epilepsy and caregivers. The survey collected demographic information, types of ASM respondents were prescribed, experiences of shortages, and the impact of shortages. Data were analysed descriptively, and subgroup analyses were conducted by medication type. (3) Results: A total of 1549 responded, of whom 1312 were people with epilepsy and their carers who were included in the analysis with a mean age of 43 years. A total of 941 respondents (71.7%) reported difficulty obtaining their prescribed ASM in the past year. Shortages were most frequently reported for sodium valproate (60.8%), lamotrigine (65.2%), carbamazepine (92.6%), clobazam (82.6%), topiramate (81.5%), zonisamide (74.0%), levetiracetam (62.8%), lacosamide (71.0%), and brivaracetam (70.5%). A total of 529 (40.4%) of the participants reported that stress and/or anxiety caused by medication shortages was associated with recurrent seizures. We did not ask whether patients missed medications because of these difficulties. (4) Conclusions: ASM shortages are a widespread issue for people with epilepsy in the UK, leading to treatment disruptions and psychological distress. Addressing supply change limitations and identifying effective approaches to preventing the substitution of ASMs brands by clinicians may potentially reduce this problem.</p>
	]]></content:encoded>

	<dc:title>Experiences Reported by People with Epilepsy During Antiseizure Medication Shortages in the UK: A Cross-Sectional Survey</dc:title>
			<dc:creator>Eric Amankona Abrefa Kyeremaa</dc:creator>
			<dc:creator>Tom Shillito</dc:creator>
			<dc:creator>Caroline Smith</dc:creator>
			<dc:creator>Charlotte Lawthom</dc:creator>
			<dc:creator>Sion Scott</dc:creator>
			<dc:creator>David Wright</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060166</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-10</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-10</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>166</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060166</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/166</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/165">

	<title>Pharmacy, Vol. 13, Pages 165: Bedside Medication Management: Pharmacy Technicians Managing Patient Medication Supply to Improve Nursing Productivity and Patient Safety</title>
	<link>https://www.mdpi.com/2226-4787/13/6/165</link>
	<description>Audits of medication charts conducted by Royal Hobart Hospital Pharmacy revealed that dose omission was the most common medication error experienced by patients. Investigation of these errors also found that nurses spend significant time organising medication for inpatients. To address the issues contributing to these problems, an alternative model of medication management was implemented and tested. This model of bedside medication management involves medication supply managed by ward pharmacy technicians who review charts daily for changes to medicines and obtain the medicines needed for each patient. Outcomes on two intervention wards showed that the model, combined with technician involvement in controlled medicines stock management, resulted in 29.78 h of nursing time released to patient care per 20-bed ward per week, for an investment of 22.28 h of ward pharmacy technician time; a 75% reduction in delayed doses; a 44% reduction in missed doses; and an average decrease of two hours in the turnaround time for supply of inpatient medication. Introducing bedside medication management and controlled medicines stock management activities can release 1.34 h of nursing time to patient care for every hour of ward pharmacy technician time (at a lower hourly salary cost), decrease dose delays and omissions, and improve patient safety.</description>
	<pubDate>2025-11-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 165: Bedside Medication Management: Pharmacy Technicians Managing Patient Medication Supply to Improve Nursing Productivity and Patient Safety</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/165">doi: 10.3390/pharmacy13060165</a></p>
	<p>Authors:
		Tom W. Simpson
		Duncan S. Mckenzie
		Rosina G. Guastella
		Michael J. Ryan
		</p>
	<p>Audits of medication charts conducted by Royal Hobart Hospital Pharmacy revealed that dose omission was the most common medication error experienced by patients. Investigation of these errors also found that nurses spend significant time organising medication for inpatients. To address the issues contributing to these problems, an alternative model of medication management was implemented and tested. This model of bedside medication management involves medication supply managed by ward pharmacy technicians who review charts daily for changes to medicines and obtain the medicines needed for each patient. Outcomes on two intervention wards showed that the model, combined with technician involvement in controlled medicines stock management, resulted in 29.78 h of nursing time released to patient care per 20-bed ward per week, for an investment of 22.28 h of ward pharmacy technician time; a 75% reduction in delayed doses; a 44% reduction in missed doses; and an average decrease of two hours in the turnaround time for supply of inpatient medication. Introducing bedside medication management and controlled medicines stock management activities can release 1.34 h of nursing time to patient care for every hour of ward pharmacy technician time (at a lower hourly salary cost), decrease dose delays and omissions, and improve patient safety.</p>
	]]></content:encoded>

	<dc:title>Bedside Medication Management: Pharmacy Technicians Managing Patient Medication Supply to Improve Nursing Productivity and Patient Safety</dc:title>
			<dc:creator>Tom W. Simpson</dc:creator>
			<dc:creator>Duncan S. Mckenzie</dc:creator>
			<dc:creator>Rosina G. Guastella</dc:creator>
			<dc:creator>Michael J. Ryan</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060165</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-07</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-07</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>165</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060165</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/165</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/164">

	<title>Pharmacy, Vol. 13, Pages 164: The Spectrum of Clinical Pharmacy Services in a Non-University Hospital&amp;mdash;A Comprehensive Characterization Including a Risk Assessment for Drug-Related Problems and Adverse Drug Reactions</title>
	<link>https://www.mdpi.com/2226-4787/13/6/164</link>
	<description>Background: Clinical pharmacy services (CPS) have been shown to confer significant advantages in patient care. It remains to be clarified how CPS resources are allocated across routine care settings. It remains to be clarified which recommendations are made to resolve the drug-related problems (DRP) identified by CPS and which adverse drug reactions (ADR) actually arise from the identified DRP. Methods: Following positive ethical approval, patient chart analyses, evaluation of pharmacy documentation on CPS and pharmacist interviews were performed to characterize CPS at all medical departments of the Bundeswehr Hospital Hamburg. We developed and pre-tested instruments for standardization: A Standard Operating Procedure (SOP) for the practical exercise and documentation of CPS by the pharmacists performing them, a standardized form (checklist) for retrospective data collection as part of this study, and a standardized questionnaire for conducting the pharmacist interviews including a risk assessment according to the NCC-MERP score. Results: In total, 1000 CPS were documented in 504 patients (mean age: 69.95 years; 229 female) on 16,705 treatment days. A total of 66.87% CPS was initiated when pharmacists participated in ward rounds. In all CPS, &amp;amp;ldquo;Indications&amp;amp;rdquo; was the topic addressed most frequently (37.70%). &amp;amp;ldquo;Agents for obstructive respiratory diseases&amp;amp;rdquo; was the most frequently involved drug class (11.32%). The most frequent processing time per CPS was 16&amp;amp;ndash;30 min (48.61%). The number of CPS ranged from 0.36/100 treatment days in dermatology to 12.47 in oncology. Severity of 358 DRP was classified &amp;amp;ldquo;very severe&amp;amp;rdquo; (5.03%), &amp;amp;ldquo;severe&amp;amp;rdquo; (42.74%), &amp;amp;ldquo;moderate&amp;amp;rdquo; (34.36%), &amp;amp;ldquo;low&amp;amp;rdquo; (15.08%), &amp;amp;ldquo;very low&amp;amp;rdquo; (1.40%), or &amp;amp;ldquo;without impact&amp;amp;rdquo; (1.40%). The probability of DRP occurrence was classified as &amp;amp;ldquo;high&amp;amp;rdquo; in 13.13% and &amp;amp;ldquo;very high&amp;amp;rdquo; in 3.35%. In 15.36% of the DRP, an ADR actually occurred. In 504 patients, 932 specific recommendations were forwarded to solve the DRP identified during CPS. Of those, 53.97% were implemented. Conclusions: In almost all CPS, a considerable number of DRP with serious clinical consequences were identified. Half of the forwarded recommendations were implemented.</description>
	<pubDate>2025-11-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 164: The Spectrum of Clinical Pharmacy Services in a Non-University Hospital&amp;mdash;A Comprehensive Characterization Including a Risk Assessment for Drug-Related Problems and Adverse Drug Reactions</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/164">doi: 10.3390/pharmacy13060164</a></p>
	<p>Authors:
		Olaf Zube
		Wiebke Schlüter
		Johanna Dicken
		Jan Hensen
		Thilo Bertsche
		</p>
	<p>Background: Clinical pharmacy services (CPS) have been shown to confer significant advantages in patient care. It remains to be clarified how CPS resources are allocated across routine care settings. It remains to be clarified which recommendations are made to resolve the drug-related problems (DRP) identified by CPS and which adverse drug reactions (ADR) actually arise from the identified DRP. Methods: Following positive ethical approval, patient chart analyses, evaluation of pharmacy documentation on CPS and pharmacist interviews were performed to characterize CPS at all medical departments of the Bundeswehr Hospital Hamburg. We developed and pre-tested instruments for standardization: A Standard Operating Procedure (SOP) for the practical exercise and documentation of CPS by the pharmacists performing them, a standardized form (checklist) for retrospective data collection as part of this study, and a standardized questionnaire for conducting the pharmacist interviews including a risk assessment according to the NCC-MERP score. Results: In total, 1000 CPS were documented in 504 patients (mean age: 69.95 years; 229 female) on 16,705 treatment days. A total of 66.87% CPS was initiated when pharmacists participated in ward rounds. In all CPS, &amp;amp;ldquo;Indications&amp;amp;rdquo; was the topic addressed most frequently (37.70%). &amp;amp;ldquo;Agents for obstructive respiratory diseases&amp;amp;rdquo; was the most frequently involved drug class (11.32%). The most frequent processing time per CPS was 16&amp;amp;ndash;30 min (48.61%). The number of CPS ranged from 0.36/100 treatment days in dermatology to 12.47 in oncology. Severity of 358 DRP was classified &amp;amp;ldquo;very severe&amp;amp;rdquo; (5.03%), &amp;amp;ldquo;severe&amp;amp;rdquo; (42.74%), &amp;amp;ldquo;moderate&amp;amp;rdquo; (34.36%), &amp;amp;ldquo;low&amp;amp;rdquo; (15.08%), &amp;amp;ldquo;very low&amp;amp;rdquo; (1.40%), or &amp;amp;ldquo;without impact&amp;amp;rdquo; (1.40%). The probability of DRP occurrence was classified as &amp;amp;ldquo;high&amp;amp;rdquo; in 13.13% and &amp;amp;ldquo;very high&amp;amp;rdquo; in 3.35%. In 15.36% of the DRP, an ADR actually occurred. In 504 patients, 932 specific recommendations were forwarded to solve the DRP identified during CPS. Of those, 53.97% were implemented. Conclusions: In almost all CPS, a considerable number of DRP with serious clinical consequences were identified. Half of the forwarded recommendations were implemented.</p>
	]]></content:encoded>

	<dc:title>The Spectrum of Clinical Pharmacy Services in a Non-University Hospital&amp;amp;mdash;A Comprehensive Characterization Including a Risk Assessment for Drug-Related Problems and Adverse Drug Reactions</dc:title>
			<dc:creator>Olaf Zube</dc:creator>
			<dc:creator>Wiebke Schlüter</dc:creator>
			<dc:creator>Johanna Dicken</dc:creator>
			<dc:creator>Jan Hensen</dc:creator>
			<dc:creator>Thilo Bertsche</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060164</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-06</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-06</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>164</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060164</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/164</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/163">

	<title>Pharmacy, Vol. 13, Pages 163: Assessment of Job Satisfaction and Intention to Quit Job Among Pharmacists in Saudi Arabia</title>
	<link>https://www.mdpi.com/2226-4787/13/6/163</link>
	<description>Background/Objectives: Job satisfaction is an essential element for organizational functions. Working entities would not effectively operate without employee contentment. This study aimed to determine the level of job satisfaction among pharmacists and investigate its correlation with demographic variables and professional personal experience. Methods: A cross-sectional online survey targeting registered pharmacists in Saudi Arabia was conducted from September to November 2024 using an IRB-approved structured questionnaire adapted from validated instruments. Reliability and validity were confirmed (Cronbach&amp;amp;rsquo;s &amp;amp;alpha; = 0.8), and a target sample of 380 was calculated to ensure representativeness. Data were analyzed using descriptive statistics, chi-squared tests, and univariate and multivariate logistic regression analyses utilizing SPSS v28, with significance set at p &amp;amp;lt; 0.05. Results: A total of 330 pharmacists responded to the survey, representing 86.8% of the calculated sample size. Of those, 57% were male and 68.5% were staffing pharmacists. More than half of participants had professional experience of &amp;amp;le;5 years (57.3%), while 31.8% had 5 to 15 years of experience. Approximately 60% of participants worked in shift systems and reported dissatisfaction with their pay (70%) and lack of benefits (66.7%). Of all participants, only 26.4% confirmed satisfaction with their job and no intention to quit, while 23% clearly reported job dissatisfaction and an intention to quit; the rest of the participants were undecided (50.6%). Significant correlations were found between job satisfaction and variables such as education, current position, organization type, monthly income, and professional experience. Additionally, most of the items assessing professional personal experience such as working in a shift system, working as a team member, gaining financial benefits, and having accomplishments or growth opportunities at work were significantly correlated with job satisfaction. Opportunities for professional development, promotion, and a positive work environment were also frequently selected as factors contributing to job satisfaction (60.6%, 75.2% and 75.5%, respectively). Interestingly, motivation showed minimal impact on participants&amp;amp;rsquo; opinions regarding job satisfaction and decisions over whether to quit their jobs. Finally, occupation and age were found to significantly influence work environments, promotions, and opportunities, which consequently impact participants&amp;amp;rsquo; satisfaction towards their jobs. Conclusions: Our findings indicate that Saudi pharmacists experience low-to-moderate job dissatisfaction, with a significant percentage considering quitting form their jobs. Improving monetary rewards, recognition, and career advancement opportunities could improve job satisfaction and retention in this crucial workforce.</description>
	<pubDate>2025-11-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 163: Assessment of Job Satisfaction and Intention to Quit Job Among Pharmacists in Saudi Arabia</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/163">doi: 10.3390/pharmacy13060163</a></p>
	<p>Authors:
		Ashwaq Alharthi
		Maha Aleiban
		Abdulrahman Alwhaibi
		Moureq Alotaibi
		Yousef Almutairi
		Sultan Alghadeer
		</p>
	<p>Background/Objectives: Job satisfaction is an essential element for organizational functions. Working entities would not effectively operate without employee contentment. This study aimed to determine the level of job satisfaction among pharmacists and investigate its correlation with demographic variables and professional personal experience. Methods: A cross-sectional online survey targeting registered pharmacists in Saudi Arabia was conducted from September to November 2024 using an IRB-approved structured questionnaire adapted from validated instruments. Reliability and validity were confirmed (Cronbach&amp;amp;rsquo;s &amp;amp;alpha; = 0.8), and a target sample of 380 was calculated to ensure representativeness. Data were analyzed using descriptive statistics, chi-squared tests, and univariate and multivariate logistic regression analyses utilizing SPSS v28, with significance set at p &amp;amp;lt; 0.05. Results: A total of 330 pharmacists responded to the survey, representing 86.8% of the calculated sample size. Of those, 57% were male and 68.5% were staffing pharmacists. More than half of participants had professional experience of &amp;amp;le;5 years (57.3%), while 31.8% had 5 to 15 years of experience. Approximately 60% of participants worked in shift systems and reported dissatisfaction with their pay (70%) and lack of benefits (66.7%). Of all participants, only 26.4% confirmed satisfaction with their job and no intention to quit, while 23% clearly reported job dissatisfaction and an intention to quit; the rest of the participants were undecided (50.6%). Significant correlations were found between job satisfaction and variables such as education, current position, organization type, monthly income, and professional experience. Additionally, most of the items assessing professional personal experience such as working in a shift system, working as a team member, gaining financial benefits, and having accomplishments or growth opportunities at work were significantly correlated with job satisfaction. Opportunities for professional development, promotion, and a positive work environment were also frequently selected as factors contributing to job satisfaction (60.6%, 75.2% and 75.5%, respectively). Interestingly, motivation showed minimal impact on participants&amp;amp;rsquo; opinions regarding job satisfaction and decisions over whether to quit their jobs. Finally, occupation and age were found to significantly influence work environments, promotions, and opportunities, which consequently impact participants&amp;amp;rsquo; satisfaction towards their jobs. Conclusions: Our findings indicate that Saudi pharmacists experience low-to-moderate job dissatisfaction, with a significant percentage considering quitting form their jobs. Improving monetary rewards, recognition, and career advancement opportunities could improve job satisfaction and retention in this crucial workforce.</p>
	]]></content:encoded>

	<dc:title>Assessment of Job Satisfaction and Intention to Quit Job Among Pharmacists in Saudi Arabia</dc:title>
			<dc:creator>Ashwaq Alharthi</dc:creator>
			<dc:creator>Maha Aleiban</dc:creator>
			<dc:creator>Abdulrahman Alwhaibi</dc:creator>
			<dc:creator>Moureq Alotaibi</dc:creator>
			<dc:creator>Yousef Almutairi</dc:creator>
			<dc:creator>Sultan Alghadeer</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060163</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-05</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-05</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>163</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060163</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/163</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/162">

	<title>Pharmacy, Vol. 13, Pages 162: Healthcare Practice Post COVID-19 Impacts: Will 21st Century Pharmacists Become Global, Agile, Collaborative and Curated?</title>
	<link>https://www.mdpi.com/2226-4787/13/6/162</link>
	<description>&amp;amp;ldquo;Those that fail to learn from history are doomed to repeat it.&amp;amp;rdquo; Winston Churchill. In recent times, globally, approximately three pandemics and thousands of natural disasters and political upheavals have been recorded. In most cases, tens to hundreds of thousands of people have died as a result, whether from droughts, famines, floods, earthquakes, tsunamis, wildfires, landslides, cyclones, typhoons, hurricanes, extreme heat, emerging or resurgent diseases or longer-term issues such as sustainability, climate change and/or global warming. Whilst many accommodations may have been made to cope with these, we propose that pharmacy education and professional practice benefit from learning from the past, from collaboration globally to manage the hectic and uncertain times that result from these disruptions and from curation and evaluation of these initiatives for ongoing and/or future use.</description>
	<pubDate>2025-11-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 162: Healthcare Practice Post COVID-19 Impacts: Will 21st Century Pharmacists Become Global, Agile, Collaborative and Curated?</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/162">doi: 10.3390/pharmacy13060162</a></p>
	<p>Authors:
		Maree Donna Simpson
		Jaimy Jose
		Jennifer L. Cox
		</p>
	<p>&amp;amp;ldquo;Those that fail to learn from history are doomed to repeat it.&amp;amp;rdquo; Winston Churchill. In recent times, globally, approximately three pandemics and thousands of natural disasters and political upheavals have been recorded. In most cases, tens to hundreds of thousands of people have died as a result, whether from droughts, famines, floods, earthquakes, tsunamis, wildfires, landslides, cyclones, typhoons, hurricanes, extreme heat, emerging or resurgent diseases or longer-term issues such as sustainability, climate change and/or global warming. Whilst many accommodations may have been made to cope with these, we propose that pharmacy education and professional practice benefit from learning from the past, from collaboration globally to manage the hectic and uncertain times that result from these disruptions and from curation and evaluation of these initiatives for ongoing and/or future use.</p>
	]]></content:encoded>

	<dc:title>Healthcare Practice Post COVID-19 Impacts: Will 21st Century Pharmacists Become Global, Agile, Collaborative and Curated?</dc:title>
			<dc:creator>Maree Donna Simpson</dc:creator>
			<dc:creator>Jaimy Jose</dc:creator>
			<dc:creator>Jennifer L. Cox</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060162</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-03</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-03</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>162</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060162</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/162</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/161">

	<title>Pharmacy, Vol. 13, Pages 161: Socioeconomic Determinants of Career Intention in Pharmacy Students in Vietnam</title>
	<link>https://www.mdpi.com/2226-4787/13/6/161</link>
	<description>Background: The pharmacy workforce in Vietnam is rapidly evolving, but little is known about how gender and socioeconomic factors shape career intentions and sector preferences of students. Understanding these determinants is essential for healthcare workforce planning. Objective: To investigate how gender and socioeconomic determinants influence intention of pharmacy students to pursue a career and their preferred sector in Vietnam. Methods: A cross-sectional survey was conducted among 462 students from 2nd to 5th year at a Vietnamese university. Demographic data, socioeconomic background, and career intentions were analyzed using chi-squared tests, multinomial logistic regression, and binary logistic regression. Results: Of 462 respondents, 71.9% intended to pursue a pharmacy career, 2.6% reported no, while 25.5% were unsure. Gender differences were evident but did not reach statistical significance (p = 0.083). Female students were more likely to choose clinical, hospital pharmacy or regulation, whereas male students showed higher preference for community, industry and academia. Binary logistic regression revealed that urban origin (OR = 1.34, 95% CI = 1.01&amp;amp;ndash;1.78, p = 0.041) and family encouragement (OR = 2.53, 95% CI = 1.60&amp;amp;ndash;3.99, p &amp;amp;lt; 0.001) significantly predicted career intention, while gender and income were non-significant. Conclusions: Family encouragement and urban upbringing influence pharmacy career pursuit, while gender may shape sectoral preferences. Policies should address gender equity and enhance support for students from rural or disadvantaged backgrounds.</description>
	<pubDate>2025-11-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 161: Socioeconomic Determinants of Career Intention in Pharmacy Students in Vietnam</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/161">doi: 10.3390/pharmacy13060161</a></p>
	<p>Authors:
		Quang Ngoc Phan
		Oanh Thi Kim Nguyen
		Hoa Thi Tran
		Ngoc Bao Dang
		Nam Hoang Tran
		</p>
	<p>Background: The pharmacy workforce in Vietnam is rapidly evolving, but little is known about how gender and socioeconomic factors shape career intentions and sector preferences of students. Understanding these determinants is essential for healthcare workforce planning. Objective: To investigate how gender and socioeconomic determinants influence intention of pharmacy students to pursue a career and their preferred sector in Vietnam. Methods: A cross-sectional survey was conducted among 462 students from 2nd to 5th year at a Vietnamese university. Demographic data, socioeconomic background, and career intentions were analyzed using chi-squared tests, multinomial logistic regression, and binary logistic regression. Results: Of 462 respondents, 71.9% intended to pursue a pharmacy career, 2.6% reported no, while 25.5% were unsure. Gender differences were evident but did not reach statistical significance (p = 0.083). Female students were more likely to choose clinical, hospital pharmacy or regulation, whereas male students showed higher preference for community, industry and academia. Binary logistic regression revealed that urban origin (OR = 1.34, 95% CI = 1.01&amp;amp;ndash;1.78, p = 0.041) and family encouragement (OR = 2.53, 95% CI = 1.60&amp;amp;ndash;3.99, p &amp;amp;lt; 0.001) significantly predicted career intention, while gender and income were non-significant. Conclusions: Family encouragement and urban upbringing influence pharmacy career pursuit, while gender may shape sectoral preferences. Policies should address gender equity and enhance support for students from rural or disadvantaged backgrounds.</p>
	]]></content:encoded>

	<dc:title>Socioeconomic Determinants of Career Intention in Pharmacy Students in Vietnam</dc:title>
			<dc:creator>Quang Ngoc Phan</dc:creator>
			<dc:creator>Oanh Thi Kim Nguyen</dc:creator>
			<dc:creator>Hoa Thi Tran</dc:creator>
			<dc:creator>Ngoc Bao Dang</dc:creator>
			<dc:creator>Nam Hoang Tran</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060161</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-02</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-02</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>161</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060161</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/161</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/158">

	<title>Pharmacy, Vol. 13, Pages 158: Barriers and Facilitators of Using MyDispense from the Student Perspective: A Systematic Review</title>
	<link>https://www.mdpi.com/2226-4787/13/6/158</link>
	<description>MyDispense is a high-fidelity, low-stakes community pharmacy simulation, allowing students to practice dispensing skills. A systematic review was conducted to identify students&amp;amp;rsquo; perceptions regarding barriers and facilitators of MyDispense in pharmacy education. PubMed, CINAHL, and EMBASE databases were searched from 2015 to 2025 in January 2025 using combined keywords, proximity searching and Boolean operators. Studies investigating MyDispense and gathering students&amp;amp;rsquo; perceptions were included. Record screening was conducted by two independent reviewers (OC and LS). Any identified records from database searching and hand searching of included study reference lists were imported to Rayyan and subjected to independent review. Conflicts were resolved through a third party (RMcC), and discussions were held until consensus was reached. Fifteen studies were included in this review. Seven studies were conducted in USA, six in Asia, one in UK, and one in Australia. All studies utilised purposive sampling. Sample sizes ranged from 33 to 322 students. All studies included surveys to gather student perceptions. Other data collection methods included semi-structured interviews and focus group discussions for students to further elaborate on survey responses. Identified facilitators were mapped to four overarching themes; &amp;amp;ldquo;Develops competency&amp;amp;rdquo;, &amp;amp;ldquo;User-Friendliness&amp;amp;rdquo;, &amp;amp;ldquo;Engaging Learning Experience&amp;amp;rdquo; and &amp;amp;ldquo;Safe Learning Environment.&amp;amp;rdquo; Key barriers were encompassed to three themes: &amp;amp;ldquo;Learning Curve&amp;amp;rdquo;, &amp;amp;ldquo;IT issues&amp;amp;rdquo; and &amp;amp;ldquo;Limited Realism and Applications&amp;amp;rdquo;. Barriers included (i) the learning curve of the platform, (ii) technical issues, and (iii) limited realism. Facilitators included perceptions of (i) improved dispensing and counselling skills and a deeper understanding of pharmacy legislation, (ii) accessibility, interactivity of the learning environment and (iii) immediate feedback. Synthesis of the evidence in this review identified students&amp;amp;rsquo; perceptions of barriers and facilitators of MyDispense in pharmacy education. This may serve as a guide to educators considering the adoption of MyDispense into their curricula.</description>
	<pubDate>2025-11-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 158: Barriers and Facilitators of Using MyDispense from the Student Perspective: A Systematic Review</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/158">doi: 10.3390/pharmacy13060158</a></p>
	<p>Authors:
		Owen Collins
		Ruth McCarthy
		Laura J. Sahm
		</p>
	<p>MyDispense is a high-fidelity, low-stakes community pharmacy simulation, allowing students to practice dispensing skills. A systematic review was conducted to identify students&amp;amp;rsquo; perceptions regarding barriers and facilitators of MyDispense in pharmacy education. PubMed, CINAHL, and EMBASE databases were searched from 2015 to 2025 in January 2025 using combined keywords, proximity searching and Boolean operators. Studies investigating MyDispense and gathering students&amp;amp;rsquo; perceptions were included. Record screening was conducted by two independent reviewers (OC and LS). Any identified records from database searching and hand searching of included study reference lists were imported to Rayyan and subjected to independent review. Conflicts were resolved through a third party (RMcC), and discussions were held until consensus was reached. Fifteen studies were included in this review. Seven studies were conducted in USA, six in Asia, one in UK, and one in Australia. All studies utilised purposive sampling. Sample sizes ranged from 33 to 322 students. All studies included surveys to gather student perceptions. Other data collection methods included semi-structured interviews and focus group discussions for students to further elaborate on survey responses. Identified facilitators were mapped to four overarching themes; &amp;amp;ldquo;Develops competency&amp;amp;rdquo;, &amp;amp;ldquo;User-Friendliness&amp;amp;rdquo;, &amp;amp;ldquo;Engaging Learning Experience&amp;amp;rdquo; and &amp;amp;ldquo;Safe Learning Environment.&amp;amp;rdquo; Key barriers were encompassed to three themes: &amp;amp;ldquo;Learning Curve&amp;amp;rdquo;, &amp;amp;ldquo;IT issues&amp;amp;rdquo; and &amp;amp;ldquo;Limited Realism and Applications&amp;amp;rdquo;. Barriers included (i) the learning curve of the platform, (ii) technical issues, and (iii) limited realism. Facilitators included perceptions of (i) improved dispensing and counselling skills and a deeper understanding of pharmacy legislation, (ii) accessibility, interactivity of the learning environment and (iii) immediate feedback. Synthesis of the evidence in this review identified students&amp;amp;rsquo; perceptions of barriers and facilitators of MyDispense in pharmacy education. This may serve as a guide to educators considering the adoption of MyDispense into their curricula.</p>
	]]></content:encoded>

	<dc:title>Barriers and Facilitators of Using MyDispense from the Student Perspective: A Systematic Review</dc:title>
			<dc:creator>Owen Collins</dc:creator>
			<dc:creator>Ruth McCarthy</dc:creator>
			<dc:creator>Laura J. Sahm</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060158</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>158</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060158</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/158</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/160">

	<title>Pharmacy, Vol. 13, Pages 160: Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report</title>
	<link>https://www.mdpi.com/2226-4787/13/6/160</link>
	<description>Background: Uremic pruritus is one of the most debilitating complications among patients with end-stage kidney disease (ESKD) receiving hemodialysis. For patients who are refractory to traditional therapies (topical analgesics, antihistamines, or gabapentinoids), the use of low-dose naltrexone can be an option where difelikefalin is not available. Case report: In our case report, we present a case of a female patient who developed intractable uremic pruritus despite the adequate trials of traditional therapies. The patient was initiated with low-dose naltrexone of 5 mg daily. Uremic symptoms improved within 3 days of naltrexone initiation. The side effects were tolerated. Conclusion: Low-dose naltrexone provided symptomatic improvement in individuals with severe uremic pruritus when difelikefalin was inaccessible. While limited to a single case, this report highlights the potential role of naltrexone and underscores the need for further research to establish its safety and efficacy.</description>
	<pubDate>2025-11-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 160: Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/160">doi: 10.3390/pharmacy13060160</a></p>
	<p>Authors:
		Dhakrit Rungkitwattanakul
		Michelle Brooks
		Simeon Adesina
		Sanaa Belrhiti
		Weerachai Chaijamorn
		Taniya Charoensareerat
		Uzoamaka Nwaogwugwu
		Constance Mere
		</p>
	<p>Background: Uremic pruritus is one of the most debilitating complications among patients with end-stage kidney disease (ESKD) receiving hemodialysis. For patients who are refractory to traditional therapies (topical analgesics, antihistamines, or gabapentinoids), the use of low-dose naltrexone can be an option where difelikefalin is not available. Case report: In our case report, we present a case of a female patient who developed intractable uremic pruritus despite the adequate trials of traditional therapies. The patient was initiated with low-dose naltrexone of 5 mg daily. Uremic symptoms improved within 3 days of naltrexone initiation. The side effects were tolerated. Conclusion: Low-dose naltrexone provided symptomatic improvement in individuals with severe uremic pruritus when difelikefalin was inaccessible. While limited to a single case, this report highlights the potential role of naltrexone and underscores the need for further research to establish its safety and efficacy.</p>
	]]></content:encoded>

	<dc:title>Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report</dc:title>
			<dc:creator>Dhakrit Rungkitwattanakul</dc:creator>
			<dc:creator>Michelle Brooks</dc:creator>
			<dc:creator>Simeon Adesina</dc:creator>
			<dc:creator>Sanaa Belrhiti</dc:creator>
			<dc:creator>Weerachai Chaijamorn</dc:creator>
			<dc:creator>Taniya Charoensareerat</dc:creator>
			<dc:creator>Uzoamaka Nwaogwugwu</dc:creator>
			<dc:creator>Constance Mere</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060160</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>160</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060160</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/160</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2226-4787/13/6/159">

	<title>Pharmacy, Vol. 13, Pages 159: Hospital Pharmacists&amp;rsquo; Perspectives on Documenting and Classifying Pharmaceutical Interventions: A Nationwide Validation Study in Portugal</title>
	<link>https://www.mdpi.com/2226-4787/13/6/159</link>
	<description>Pharmacist interventions (PIs) are central to optimising pharmacotherapy, preventing drug-related problems, and improving patient outcomes. In Portugal, the absence of a validated tool to consistently document and classify PIs limits data comparability and service development. Given these gaps, this study aimed to describe hospital pharmacists&amp;amp;rsquo; attitudes towards PI documentation and classification, following confirmatory factor analysis (CFA) of a survey instrument, and to provide a comprehensive overview of current practices and behaviours in hospital settings across Portugal. An online questionnaire, previously validated, was distributed online to all hospital pharmacists registered with the Portuguese Pharmaceutical Society (October&amp;amp;ndash;December 2024). Sociodemographic data and the cognitive and behavioural domains of pharmacists&amp;amp;rsquo; attitudinal model were analysed descriptively, and CFA tested the three-factor structure (Process, Outcome, Satisfaction) of the attitudinal affective domain. Of 1848 pharmacists, 260 responded (14%). Respondents reported performing a mean of 49 PIs/month (SD = 196), although many never recorded (28.8%), classified (56.2%), or analysed (52.3%) interventions. Only 2.7% declared to use a validated classification framework. The CFA supported the structural coherence of the Process factor but revealed some overlapping between Process and Outcome and instability in the Satisfaction factor. The nationwide scope and application of CFA provided partial support for the hypothesised model and highlighted areas for refinement, including revision of Satisfaction items and reconsideration of Process and Outcome as overlapping constructs. Findings highlight strong professional commitment to PIs but persistent barriers, including less clear procedures and satisfaction, underscoring the need for a unified, standardised national system to support consistent recording, classification, and evaluation.</description>
	<pubDate>2025-11-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Pharmacy, Vol. 13, Pages 159: Hospital Pharmacists&amp;rsquo; Perspectives on Documenting and Classifying Pharmaceutical Interventions: A Nationwide Validation Study in Portugal</b></p>
	<p>Pharmacy <a href="https://www.mdpi.com/2226-4787/13/6/159">doi: 10.3390/pharmacy13060159</a></p>
	<p>Authors:
		Sara Machado
		Fátima Falcão
		Afonso Miguel Cavaco
		</p>
	<p>Pharmacist interventions (PIs) are central to optimising pharmacotherapy, preventing drug-related problems, and improving patient outcomes. In Portugal, the absence of a validated tool to consistently document and classify PIs limits data comparability and service development. Given these gaps, this study aimed to describe hospital pharmacists&amp;amp;rsquo; attitudes towards PI documentation and classification, following confirmatory factor analysis (CFA) of a survey instrument, and to provide a comprehensive overview of current practices and behaviours in hospital settings across Portugal. An online questionnaire, previously validated, was distributed online to all hospital pharmacists registered with the Portuguese Pharmaceutical Society (October&amp;amp;ndash;December 2024). Sociodemographic data and the cognitive and behavioural domains of pharmacists&amp;amp;rsquo; attitudinal model were analysed descriptively, and CFA tested the three-factor structure (Process, Outcome, Satisfaction) of the attitudinal affective domain. Of 1848 pharmacists, 260 responded (14%). Respondents reported performing a mean of 49 PIs/month (SD = 196), although many never recorded (28.8%), classified (56.2%), or analysed (52.3%) interventions. Only 2.7% declared to use a validated classification framework. The CFA supported the structural coherence of the Process factor but revealed some overlapping between Process and Outcome and instability in the Satisfaction factor. The nationwide scope and application of CFA provided partial support for the hypothesised model and highlighted areas for refinement, including revision of Satisfaction items and reconsideration of Process and Outcome as overlapping constructs. Findings highlight strong professional commitment to PIs but persistent barriers, including less clear procedures and satisfaction, underscoring the need for a unified, standardised national system to support consistent recording, classification, and evaluation.</p>
	]]></content:encoded>

	<dc:title>Hospital Pharmacists&amp;amp;rsquo; Perspectives on Documenting and Classifying Pharmaceutical Interventions: A Nationwide Validation Study in Portugal</dc:title>
			<dc:creator>Sara Machado</dc:creator>
			<dc:creator>Fátima Falcão</dc:creator>
			<dc:creator>Afonso Miguel Cavaco</dc:creator>
		<dc:identifier>doi: 10.3390/pharmacy13060159</dc:identifier>
	<dc:source>Pharmacy</dc:source>
	<dc:date>2025-11-01</dc:date>

	<prism:publicationName>Pharmacy</prism:publicationName>
	<prism:publicationDate>2025-11-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>159</prism:startingPage>
		<prism:doi>10.3390/pharmacy13060159</prism:doi>
	<prism:url>https://www.mdpi.com/2226-4787/13/6/159</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
